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This thesis describes the design and synthesis of two 3-D building blocks for potential use 
in medicinal chemistry. The design and synthesis of normorphan-derived 3-D building block 
A and morphan-derived 3-D building block B is outlined. Further functionalisation of the 
normorphan-derived 3-D building block into lead-like compounds is also presented. 
 
Section 2.1 describes the design consideration, vector analysis and proposed route for the 
synthesis of normorphan-derived 3-D building block A. Section 2.2 presents the racemic 
synthesis of normorphan-derived building block A which was achieved with a 30% overall 
yield on a multi-gram scale via a seven-step sequence. Section 2.3 describes the investigation 
of routes for the synthesis of enantioenriched normorphan-derived 3-D building block A by 
asymmetric cyclisation and diastereomeric resolution approaches. 
The design, vector analysis and proposed route for morphan-derived 3-D building block B 
are presented in Section 3.1. Initial approaches for the synthesis of morphan-derived building 
block B using sulfonamide protecting groups are presented in Section 3.2. Further 
approaches for the synthesis of morphan-derived building block B using an N-Boc protecting 
group are then outlined in Section 3.3. However, unfortunately, both these routes were 
ultimately unsuccessful in providing the desired 3-D building block B. 
Finally, Chapter 4 showcases the functionalisation potential of normorphan-derived building 
block A for the synthesis of medicinally-relevant lead-like compounds. Section 4.1 presents 
the Suzuki-Miyaura arylation of 3-D building block A with a variety of aryl bromides while 
Section 4.2 shows further functionalisation of the building block into compounds such as 
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Chapter 1 Introduction 
1.1. Building Blocks in Medicinal Chemistry 
With the advent of high-throughput screening (HTS), pharmaceutical research and 
development (R&D) has begun to research different approaches for the exploration of 
chemical space.1 On top of this, concepts such as “lead-oriented synthesis”,2 “escape from 
flatland”,3 “conformational restriction”4 and “scaffold hopping”5 have turned chemists’ 
attention into developing high quality and more diverse sets of building blocks.6-9 
Building blocks represent one of the main toolkits that medicinal chemists use to access lead 
compounds and to increase the diversity of lead-like structures.10 Building blocks often 
constitute the main backbone of lead-like scaffolds and it is common for the same building 
block to be incorporated into varied lead structures across different projects.10 Thus, the idea 
that higher quality and more diverse building blocks can improve the overall quality and 
success of discovery projects has been widely presented and adopted by various 
pharmaceutical companies such as AstraZeneca11 and Pfizer.12 In particular, the desired 
features in building blocks for medicinal chemistry have been outlined by AstraZeneca.11 
The presence of chemical functionality for easy incorporation into the lead structure, the 
‘Rule of 2’ (MW <200, clogP <2, H-bond donors ≤2 and H-bond acceptors ≤4) and the lack 
of redox-active functionality once incorporated into the structure were initially selected as 
high quality hallmarks for a building block.11  
Additional analyses into the impact of aromatic ring counts on compound developability 
suggested that increasing numbers of aromatic rings present in lead compounds had 
detrimental effects on the physicochemical properties of compounds thus lowering their 
applicability in discovery projects.13 On top of this, the “escape from flatland” concept was 
introduced by Lovering et al.3 This concept explored the correlation between the progression 
of molecules through drug development stages and clinical trials and the fraction of sp3 
hybridised carbon atoms (Fsp3, number of sp3 hybridised carbon atoms divided by the total 
number of carbon atoms) as well as stereogenic centres present within the molecule. 
Lovering et al. analysed compounds that had reported biological activity or were described 
in a medicinal chemistry patent between 1980 and 2009 and they found that a correlation 
existed between increased Fsp3 and the progression of a drug through the drug development 
stages. The paper also found a 33% increase in the stereogenic centre count from discovery 
molecules to drugs. They also found that increased saturation had a beneficial effect on the 
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physical properties of drug candidates such as increased solubility and decreased melting 
points. These studies are taken as examples in support of the idea that increased 3-D shape 
of drug candidates and their building blocks can increase the likelihood of successful 
progression through clinical trials. 
Following this and the widespread presence of diverse cyclic systems in drug-like 
molecules,14 the concepts of “conformational restriction” and “scaffold hopping” have come 
into play for lead-oriented synthesis.2 In this context, the use of conformationally restricted 
cyclic systems as surrogates for flexible rings (e.g. piperidines, morpholines, azepanes) has 
become popular.6 Selected examples of said types of building blocks are presented below. 
Carreira and co-workers15 developed a series of azaspirocycles as surrogates for piperazine-
like motifs (Figure 1.1). During their studies, Carreira et al. found that these azaspirocycles 
showed favourable pharmacokinetic properties with respect to their parent ring systems 
allowing for the synthesis of a ciprofloxacin analogue (Figure 1.1) with a better 
pharmacokinetic profile. 
 
Figure 1.1 - Carreira’s azaspirocycles and a ciprofloxacin analogue  
Mykhailiuk and co-workers16,17 presented in 2017 an extensive set of spirocyclic 
pyrrolidines with either two or three diversity points as building blocks for medicinal 
chemistry. These spirocyclic pyrrolidines showed comparable physicochemical properties 
to their analogous piperidine and morpholine systems with slightly increased lipophilicity 
but significantly improved metabolic stability. Some selected examples are presented in 
Figure 1.2. One of the spirocyclic pyrrolidines was also studied as a substituent in a 




Figure 1.2 - Mykhailiuk's spirocyclic pyrrolidine building blocks 
Also in 2017, Miykhailiuk and co-workers6 reported the synthesis of 3-
azabicyclo[3.2.0]heptane building blocks as surrogates for piperidine motifs. These bicyclic 
building blocks had similar physicochemical properties to their parent piperidines but 
occupied a slightly different part of chemical space according to their exit vectors (see 
Section 1.2). Some examples of these scaffolds are shown in Figure 1.3 together with 
Belaperidone, an antischizophrenia agent, which was prepared using one of the building 
blocks. 
 
Figure 1.3 - Miykhailiuk’s azabicyclo[3.2.0]heptane building blocks 
4 
 
It is finally worth noting that Pfizer12 has recently developed a building block library in 
collaboration with various chemical companies that contains various high Fsp3 and 
conformationally restricted building blocks (Figure 1.4). This set of building blocks has been 
incorporated into the company’s discovery pipeline in recent years. 
 
 
Figure 1.4 - Selected examples from Pfizer's quick building block library 
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1.2 Exit Vector Analysis 
Exit vector analysis is a way of visualizing chemical space, originally introduced for 
CAVEAT software in the 1990s,18 and recently popularised by Grygorenko and co-
workers19 for the geometric description of functionalisation vectors for bifunctional 
scaffolds. Exit vector analysis uses the relative orientation of the two diversity vectors n1 
and n2 that can be described according to four geometric parameters. For example, in the 
case of a 1,4-disubstituted cyclohexane (Figure 1.5): the distance between the variation 
points C1 and C2, r, the plane angles Φ1 (between vector n1 and C1-C2) and Φ2 (between 
vector n2 and C1-C2) and the dihedral angle θ defined by the vectors n1, C1-C2 and n2. These 
parameters can be determined from the atomic coordinates and allow for the construction of 
Ramachandran-like plots.19 
 
Figure 1.5 - Visual representation of variation vectors. 
Extensive work has been performed by Grygorenko and coworkers19,20 in the classification 
of simple saturated carbo- and heterocyclic systems. Initial studies by Grygorenko into 
simple 3- to 7-membered carbocyclic compounds showed clustering that allowed for 
systematic categorisation of these structures into four distinct regions (Figure 1.6).19 Region 
α mainly comprises cis- and trans-1,2 systems. Cis-1,3 scaffolds as well as cis-1,4 6-
membered rings form the β region. On the other hand, the γ region is formed by trans-1,4 6-
membered rings while region δ includes trans-1,3 6-membered rings alongside some trans-
1,3 5-membered scaffolds. Within this initial analysis by Grygorenko, there were only two 




Figure 1.6 - Grygorenko's 4- to 7-membered ring carbocycle exit vector analysis19 
Further studies by Grygorenko and co-workers20 on heterocyclic scaffolds demonstrated 
that, despite their apparent similarities to their carbocyclic counterparts, the plane and 
dihedral angles for these scaffolds differed significantly. Particularly, it was found that 1,3-
substituted scaffolds occupied an area previously unoccupied at r = 2.5 Å between the β and 
δ regions in the dihedral angle plot (Figure 1.7a) while still occupying a distinct region in 
plane angle plots (Figure 1.7b,c). This led to the definition of a new region ε for these 1,3- 
disubstituted heterocycles. Region β was also extended to encompass some 1,4- and some 









Figure 1.7 - Grygorenko's heterocycle exit vector analysis a) r-θ plot (polar coordinates); b) θ-Φ1/Φ2 plot; c) 
Φ1-Φ2 plot.20 
Grygorenko and co-workers20,21 have also extended their exit vector analysis to a series of 
conformationally restricted, bicyclic amines (Figure 1.8). In this analysis, it was found that 
bicyclic scaffolds could access previously untapped areas of chemical space. In particular, 
they found that larger values of r could be easily accessed with these scaffolds. Grygorenko 
also found that the variety of structures encompassed in this set allowed for access to a wide 
variety of predictable elaboration vectors outside the areas previously stablished (Figure 
1.9). 
 





Figure 1.9 - Grygorenko's bicyclic diamine exit vector analysis a) r-θ plot (polar coordinates); b) θ-Φ1/Φ2 
plot; b) Φ1-Φ2 plot 
Exit vector analysis has also been applied to various other compounds such as 3-
((hetera)cyclobutyl)azetidines,22 propellanes23 and sultams24 and it has become an easy, well 








1.3 Normorphan 6-Azabicyclo[3.2.1]octane Scaffold 
1.3.1 Introduction to the Normorphan Scaffold 
In recent years, normorphan-derived scaffolds have been a focus of interest in synthetic 
chemistry mainly due to their applications in the pharmaceutical industry25 and their wide 
presence in diverse natural products.26-29 Consequently, attention towards the synthesis and 
applications of this bicyclic scaffold has been continuously expanding. The normorphan 
scaffold has as its core a bicyclic [3.2.1]octane structure where the 6-position of the scaffold 
has been replaced with an amino group (Figure 1.10). This amine or amide, alongside the 
variety of substitution patterns that emerge from the different synthetic approaches, allow 
for a diverse set of functionalisation vectors in pharmaceutical space. The normorphan core 
also shows potential for scaffold hoping, which alongside its 3-dimensionality make it a 
suitable candidate as a medicinal chemistry building block. 
 
Figure 1.10 - Normorphan bicyclo[3.2.1]octane scaffold 
In the context of pharmaceutical applications, 2,3-disubstituted normorphans have been 
investigated as novel dopamine transporter (DAT) inhibitors by Bonjoch and co-workers.25 
During their studies, it was found that normorphan 1 showed comparable potency to that of 
currently-used DAT inhibitors while showing less potential side-effects. Likewise, 
normorphan 2 is currently being investigated as a potential antitumor agent against diffuse 
large B-celllymphomas.30 Azaprophen 3 has been widely investigated for the treatment of 
Alzheimer’s disease due to its high potency as a muscarinic acetylcholine receptor 
antagonist.31-33 Finally, normorphan CGP48506 has been investigated as a calcium-




Figure 1.11 - Pharmaceutically-relevant normorphans 
On the other hand, several natural products also contain the normorphan 6-
azabicyclo[3.2.1]octane scaffold (Figure 1.12). For example, peduncularine 4 has been a 
synthetic target of notable interest with seven formal and total syntheses published so far.27 
Additionally, actinobolamine 5 has also been a relevant synthetic target for chemists since 
its structural elucidation by Munk and co-workers in 1967.28,35 
 
Figure 1.12 - Penduncularine 4 and Actinobolamine 5 
1.3.2 Overview of Racemic Approaches for the Synthesis of the Normorphan Scaffold 
In this Section, an overview of previously reported racemic approaches for the synthesis of 
the normorphan and structurally related scaffolds is presented. Among the first approaches 
for the synthesis of the normorphan core were the thermal lactamisation of 1,3 aminoacids,36 
Beckmann rearrangements of bicyclo[2.2.1]hetan-2-one oximes,37 amide alkylation,38 
Hofmann-Loeffler-Freytag reactions39 and aza-Michael additions.40 However, while these 
reactions afforded the desired normorphan cores in moderate to good yields, many of them  
had poor functional group tolerance and/or required lengthy syntheses for their starting 
materials. Many of them also required the installation of a precursor bicyclic scaffold.41 
While investigating the synthesis of peduncularine 4, Speckamp and co-workers42 generated 
an electrophilic N-acyliminium cation 6 by acid treatment of lactam 7 which subsequently 
cyclised to give normorphan 8 in 87% yield (Scheme 1.1). However, while this methodology 
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showed a good functional group tolerance and excellent yield, it required a six-step sequence 
to obtain precursor lactam 7. 
 
Scheme 1.1 
A somewhat curious approach to the synthesis of the normorphan scaffold was developed 
by Hoyt Meyer and co-workers43 for the synthesis of peduncularine 4. In it, they utilised a 
Cr(0)-mediated [6+2] cycloaddition under photochemical conditions between isopropyl 
isocyanate and cycloheptatriene 9 to give bicyclic scaffold 10 as a single diastereomer in 
37% yield. Bicycle 10 was then treated with Tl(NO3)3 to give normorphan 11 in 13% yield 
over the two-step sequence (Scheme 1.2). Nonetheless, it is evident that the low yields and 
use of toxic metals render this methodology unattractive.  
 
Scheme 1.2 
Other approaches have also been used to synthesise the normorphan core during the 
synthesis of peduncularine 4 such as ring closing metathesis between the 3- and 4- positions 
of the ring,44 radical cyclisation of oximes,45 [3+2] annulation of allylic silanes46 and 
iminium ion-promoted rearrengements.27 However, only the [3+2] annulation of allylic 
silanes was studied beyond the synthesis of their target. For example, Woerpel and co-
workers26 used silylated cyclohexadiene 11 to access normorphan 12 by treatment with 
chlorosulfonyl isocyanate. Here, the allylic silyl species adds to the isocyanate to generate 
the zwitterionic intermediate 13 which undergoes 1,2-silyl migration to give allylic cation 
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14. Cation 14 then rapidly cyclises to give a 91:9 mixture of regioisomers with addition at 
the 1-position being the main product (Scheme 1.3).46 This approach was one of the first 
approaches to normorphans that required few steps towards the synthesis of its starting 




In 2004, Johnson and co-workers25 developed a method to quickly access simple 
normorphans. By using a Diels-Alder reaction between N-Me-pyridone 15 and acrylic acid 
at 200 °C for 10 days and forming the methyl ester, normorphan 16 was obtained in 36% 
yield over the two-step sequence (Scheme 1.4). This was achieved by initial formation of 
the Diels-Alder adduct 17 which rearranged via tricyclic intermediate 18 to give normorphan 
19. Normorphan 19 was finally methylated using MeI and K2CO3 to give normorphan 16. 
Even though the starting materials for the methodology are readily available, the high 





In 2011, Nevado and co-workers47 developed a methodology for the regioselective oxidative 
difunctionalisation of unactivated alkenes. However, while their methodology was not aimed 
at the synthesis of the normorphan scaffold, they found that while using sulfonamides 20, a 
gold catalyst and hypervalent iodine compound 21, their substrates rearranged to form 
benzo-fused normorphans 22 in moderate to good yields as single diastereomers (Scheme 
1.5). Due to the need for the electron rich phenyl groups in the starting material, this 
methodology has a very limited substrate scope. 
 
Scheme 1.5 
Another racemic approach for the synthesis of the normorphan core was reported in 2014 by 
Xue and co-workers.48 Here, they found that treating cyclohexanone 23 with DPPA  and 
Et3N gave normorphan 2 in 76% yield via a Curtius rearrangement into isocyanate 24 which 
was trapped by an enolate generated from the ketone in 23 (Scheme 1.6). Unfortunately, no 





On the other hand, Grainger and co-workers29,49 studied the semipinacol rearrangement of 
cis-fused β-lactam diols as a way to access bridged bicyclic lactams such as normorphans. 
In their work, β-lactam 25 was treated with triphenylphosphine and C2Cl6 at reflux to afford 
normorphans 26 in good to excellent yields (Scheme 1.7). This transformation occurs via a 
cyclic phosphorane 27 formed from the diol present in lactam 25 and in situ generated 
Ph2PCl2 which undergoes migration to release Ph3PO and form the ketone in the 2-position. 
However, even though this methodology gave normorphans 26 in good to excellent yields 
with different protecting groups, the lengthy five-step sequence required to access β-lactam 
25 is its main drawback. 
 
Scheme 1.7 
A concise and flexible route to access normorphan 26 was reported by Bonjoch and co-
workers50 in 2015. Thus, trichloroamidoketones 28 were treated with pyrrolidine in toluene 
under µW irradiation to give normorphans 26 respectively in moderate to excellent yields 
(Scheme 1.8). Additionally, trichloroamidoketones 28 were easily obtained in a three-step 
sequence with a single purification from cyclohexanone 29 and the corresponding amine. Of 
note, Bonjoch’s methodology tolerated different functionalities both in the 3- and 5-positions 






A different approach for the synthesis of the normorphan scaffold was reported in 2017 by 
Lin and co-workers.51 Treatment of N-Ts enynamides 30 with AlCl3 afforded a wide variety 
of 2-chloro normorphans 31 in moderate to good yields (Scheme 1.9). 
 
Scheme 1.9 
As a final example, Dong and co-workers52 described a Pd-catalysed cyclisation of alkyne-
linked cyclohexanones into normorphans in 2019. While mostly applicable to 6-oxa-
bicyclo[3.2.1]octanes, they reported that when cyclohexanone 32 was treated with 
[Pd(allyl)Cl]2 and bis-phosphine (S,S)-33, CsOPiv and benzoic acid at 130 °C, normorphan 
34 was obtained in 42% yield as a 70:30 mixture of diastereomers (Scheme 1.10). Of note 
is the use of enantiomerically pure ligand (S,S)-33 which was required for the sole purpose 
of increasing the diastereoselectivity of the reaction. Accordingly, no enantioselectivities 





1.3.3 Overview of Asymmetric Approaches to the Normorphan Scaffold 
Successful examples of the asymmetric synthesis of normorphans are quite scarce.53 In 2014, 
Chemler and co-workers54 reported a methodology for asymmetric normorphan synthesis 
similar to that of Nevado and co-workers (see Scheme 1.5) which proceeded via a Cu-
catalysed carboamination. Use of sulfonamide 35, Cu(OTf)2, a chiral bisoxazoline ligand 
(R,R)-36, K2CO3 and MnO2 at 110 °C afforded the benzo-fused normorphan 37 in 76% yield 
and 97:3 er (Scheme 1.11). Unfortunately, however, only a modest diversity of substituents 
in the aromatic ring could be accommodated, with substitution outside the aromatic ring 
causing complete inhibition of the reaction. 
 
Scheme 1.11 
During their studies into the racemic synthesis of normorphans, Bonjoch and co-workers50 
briefly explored the use of chiral amino acid-derived organocatalysts for the cyclisation step. 
However, they found that while (S)-prolinamide (S)-38 gave the best result, normorphan 26 
was obtained in only 50% yield and 81:19 er (Scheme 1.12). Several other (S)-proline and 
amino acid-derived organocatalysts were explored with little to no success. Due to the poor 






Finally, in 2019 whilst the work described in this thesis was being carried out, Ye and co-
workers53 reported an asymmetric variant of a Conia-Ene type carbocyclisation for the 
synthesis of normorphans.  Alkyne-linked cyclohexanones such as 39 were treated with 
chiral amine (R)-40 to give normorphan 41 in 53% yield and 95:5 er (Scheme 1.13). This 
represents one of the only examples of the successful asymmetric synthesis of the 
normorphan scaffold. This methodology could accommodate diverse substitution on the 
aromatic ring. However, non-aromatic substituents on the alkyne led to the production of a 
[3.3.1]nonane scaffold instead of the [3.2.1]octane (see Section 1.4.3). Diverse 
functionalisation of the normorphan scaffold was explored such as hydrogenation of the 





1.4  Morphan 2-Azabicyclo[3.3.1]nonane Scaffold 
1.4.1 Introduction to the Morphan Scaffold 
Morphan-derived scaffolds have long been of great interest in synthetic chemistry primarily 
due to their extensive presence in natural products such as those from the daphniphyllum 
and strychnos alkaloid families,55-57 and their presence in diverse compounds of 
pharmaceutical interest.58-61 Accordingly, the investigation of synthetic methods and 
applications for the morphan scaffold are continuously on the rise. The morphan scaffold 
has as its core a bicyclic [3.3.1]nonane structure where the 2-position has been replaced with 
an amino group (Figure 1.13). This amine, together with the diverse substitution patterns 
that arise from the different synthetic approaches allow for a varied set of functionalisation 
vectors in pharmaceutical space. The 3-dimensionality of the morphan core along the regions 
of pharmaceutical space it can occupy (see Figure 1.9) make it an adequate candidate as a 
medicinal chemistry building block. 
 
Figure 1.13 - Morphan bicyclo[3.3.1]nonane scaffold 
In the context of natural products, the morphan core is present in a wide variety of alkaloids 
such as daphniyunnine A which is a potent cytotoxic agent55 and morphine which is widely 
known for its therapeutic and anaesthetic properties.62 Meanwhile, FR901483 has found 
application as an immunosupressant59 while morphan 42 and derivatives were reported by 
Thomas and co-workers61 as opioid receptor antagonists. During their studies, Thomas found 
that morphan 42 in particular showed similar potency to Naloxone® for the treatment of 
opioid overdoses without some of the potential side effects associated with it (Figure 1.14). 
Several other natural products contain the morphan scaffold in their structure and have been 
relevant synthetic targets throughout the years. Worthy of mention is strychnine and other 
alkaloids of the strychnos family such as kopsone as well as macrocyclic natural products 





Figure 1.14 - Relevant morphans 
1.4.2 Overview of Racemic Approaches for the Synthesis of the Morphan Scaffold 
A wide variety of synthetic methods for the synthesis of the morphan core have been 
described and the topic has been the focus of various reviews.56 As such, a non-exhaustive 
list of some of the most recent and/or relevant methods to the current work will be presented 
in this Section. In 1982, Mullican and co-workers63 reported a method for the synthesis of 
simple morphans by intramolecular enolate alkylation. In this work, the alkene in allylamine 
43 was cleaved via ozonolysis to give an aldehyde which was reduced to give keto alcohol 
44 after ketal deprotection. Keto alcohol 44 was then mesylated and treated with base to give 
morphan 45 in 26% yield from allylamine 43 (Scheme 1.14). This method has the major 
drawback of requiring a lengthy five-step sequence to access morphan 45 on top of the 





In 1999, Bonjoch and co-workers64 reported a radical ring closure to access morphan 
scaffolds. Treating trichloroamidoketone 28 with TMSI and HMDS at –20 °C gave silyl enol 
ether 46 which was cyclised and de-chlorinated by treatment with Bu3SnH and AIBN at 
reflux to give morphan 47 in 70% yield from 28 (Scheme 1.15). This work represented a 
significant improvement over previous methods for the synthesis of morphans. However, the 
harsh conditions necessary for the cyclisation presumably meant that no additional 
substitution was explored by Bonjoch. 
 
Scheme 1.15 
Another racemic route to access the morphan scaffold was described by Bonjoch and co-
workers in 2005.65 In this work, Bonjoch used a Pd-catalysed enolate alkenylation to 
generate the morphan core from the Daphniphyllum alkaloid family (see Figure 1.14). Use 
of ketone 48, PhOK and Pd(PPh3)4 in THF at reflux gave morphan 49 in 45% yield (Scheme 
1.16). However, since the development of this methodology was made in the context of 
synthesising the morphan core for the Daphniphyllum alkaloid family, no further exploration 
of the scope was performed. 
 
Scheme 1.16 
On the other hand, Chiba and coworkers66 described the synthesis of diverse morphan 
scaffolds via Mn(III)-mediated reactions of cyclopropanols with vinyl azides. In this work, 
it was found that when vinyl azides 50 were reacted with cyclopropyl fused cyclopentanols 
51 in the presence of Mn(III), 1-hydroxy-morphans 52 were formed in moderate to excellent 
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yields and diastereoselectivities (Scheme 1.17). The reaction proceeds via formation of 
cyclohexanone carbon-centred radical 53 which adds to the vinyl azide with loss of N2 to 
form a nitrogen-centred radical 54. This nitrogen-centred radical then adds to the ketone to 
form the 1-hydroxy-morphan. Despite the somewhat limited functionality this methodology 
offers, it was demonstrated that further functionalisation such as deoxygenation, reduction 
of the imine or substitution of the hydroxyl group was easily carried out. 
 
Scheme 1.17 
Based on Bonjoch’s work (see Scheme 1.15), Belderrain and co-workers67 described a Cu-
catalysed radical cyclisation of trichloroacetamide 55 into a highly substituted morphan. Use 
of trichloroacetamide 55 with CuCl, TPMA and AIBN in DCE at 60 °C gave morphan 56 in 
55% yield (Scheme 1.18). It is notable that, under these conditions, full de-chlorination did 
not occur. Little substrate scope was investigated by Belderrain, but further functionalisation 
such as diastereoselective de-chlorination, and substitution was described.  
 
Scheme 1.18 
In their effort to develop an asymmetric synthesis for the morphan scaffold, Dixon and co-
workers68 described the use of an organocatalytic intramolecular Michael addition of a 4-
substituted cyclohexanone to obtain the morphan scaffold. Thus, treatment of α,β-
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unsaturated ester 57 with propylamine and benzoic acid in CH2Cl2 afforded morphan 58 in 
89% yield as a single diastereomer (Scheme 1.19). α,β-Unsaturated esters similar to 57 were 
obtained in good yields in three- to four-step sequences with a single purification. However, 
the scope of the reaction was only explored for the developed asymmetric variant which is 
discussed in detail in Section 1.4.3. 
 
Scheme 1.19 
Dixon and co-workers69 reported another approach for the synthesis of morphans from 4-
substituted cyclohexanones in 2017. In this work, use of an alkyne-linked cyclohexanone 
59, pyrrolidine, Cu(OTf)2 and PPh3 in THF led to the formation of morphan 60 in 78% yield 
(Scheme 1.20). The scope of this reaction was only explored further for the asymmetric 
variant (see Section 1.4.3). 
 
Scheme 1.20 
Another method for the synthesis of morphans via Michael addition was described by Yan 
and co-workers70 in 2017. Thus, the reaction between ketene aminals 61 and quinone 
monoketals 62 in water at 60 °C led to the formation of morphans 63 in good to excellent 
yields (Scheme 1.21). This occurs via a Michael addition of the aminal 61 to the quinone 62 
followed by an aza-Michael addition of the aminal nitrogen into the quinone’s second 
alkene. An attractive feature of this reaction is that it is carried out in water with no other 
reagents. The methodology was able to accommodate different electron withdrawing groups 
in the aminal 61 such as NO2, methyl ketone and acetophenone. The method could also 
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accommodate methyl substituents in the 1- and 2-positions of the quinone and different ketal 
protecting groups. However, it has the major drawback of being limited to cyclic ketene 
aminals with no further functionalisation of the product being explored. 
 
Scheme 1.21 
Yan and co-workers71 made use of a similar approach to their ketene aminal variant (see 
Scheme 1.21) by using monoacetal protected quinones 64 and a enaminones 65. As such, 
treating quinones 64 with enaminones 65 and DBU in acetone at reflux afforded morphans 
66 in good to excellent yields (Scheme 1.22). However, their scope was limited to N-Ar and 






As a final example of a racemic approach for the morphan scaffold, the nitroso-ene 
cyclisation reaction has also been used as a way to synthesise morphan cores. In 2017, Hong 
and co-workers72 described a way of accessing the morphan core from an in situ generated 
N-acyl nitroso compound. Amide 67 was treated with n-PrN+IO4
– to generate acyl nitroso 
compound 68 which spontaneously cyclised via a nitroso-ene reaction of 68 to give an N-
hydroxy morphan. The N-hydroxy morphan was then acetylated to give morphan 69 in 85% 
yield and moderate selectivity for the two-step sequence (Scheme 1.23). Different 
functionality in the 8-position of the morphan scaffold was explored such as silyl ethers and 
acyl protected amines. The 6-position of the scaffold could also be replaced by an ether or a 
protected amine motif. Of note, the synthesis of alkaloid (±)-kospone, which is one of the 
simplest alkaloids from the Daphniphyllum family, was achieved using this methodology. 
 
Scheme 1.23 
1.4.3 Overview of Asymmetric Approaches for the Synthesis of the Morphan Scaffold 
Since many of the synthetic methodologies for the morphan scaffold have been developed 
with a view to the total synthesis of one of the many natural products that contain them, there 
are more asymmetric methodologies for the synthesis of this scaffold compared to 
normorphans. In 2009, Bonjoch and co-workers73 developed an organocatalytic 
desymmetrisation of a 4-substituted cyclohexanone under µW irradiation to access the 
morphan scaffold. The approach used cyclohexanone 70, proline-derived organocatalyst (R-
S)-71 and water in CH3CN under µW irradiation to give morphan 72 in 70% yield and 85:15 
25 
 
er (Scheme 1.24). Multiple proline-derived catalysts were explored with little success. 
However, the use of catalyst 71 with water as additive gave a good yield and adequate 
enantioselectivity. Unfortunately, the scope of the reaction to access different substitution 
patterns on the morphan scaffold was not further explored. 
 
Scheme 1.24 
Following this, the same group developed an alternative organocatalysed asymmetric 
synthesis of morphans by making use of a Robinson-type annulation.74 Treatment of 
ketoesters 73 and aldehyde 74 with proline-derived catalyst (R)-75 and water with LiOH 
gave morphans 76 in moderate to good yields and excellent enantioselectivities (Scheme 




Expanding the methodology previously proposed (see Scheme 1.19), Dixon and co-
workers68 developed an asymmetric variant of their organocatalysed Michael addition. 
Replacing propylamine with thiourea (R,R)-77 and using cyclohexanones 78 in CH2Cl2 in a 
sealed tube at 50 °C gave morphans 79 in good to excellent yields with good 
enantioselectivities as single diastereomers (Scheme 1.26). Computational analysis of the 
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organocatalyst used identified relatively simple thiourea (R,R)-77 as a suitable catalyst. 




Another example of the asymmetric synthesis of morphans was described by Jia and co-
workers75 in 2016. Jia developed a Pd/proline- co-catalysed asymmetric arylative 
desymmetrisation of cyclohexanones. For example, treatment of cyclohexanone 80 with (S)-
proline (S)-81, Pd(OAc)2, PPh3, AcOH and K3PO4 in MeOH at 85 °C afforded morphan 82 
in 91% yield and 99:1 er (Scheme 1.27). However, this methodology could only 
accommodate limited substitution in the 4- and 5-positions of the aromatic ring. 
 
Scheme 1.27 
As a complement to their racemic methodology (see Scheme 1.20), Dixon and co-workers69 
described the asymmetric synthesis of morphans using cooperative silver and amine 
catalysis. Thus, treatment of alkyne-linked cyclohexanones 83 with AgNTf2, chiral amine 
(S)-40, chiral phosphine 84 and 2,4-dinitrophenol in i-PrOH gave morphans 60, 85-91 in 
moderate to excellent yields and good to excellent enantioselectivities (Scheme 1.28). It was 
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found that sulfonamides attached to electron releasing groups such as Ts and 4-
MeOC6H4SO2 gave their corresponding morphans 60 and 85 in excellent yields and 
enantioselectivities. Sulfonamides with electron withdrawing groups such as 4-Ns gave 
moderate yields with slightly decreased enantioselectivities (86). By contrast carbamate 
protecting groups such as N-Boc (87) and N-Cbz (88) suffered from diminished yields and 
enantioselectivities. There was also a strong match/mismatch effect between the chiral amine 
and phosphine components of the reaction. 
 
Scheme 1.28 
As a final example, the methodology described by Ye and co-workers53 (see Scheme 1.13) 
could be easily adapted for the asymmetric synthesis of the morphan core. Use of 
cyclohexanones 92 with amine (S)-40 and Et3N in benzotrifluoride afforded morphans 93 in 
good to excellent yields and moderate to excellent enantioselectivities (Scheme 1.29). The 
reaction could easily accommodate a variety of alkyl, alkenyl and aryl substituents in the 4-








1.5 Project Outline 
Over recent years, the use of 3-D shaped building blocks in medicinal chemistry has received 
increased interest. Therefore, there is a need to explore the design and development of 
synthetic methodology to obtain complex, bifunctional, high Fsp3 building blocks for use in 
medicinal chemistry. The synthesis of medicinally-relevant compounds and the development 
of methodology for medicinal chemistry has long been of interest to the O’Brien group. It 
was planned that this project would focus on the design and synthesis of novel bifunctional 
3-D building blocks 94 (normorphan scaffold) and 95 (morphan scaffold) containing a vinyl 
MIDA boronate and an amine or amide functionality for use in medicinal chemistry (Figure 
1.15). It was decided that the development of synthetic methodology for the synthesis of 3-
D building blocks 94 and 95 as both racemic samples and single enantiomers would be 
investigated. Previous work by Bonjoch50 was envisaged as a way to obtain the racemic 
normorphan scaffold in building block 94 and the development of an enantioselective variant 
would be investigated. On the other hand, methodology developed by Dixon69 would be 
utilised to access both the racemic and enantioenriched morphan scaffold in building block 
95. The results of these investigations are presented in Chapters 2 and 3. 
 
Figure 1.15 - Envisaged normorphan and morphan 3-D building blocks 94 and 95 
It was also planned to showcase the potential of the building blocks by outlining different 
functionalisation reactions that could be achieved with them. This would be done by 
exploring the scope of Suzuki-Miyaura cross couplings on the vinyl MIDA boronate 
functionality, demonstrating the diastereoselective hydrogenation of the building block as 
well as deprotection for the amide or amine protecting group. In the end, these studies were 
carried out only on building block 94 and the results are presented in Chapter 4.
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Chapter 2 Design and Synthesis of a Normorphan-Derived 3-D 
Building Block 
In this Chapter, the design and development of synthetic methodology required to access 
3-D building block 94 (Figure 2.1) is described. Section 2.1 covers the design 
considerations and the vector analysis of various derivatives of 94 as well as the proposed 
synthetic strategy towards the 3-D building block. Section 2.2 discusses the synthesis of 
the building block, alongside optimisation of the cyclisation, enol triflate formation and 
borylation reactions. Section 2.3 outlines different approaches for the synthesis of 
enantioenriched building block 94 including studies on an organocatalytic cyclisation 
approach as well as a resolution approach with chiral MIDA boronate derivatives. Finally, 
Section 2.4 provides an overview of the results presented in this chapter.  
 
 





2.1 Design Considerations, Vector Analysis and Proposed Route for the Synthesis of 
a Normorphan-Derived 3-D Building Block 
With the prominence of the bicyclo[3.2.1]octane core in the medicinal chemistry 
literature25,41,76 and the available synthetic routes to diverse substitution patterns on these 
normorphan bicyclic cores presented in Section 1.3, our attention turned to a 6-aza-
bicyclo[3.2.1] bifunctional building block 94 with a 2-substituent as our first target (Figure 
2.2). It was envisaged that building block 94 could be obtained based on previous work by 
Bonjoch et al.50 as presented in Section 1.3.2. 
 
Figure 2.2 - Normorphan building block 94. 
It was expected that the bicyclic structure in building block 94 would provide conformational 
rigidity to allow for a set of predictable vectors from the functionalisation handles. With this 
in mind, the set of elaboration vectors were calculated for a group of structures which we 
hypothesised could be easily accessed by simple, reliable reactions. For example, Suzuki-
Miyaura cross-coupling on building block 94 should give arylated normorphan 96 which 
could be: (i) immediately deprotected and N-functionalised to give amides 97 and 98; (ii) 
hydrogenated diastereoselectively then deprotected and N-functionalised to give amides 99 
and 100; (iii) reduced into amine 101 then hydrogenated and functionalised to give amines 
102, 103 and 104 or (iv) reduced into amine 101 then deprotected and functionalised to give 
amines 105, 106 and 107 (Scheme 2.1). For the hydrogenation steps, we predicted that 






The set of structures shown in Scheme 2.1 gives an idea of the different elaboration vectors 
that can be achieved with building block 94. Using a Pipeline Pilot protocol previously 
developed in the O’Brien group,77 the lowest energy conformer for each molecule was 
generated using molecular mechanics. On these conformers, the set of variation vectors for 
each molecule was selected and then calculated using an algorithm developed by 
Grygorenko and co-workers19 to give the results shown in Figure 2.3. Figure 2.3a defines 
the vectors for the case of a 1,4 disubstituted cyclohexane, namely, the distance between the 
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variation points C1 and C2, r, the plane angles Φ1 (between vector n1 and C1-C2) and Φ2 
(between vector n2 and C1-C2) and the dihedral angle θ defined by the vectors n1, C1-C2 
and n2. 
Comparing our set of vectors to those calculated by Grygorenko and co-workers19,20  for a 
variety of cyclic compounds reveals that building block 94 has vectors that lie outside the 
clusters normally associated with simple 3- to 7-membered cyclic scaffolds (see Section 1.2). 
They also have distinct vectors compared to a diverse set of [3.3.n]propellanes23 and 
cyclobutyl-azetidine-based scaffolds synthesised by the same group.22 Our set also shows a 
good level of conformational rigidity where most of the structures are clustered together in 
the r-θ plot (Figure 2.3b). However, some changes are observed between the hydrogenated 
products and their parent compounds with distinct clusters differing mainly by the Φ1 angle 
due to the change in hybridisation on the variation point C1. Additionally, N-methyl 
derivatives of the amine-based scaffold 103 and 106 seem to be outliers with regards to 
angles θ, Φ1 and Φ2 (Figure 2.3b,c,d), This, due to the sp
3 hybridization of nitrogen and its 




Figure 2.3 - Vector analysis for building block 94 in: a) r-θ plot (polar coordinates); b) visual representation 
of variation vectors; c) Φ1-Φ2 plot; c) θ-Φ1/Φ2 plot.  
Our initial proposed route for the synthesis of 3-D building block 94 is outlined in Scheme 
2.2. As previously mentioned, the scaffold construction is based on previous work by 
Bonjoch et al.50 and the route reported by Bonjoch appeared to offer a quick and reliable 
way to access the racemic normorphan scaffold from an organocatalytic cyclisation of a 
trichloroacetamide (see Scheme 1.8). Using this approach, we envisaged that 
trichloroamidoketone 108 could be obtained from monoprotected cyclohexadione 29 in three 
steps and then, using Bonjoch’s organocatalytic cyclisation, we could obtain normorphan 
scaffold 109. After the cyclisation, elaboration into vinyl MIDA boronate 94 was envisioned 
via vinyl triflate formation to give 110, followed by a Pd-catalysed Miyaura borylation78 
using B2pin2 to give vinyl pinacol boronate 111 and transesterification sequence to introduce 
the MIDA group. Additionally, it was hoped that an asymmetric organocatalytic variant of 





In Bonjoch’s work, a benzyl group was used as the protecting group for the amine (see 
Scheme 1.8). However, in the case of amides, benzyl groups are notoriously hard to 
deprotect.79 Therefore, we proposed the use of 2,4-dimethoxybenzyl (DMB) protection since 
it should be more easily removed under either acidic or oxidative conditions during further 
functionalisation of the building block. A different protecting group such as Boc was not 
selected as we were unsure of the effect of an imide in the pyrrolidine-catalysed cyclisation. 
Finally, it is worth noting that the decision of using a vinyl MIDA boronate in the finalised 
building 94 block arose from the fact that MIDA boronates, popularised by Burke and co-
workers,80-82 tend to be easy to handle, bench-stable, crystalline solids, that are easily 




2.2 Development of a Racemic Synthesis of a Normorphan-Derived 3-D Building 
Block 
To begin the studies towards the synthesis of the desired building block, it was necessary to 
access trichloroacetamide 108. To this end, the previously reported synthesis for the N-Bn 
variant of the trichloroacetamide 28 by Bonjoch and co-workers50 (see Scheme 1.8) was used 
as a model to obtain the N-DMB derivative 108. Reductive amination of 1,4-cyclohexadione 
monoethylene acetal 29 (5.6 mmol scale) with a stoichiometric amount of 2,4-
dimethoxybenzylamine and using NaBH(OAc)3 (1.4 eq.) as a reducing agent quantitatively 
afforded the crude amine that was, after work-up, sufficiently pure for the next reaction. 
Hydrolysis of the ketal with 3 M HCl(aq) quantitatively gave the crude ketone as a sufficiently 
pure product that was taken on to amide formation using an excess (1.8 eq.) of trichloroacetyl 
chloride in the presence of Et3N (1.9 eq.). After purification by chromatography, 




Formation of trichloroacetamide 108 was confirmed by HRMS and both 1H and 13C NMR 
spectroscopy where, despite the presence of rotamers (65:35 ratio) about the amide’s C–N 
bond, diastereotopic signals were observed for the attached DMB group (δH 4.60–4.52 (m, 
1.3H, ArCHN), 4.04–3.92 (m, 0.35H, ArCHN), 3.84–3.74 (m, 6.35H, ArCHN, OMe)). 
Additionally, the 13C NMR spectrum showed signals at δC 93.8 and 160.7 that were assigned, 
by analogy with the N-Bn variant 28 (δC 93.5, 160.5),
64 as the CCl3 and C(O)N signals 
respectively.  
Scale-up of the procedure to 26 mmol of substrate gave a 90% yield of amidoketone 108 
when purified by chromatography (Scheme 2.3). However, since it was desired to achieve a 
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more efficient purification, avoiding the large amounts of solvent and silica required for 
chromatography, an alternative purification was attempted on a 26 mmol scale. With the 
knowledge that the N-Bn variant can be purified by recrystallisation from Et2O, purification 
by triturating the crude product with Et2O was attempted. This gave trichloroacetamide 108 
in 60% yield which, despite being significantly lower than that obtained using 
chromatography, provides a useful alternative when purifying this early-stage product in 
large quantities. 
Next, trichloroacetamide 108 was subjected to an organocatalytic cyclisation using 
Bonjoch’s conditions50 with pyrrolidine to afford normorphan 109. This reaction proceeds 
via formation of enamine 112 from pyrrolidine and the ketone, with enamine 112 adding to 
the trichloroacetamide with concomitant elimination of –CCl3. However, initial results using 
toluene as a solvent at reflux gave normorphan 109 in only 45% yield (Scheme 2.4). The 1H 
NMR spectrum of normorphan 109 showed the expected signal of the newly formed CH α 
to the two carbonyl groups as a doublet at δH 3.18, having only one significant coupling (
3J 
= 5.0 Hz) to one of the methylene bridge protons and a negligible coupling to the other.  
 
Scheme 2.4 
With this result in hand, we set out to find an adequate set of conditions for this cyclisation 
reaction (Table 2.1). Increasing the reaction time from 45 min to 3 h at reflux in toluene had 
a detrimental effect on the yield (33% of 109, Entry 2). Thus, using the alternative method 
proposed by Bonjoch, a change into neat, sealed tube conditions and lowering the pyrrolidine 
equivalents was made. In this way, a good yield (63%) of normorphan 109 was obtained 
(Entry 3). Finally, since solubility problems were observed in the early stages of the reaction, 
we wondered whether increasing the equivalents of pyrrolidine to 1.0 and adding a small 
amount of toluene (4.0 M concentration) could prove beneficial. To our delight, this set of 
conditions afforded the best, most reproducible result (80% of 109, Entry 4). Using these 
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conditions, normorphan 109 was isolated in 80% yield on a 1.22 mmol scale with no erosion 
of the yield when scaled up to 17.1 mmol scale (Entry 5). 













1 2.0 Toluene 0.3 Reflux 45 
min 
0.49 45 RBFd 
2 2.0 Toluene 0.3 Reflux 3 h 0.98 33 RBFd 
3 0.5 Neat 100 1 h 1.22 63 Sealed 
tube 
4 1.0 Toluene 4.0 100 1 h 1.22 80 Sealed 
tube 
5 1.0 Toluene 4.0 100 1h 17.1 80 Sealed 
tube 
a) Concentration of substrate (mmol/mL); b) Temperature measured in oil bath; c) Isolated % yield; d) 
RBF = round-bottomed flask. 
 
With an optimised cyclisation in hand, vinyl triflate formation from the ketone in 
normorphan 109 was the next step to be investigated. Relying on Bredt’s rule for 
regioselectivity and a reported literature procedure83 for a similar normorphan that lacked 
the amide, use of LDA as a base and PhNTf2 as a triflate source was attempted. Thus, 
normorphan 109 was treated with LDA at –78 °C in THF to give the enolate which was 
trapped with PhNTf2 to give vinyl triflate 110 in 30% yield after purification by 
chromatography (Scheme 2.5). Vinyl triflate formation was confirmed by 1H NMR 
spectroscopy, in which a narrow 1H multiplet was observed at δH 5.56–5.51 and assigned to 
the alkene CH. 13C NMR spectroscopy also showed a quartet (J = 320.0 Hz) at δC 118.6 
corresponding to the CF3 carbon. Signals corresponding to the newly-formed alkene at δC 






A range of conditions were then explored with the aim to increasing the yield for the 
formation of vinyl triflate 110 (Table 2.2). We first attempted to change  the triflate source 
to a more reactive triflimide (Comins’ reagent 113) which has shown use with unreactive 
substrates in previous studies.84 However, only a marginal increase in yield was observed 
(33% of 110, Entry 2) suggesting issues with deprotonation of ketone 109 rather than 
problems with trapping the formed enolate. Thus, a brief screen of bases was performed. 
Using LiHMDS and Comins’ reagent gave only traces of enol triflate 110 (Entry 3). 
Changing to NaHMDS showed promise giving 110 in 54% yield (Entry 4). However, the 
product from this reaction was isolated as an 85:15 mixture with triflamide 114, derived 
from Comin’s reagent, that proved impossible to separate by chromatography. On the other 
hand, using KHMDS as a base and returning to PhNTf2 as the triflate source gave only traces 
of product (Entry 5). It has been suggested85 that a wash with cold 1 M NaOH(aq) in the work-
up can be effective at removing side-products from the triflating agent. Following this, using 
NaHMDS with both PhNTf2 and Comins’ reagent 113 gave vinyl triflate 110 as a pure 
product albeit in a diminished yield suggesting decomposition of 110 in the work-up (Entries 
6 and 7). Finally, using NaHMDS and PhNTf2 as a triflate source without the NaOH wash 
gave vinyl triflate 110 in a moderate and consistent yield (Entry 8) but increasing the reaction 
time proved detrimental to the yield (Entry 9). Thus, using NaHMDS as a base and PhNTf2 
as the triflate source with a trapping time of 18 h and without a NaOH wash in the work-up 
proved to be the most effective way to obtain vinyl triflate 110. These conditions also 
allowed the reaction to be scaled up to 12.3 mmol scale without any detrimental effect on 






Table 2.2 - Formation of vinyl triflate 110 
 




1 LDAb 1.2 PhNTf2 1.4 18 30 
2 LDAb 1.2 113 1.3 72 33c 
3 LiHMDS 1.4 113 1.3 18 10d 
4 NaHMDS 1.3 113 1.3 18 54e 
5 KHMDS 1.3 PhNTf2 1.4 18 8 
6 NaHMDS 1.8 PhNTf2 1.3 18 45
f 
7 NaHMDS 1.8 113 1.3 18 36f 
8 NaHMDS 1.8 PhNTf2 1.3 18 61
g 
9 NaHMDS 1.8 PhNTf2 1.3 48 33 
a) Isolated % yield; b) Prepared in situ by the addition of n-BuLi to i-Pr2NH; c) Isolated 
as an 80:20 mixture with 114; d) Estimated by 1H NMR spectroscopy; e) Isolated as 
an 85:15 mixture with 114; f) cold 1 M NaOH(aq) wash; g) 12.3 mmol scale 
 
The next step involved converting vinyl triflate 110 into vinyl pinacol boronate intermediate 
111 and then into the desired vinyl MIDA boronate 94. This was initially attempted using a 
literature procedure,78 with dppf as a ligand for the Pd and KOAc as base, which gave vinyl 
pinacol boronate 111 as an inseparable mixture with B2pin2 derived impurities which was 
submitted to vinyl MIDA boronate formation. This was carried out using a large excess of 
MIDA and HC(OEt)3 at 100 °C in DMSO,
86 giving vinyl MIDA boronate 94 in 20% yield 





Formation of both vinyl pinacol boronate 111 and vinyl MIDA boronate 94 was confirmed 
by HRMS and NMR spectroscopy. Particularly, for vinyl pinacol boronate 111, the signal 
corresponding to the alkene proton shifted downfield from δH 5.56–5.51 in vinyl triflate 110 
to δH 6.40–6.37 in vinyl pinacol boronate 111. Additionally, the signal corresponding to the 
C–OTf carbon resonance in vinyl triflate 110 which was observed at δC 148.4 disappeared 
for the newly formed C–Bpin in vinyl pinacol boronate 111. This is due to coupling between 
the carbon and the quadrupolar boron atom which gives rise to signals that occasionally are 
not well resolved in the 13C NMR spectrum.87 On the other hand, for vinyl MIDA boronate 
94, the signal corresponding to the alkene signal was observed at δH 5.98 (ddd, J = 3.0, 3.0, 
3.0 Hz). Additionally, the incorporation of the MIDA moiety on building block 94 was 
confirmed with the proton signals corresponding to the two diastereotopic CH2 groups. Three 
of these protons appeared alongside one of the benzylic protons at δH 4.27–4.07 (m, 4H), 
with the other one coming at δH 3.96 (d, J = 17.0 Hz, 1H). The N-Me signal was also observed 
as a 3H singlet at δH 2.84. Finally, the 
13C NMR spectrum showed the alkene CH signal at 
δC 134.1 with signals for quaternary protons appearing at δC 169.2 and 167.9 which were 




Figure 2.4 - Key 1H and 13C NMR spectroscopic signals for building block 94. 
With building block 94 in hand and the observed problems in the formation of vinyl pinacol 
boronate 111, our attention turned to finding conditions suitable for the synthesis of vinyl 
MIDA boronate 94 in higher yield. It has been reported88 that for challenging substrates 
changing the ligand in Miyaura’s borylation to PPh3 and the base to KOPh can give better 
results. However, use of these conditions in toluene with vinyl triflate 110 gave only impure 
vinyl pinacol boronate 111 after chromatographic separation. With this result and upon 
performing 2-D TLC analysis of the impure pinacol boronate 111, it was concluded that 
decomposition under chromatography conditions was occurring. Nonetheless, this impure 
product was submitted to the previously used MIDA boronate formation conditions, 
affording a 54% yield of vinyl MIDA boronate 94 over the two steps (Table 2.3, Entry 1). 
With these results in hand, and the evidence of vinyl pinacol boronate 111 decomposition 
under column chromatography conditions, Miyaura’s borylation was once more attempted 
and the crude product directly submitted to MIDA boronate formation. This gave a 70% 
yield of vinyl MIDA boronate 94 over the two steps. However, a significant amount of 
alkene 115 (17%) was also observed for reactions in which vinyl pinacol boronate 111 was 
not purified (Entry 2). Additionally, since the formation of vinyl MIDA boronate 94 required 
a large excess of both of the reagents used, an attempt at diminishing the equivalents of 
MIDA from 6.5 to 4.0 and of HC(OEt)3 from 4.5 to 4.0 was made. However, a decrease in 
the yield of vinyl MIDA boronate 94 to 60% was observed while the isolated quantity of 
alkene 115 remained mostly similar (Entry 3). The formation of alkene 115 was determined 
from its characteristic alkene signals. Namely, two signals were observed at δH 6.07 (dddd, 
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J = 9.0, 7.5, 1.0, 1.0 Hz, 1H) and 5.51 (dddd, J = 9.0, 3.5, 3.0, 1.5 Hz, 1H) which were 
consistent with the two alkene protons in 115. Likewise, the 13C NMR spectrum showed two 
signals corresponding to =CH carbons at δC 129.2 and 126.0. 











1 6.2 4.0 54 N.D.b 
2c 6.5 4.5 70 15 
3c 3.0 4.0 60 17 
a) % yield after chromatography; b) not determined; c) no intermediate 
purification of pinacol boronate 111 was attempted.  
 
Additional 1H NMR spectroscopic analysis of the crude mixtures for both the intermediate 
vinyl pinacol boronate 111 and the vinyl MIDA boronate 94 indicate that alkene 115 seems 
to be generated primarily as a by-product of Miyaura’s borylation step, presumably by a 
protodeborylation-type process. This is evidenced by the appearance of the signals 
associated with the alkene protons in 115, and their ratios with respect to the alkene signals 
in both 111 and 94 in the crude spectra for both reactions (Figure 2.5). This together with 
the fact that Entry 4 (Table 2.3) gave a diminished yield for MIDA boronate 94 but a similar 
yield for alkene 115 when compared to Entry 3, leads us to conclude that alkene 115 is 
mainly a product that arises from the Miyaura borylation of vinyl triflate 110 into vinyl 




Figure 2.5 - 1H NMR spectrum of the crude product of the Miyaura borylation reaction (blue) and subsequent 
MIDA transesterification (red). 
Thus, the synthesis of vinyl MIDA boronate building block 94 was achieved with a 30% 
overall yield on a multigram-scale from ketone 29 (Scheme 2.7). This was accomplished 
using a three-step sequence to give amidoketone 108, followed by an organocatalytic 
cyclisation into normorphan 109 and finishing with a vinyl triflate formation to give 110 and 





2.3 Investigation of Routes for the Synthesis of Enantioenriched Normorphan-
Derived 3-D Building Block 
With the need to obtain enantioenriched building block 94, two alternative and 
complementary strategies to achieve this were envisaged. Based on the literature precedent 
presented in Section 1.3.3, we hypothesised that an asymmetric variant for the 
organocatalytic cyclisation could be developed to access the enantioenriched normorphan 
scaffold. The second strategy would be based on a resolution approach based on chiral 
MIDA derivatives.  
The organocatalytic cyclisation approach would require the exploration of different 
organocatalysts to those tried by Bonjoch50 to improve both the yield and enantioselectivity. 
Thus, we set out to find a small set of catalysts which could prove adequate to allow the 
asymmetric cyclisation of 108 into 109. Previous research by Bonjoch and co-workers50 
identified commercially available (S)-prolinamide (S)-38 as a possible catalyst for this 
transformation (see Scheme 1.12). On the other hand, Dixon’s68 thiourea (R,R)-77 (see 
Scheme 1.26) presented itself as a suitable option that could be synthesised in two steps with 
a single purification. Finally, Tang-and coworkers89 outlined the use of thiourea (S)-116 
which could be also be obtained in two steps with a single purification (Figure 2.6). 
 
Figure 2.6 - Possible organocatalysts identified for the asymmetric cyclisation 
Having assembled this short list of possible catalysts, we set out to synthesise them. As 
previously mentioned, catalyst (R,R)-77 could be synthesised in two steps from 
commercially available N-Boc-diamine (R,R)-117 and methyl isothiocyanate, which in our 
hands gave a 90% yield of (R,R)-118. Subsequent deprotection and free-basing of the 
hydrochloride salt afforded thiourea (R,R)-77 in an 86% overall yield (Scheme 2.8). 
Likewise, thiourea (S)-116 was prepared in two steps by using N-Boc pyrrolidine (S)-119 
and the appropriate isothiocyanate 120 to afford (S)-121 in 85% yield which was deprotected 
and free-based quantitatively to afford thiourea (S)-116 (Scheme 2.9). Data for both 








With our catalysts in hand and Bonjoch’s precedent, we first attempted the asymmetric 
cyclisation of 108 into 109 using (S)-prolinamide (S)-38. Thus, use of trichloroamidoketone 
108 with (S)-prolinamide (S)-38 in DMSO at 50 °C for 5 days gave normorphan 109 in 25% 
yield and 77:23 er (Scheme 2.10). This was consistent the result previously obtained by 
Bonjoch50 with the N-Bn analogue (see Scheme 1.12). The er was determined using chiral 
stationary phase HPLC in comparison with a racemic standard. Unfortunately, we were not 
able to determine the absolute configuration of the major enantiomer. 
 
Scheme 2.10 
Following this, use of Dixon’s thiourea (R,R)-77 under the reported conditions68 was 
attempted. However, using trichloroamidoketone 108 with thiourea (R,R)-77 and PhCOOH 
in CH2Cl2 in a sealed tube at 50 °C for 7 days gave no product (Entry 2). Using our initial 
conditions of trichloroamidoketone 108 in DMSO with thiourea (R,R)-77 at 50 °C for 5 days, 
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normorphan 109 was obtained in 12% yield and 60:40 er (Entry 3). Finally, use of thiourea 
(S)-116 as catalyst in DMSO at 50 °C for 5 days gave a 30% yield of normorphan 109 in 
only 55:45 er (Entry 4). Due to these disappointing yields and enantioselectivities, no further 
work was carried out on this approach. 
Table 2.4 - Asymmetric cyclisation of 108 into 109 
 
Entry Catalyst Conditions Time Yielda 
(%) 
erb 
1 (S)-38 (50 mol%) DMSO, 50 °C 5 days 25 77:23 
2 (R,R)-77 (10 mol%) PhCOOH (0.05 eq.), 
CH2Cl2, 50 °C 
7 days No Reaction 
3 (R,R)-77 (50 mol%) DMSO, 50 °C 5 days 12 60:40 
4 (S)-116 (50 mol%) DMSO, 50 °C 5 days 30 55:45 
a) % yield after chromatography; b) er determined using chiral stationary phase HPLC 
 
Next, we considered the resolution approach using chiral MIDA derivatives. Previous 
research by Cheon and co-workers90 had shown that racemic BINOL-derived boronic acid 
122 could be resolved by converting it into their diastereomeric MIDA* boronates 123a and 






Likewise, Burke and co-workers81 described the resolution of racemic  carbon-centred sp3 
boronic acids using chiral MIDA derivative 125. In one example, racemic boronic acid rac-
126 was reacted with chiral MIDA 125 to give separable B(MIDA*) derivatives 127a and 
127b in good yields (Scheme 2.12). In Burke’s approach, the produced chiral MIDA* 
boronates 127a/127b were hydrolysed in situ in order to perform a stereoretentive Suzuki-
Miyaura cross-coupling reaction.  
 
Scheme 2.12 
As such, we planned to explore different chiral MIDA* derivatives that would allow us to 
obtain diastereomeric vinyl MIDA* boronates which we could then separate using 
chromatography. The chiral MIDA* derivatives utilised by Cheon and Burke were proposed 
alongside a simpler α-methyl-cyclohexylamine derived MIDA*. However, in our hands, 
when attempting the transesterification reaction for this substrate with the chiral MIDA 
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derivatives, negligible formation of the desired vinyl MIDA* boronates 128a and 128b was 
observed. Instead, we observed mainly the formation of alkene 115 (Scheme 2.13). At this 






To summarise, the racemic synthesis of normorphan 3-D building block 94 was achieved in 
30% overall yield over seven steps. This was achieved via a three-step sequence to form 
amidoketone 108 that was submitted to an organocatalytic cyclisation with pyrrolidine to 
give the normorphan scaffold. Normorphan 109 was converted into the vinyl triflate 110 and 
finally into the MIDA boronate 94 by a telescoped borylation-transesterification sequence. 
Two different approaches for the synthesis of enantioenriched 3-D building block 94 were 
also explored. Initial approaches exploiting the organocatalytic cyclisation with three chiral 
catalysts attempted with little success, with (S)-prolinamide (S)-38 affording the best results 
giving the desired scaffold 109 in 25% yield and 77:23 er. Chiral thioureas developed by 
Dixon and Tang were also explored with little success. Likewise, attempting to resolve the 
formed diastereomers of the chiral derived MIDA* boronates was not fruitful since alkene 
115 was the main product. 
Suzuki-Miyaura cross coupling alongside further functionalisation of the synthesised 
normorphan 3-D building block towards lead-like compounds is described in Chapter 4. 
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Chapter 3 Design and Studies Towards the Synthesis of a 
Morphan-Derived 3-D Building Block 
The design and development of synthetic methodology towards accessing 3-D building 
block 95 (Figure 3.1) is described in this chapter. The design considerations and vector 
analysis of various derivatives of 95 as well as the proposed synthetic strategy towards the 
3-D building block are discussed in Section 3.1. Section 3.2 discusses initial approaches 
for the synthesis of the building block using N-sulfonamide protected derivatives while 
Section 3.3 describes the synthesis of the normorphan building block 95 from an N-Boc 
protected amine. Finally, an overview of the results presented in this chapter and future 
work are discussed in Section 3.4.  
 
 





3.1 Design Considerations, Vector Analysis and Proposed Route for the Synthesis of a 
Morphan-Derived 3-D Building Block 
The bicyclo[3.3.1]nonane core is an important structural motif that is found in a diverse 
range of bioactive molecules and natural products.55,59,91 As such, many synthetic routes for 
different substitution patterns on these morphan bicyclic cores have been developed (see 
Section 1.4).  With this in mind, our attention turned to 2-aza-bicyclo[3.3.1]nonane 
bifunctional building block 95 with a 4-methyl substituent as our next target (Figure 2.2). It 
was envisaged that building block 95 could be obtained based on some of the previous work 
developed by Dixon et al.69 which was presented in Section 1.4.2. 
 
Figure 3.2 - Morphan building block 95. 
As in the case of normorphan building block 94 (see Section 2.1), it was expected that the 
bicyclic structure in building block 95 would provide conformational rigidity and a set of 
predictable functionalisation vectors. With this in mind, the set of elaboration vectors was 
calculated for a group of structures which we hypothesised could be easily accessed by 
simple, reliable reactions as previously established for building block 94. For example, 
Suzuki-Miyaura cross-coupling on building block 95 should give arylated morphan 129 
which could be: (i) immediately deprotected and N-functionalised to give amines 130-132 
(ii) hydrogenated diastereoselectively then deprotected and N-functionalised to give amines 
133-135 (Scheme 3.1). Similar to normorphan scaffold 94, we predicted that hydrogenation 








The set of structures shown in Scheme 3.1 gives an idea of the different elaboration vectors 
that could be achieved with 3-D building block 95. By following the same procedure as that 
for normorphan 3-D 94 (see Section 2.1), the set of variation vectors for each molecule was 
selected and then calculated using Grygorenko and co-workers’19 algorithm to give the 
results shown in Figure 3.3.  
Similar to the case of normorphan building block 94, morphan building block 95 has a set 
of elaboration vectors that lie outside the clusters normally associated with simple 3- to 7-
membered ring cyclic scaffolds (see Section 1.2) whilst also having distinct vectors from the 
set of [3.3.n]propellanes23 and cyclobutyl-azetidine based scaffolds synthesised by the same 
group.19,20,22 The set shows slightly lower conformational rigidity where the structures 
appear to be more loosely clustered than those previously calculated for normorphan 94 in 
the r-θ plot (Figure 3.3b). This is likely due to the larger ring sizes in the morphan 95 
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[3.3.1]nonane bicyclic core compared to the [3.2.1]octane in the normorphan 94. Just as 
observed for normorphan 94, some changes are observed between the hydrogenated products 
and their parent compounds which are observed by distinct clusters differing mainly by the 
Φ1 angle due to the change in hybridisation on the variation point C1. Additionally, N-phenyl 
derivatives of the scaffold, 130 and 133, seem to be outliers with regards to angles θ, Φ1 and 
Φ2 (Figure 3.3b,c,d). It is noteworthy that, similar to normorphan 94, the N-Me derivatives 
of scaffold 95 are ionized at the pH at which the conformer generation is performed (7.4) 
stopping inversion at the sp3 nitrogen. 
 
Figure 3.3 - Vector analysis for morphan building block 95 (red) and normorphan 94 (blue) in: a) visual 
representation of variation vectors; b) r-θ plot (polar coordinates); c) Φ1-Φ2 plot; d) θ-Φ1/Φ2 plot.  
Our proposed plans to obtain 3-D building block 95 are presented in Scheme 3.2. The 
scaffold construction is based on previous work by Dixon et al.69 and appeared to offer a 
quick and reliable way to access both the racemic and the enantioenriched normorphan 
scaffold from a Ag or Cu and amine co-catalysed cycloisomerisation of an alkyne-linked 
cyclohexanone (see Scheme 1.20). Following Dixons’s approach, we envisaged that amino 
ketones 136/59 could be obtained from monoprotected cyclohexadione 29 in three steps and 
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then, using the organocatalytic cycloisomerisation, we could obtain morphan scaffolds 
137/60. After the cyclisation, hydrogenation of the exocyclic alkene and sulfonamide 
protecting group exchange into a tert-butyl carbamate to give morphan 138 was proposed 
for N-Ts morphan 60. For N-(4-Ns) morphan 86, in order to avoid hydrogenation of the NO2 
functionality in the sulfonamide, protecting group exchange and then hydrogenation would 
be performed. Finally, elaboration into vinyl MIDA boronate 95 was envisioned  via vinyl 
triflate formation to give 139, followed by a Pd-catalysed Miyaura borylation78 using B2pin2 
and transesterification sequence to introduce the MIDA group. Additionally, it was expected 
that our developed route could be applied to enantioenriched morphans 86/60 produced by 




In Dixons’s work, sulfonamide protected amines afforded higher yields and better 
enantioselectivities than carbamate or acetyl protected ones in the enantioselective variant 
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(see Scheme 1.28). Additionally, it was reported that enantioenriched sulfonamide protected 
morphans such as 86 and 60 could be easily recrystallised to enantiopurity.69 As such, despite 
the possibility of needing harsher conditions for the deprotection of these sulfonamides, we 
proposed exploring the route starting with an N-Ts protected amine and exchanging it to a 
Boc after the enantiopure building block had been obtained. The use of an N-(4-Ns) protected 
amine was also proposed as it can be more easily removed via a SNAr reaction.
92 It was also 
ultimately necessary to explore the N-Boc protected series of compounds.  
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3.2 Initial Approaches for the Synthesis of a Morphan-Derived 3-D Building Block 
Using Sulfonamide Protecting Groups 
The first step in the synthesis of the desired building block involved accessing amino ketones 
136 and 59. To this end, the previously reported synthesis by Dixon and co-workers69 was 
used. Reductive amination of 1,4-cyclohexadione monoethylene acetal 29 with 
propargylamine and using NaBH(OAc)3 as a reducing agent quantitatively afforded the 
crude amine that was, after work-up, sufficiently pure for the next reaction. Hydrolysis of 
the ketal with 3 M HCl(aq) in THF gave the crude ketone as a sufficiently pure product. This 
ketone was the diversification point for the protecting group. As such, it was used in 
sulfonamide formation using either p-toluenesulfonyl chloride or 4-nitrobenzenesulfonyl 
chloride in the presence of Et3N and catalytic DMAP. After purification by chromatography, 
N-Ts-amino ketone 59 was obtained in 85% yield over the three-step sequence whereas N-
(4-Ns)-amino ketone 136 was obtained in 45% yield (Scheme 3.3). 
 
Scheme 3.3 
Formation of N-(4-Ns)-amino ketone 136 was confirmed by HRMS and both 1H and 13C 
NMR spectroscopy where signals for the protons next to nitrogen were observed at δH 4.36–
4.18 (m, 1H) and 4.18 (d, J = 2.5 Hz, 2H). The 2.5 Hz coupling of the NCH2 protons can be 
explained by a long distance 4J coupling to the alkyne proton. Furthermore, the alkyne proton 
was observed as a triplet at δH 2.17. Incorporation of the sulfonamide group was evidenced 
by the signals in the aromatic region at δH 8.41–8.31 and 8.20–8.08. Likewise, N-Ts 
protected amine 59 showed a similar 1H NMR spectrum with the signal for the Me group 
overlapping with another signal at δH 2.46–2.33. 
Next, amino ketones 136 and 59 were subjected to a copper and amine co-catalysed 
cycloisomerisation using Dixon’s conditions.69 Thus, reaction of each amino ketone with 
Cu(OTf)2, PPh3 and pyrrolidine afforded racemic morphans 86 and 60. These reactions 
proceed via formation of enamine 140 between pyrrolidine and the ketone, with enamine 
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140 adding to the Cu-activated alkyne to perform a 6-exo-dig cyclisation. This gave racemic 
morphans 86 and 60 in 85% and 83% yield respectively (Scheme 3.4). In the 1H NMR 
spectrum of morphan 86, signals were observed in the alkene region at δH 5.14 and 5.07 
(both doublets) which were assigned to the =CH2 protons. Additionally, all data from 
morphans 136 and 59 were consistent with those reported in the literature.69 
 
Scheme 3.4 
During purification, it became apparent that N-(4-Ns) morphan 86 showed poor solubility in 
most organic solvents with the exception of CH2Cl2. This made both purification and further 
handling of morphan 86 inconvenient, leading us to make the decision of discarding the 4-
Ns sulfonamide protecting group in favour of the Ts sulfonamide. With this in mind, we set 
out to try the planned hydrogenation of the exocyclic double bond. However, our first 
attempt using a set of conditions reported by Bonjoch for a similar morphan,65 using  




Nonetheless, a change in solvent from MeOH to EtOAc and increasing the amount of 10% 
Pd/C from 0.10 eq to 0.25 eq gave a better result. In this way, a 72:25 mixture of 
diastereomeric morphans endo- and exo-141 was isolated in 40% yield. However, we also 
found that enamine 142 appeared as a by-product of the reaction, isolated in 56% yield as a 





Formation of hydrogenated morphans endo- and exo-141 was confirmed by both HRMS and 
NMR spectroscopy and the diastereomeric outcome of this reaction was identified by 1H 
NMR spectroscopy. In particular, the signals corresponding to the NCH2 protons in each 
diastereomer were diagnostic. The major diastereomer showed signals at δH 3.83 (dd, J = 
13.5, 6.0 Hz, 1H) and 2.81 (dd, J = 13.5, 12.5 Hz, 1H) (Figure 3.3). The signal at δH 3.83 
was assigned as the equatorial proton, having one large 2J = 13.5 Hz coupling and a small 
3Jeq-ax = 6.0 Hz coupling to the adjacent CH proton. The other signal, at δH 2.81, was assigned 
as the NCH2 axial proton and showed two large couplings, one 
2J = 13.5 Hz and one 3Jax-ax 
= 12.5 Hz to the CH proton. These J values were consistent with assigning the major product 
as endo-141. In contrast, the minor diastereomer’s NCH2 signals appeared at δH 3.25 (dd, J 
= 12.5, 5.0 Hz, 1H) and 2.98 (dd, J = 12.5, 6.0 Hz, 1H). Each showed one large 2J = 12.5 Hz 
coupling and a second small 3Jax-eq or 
3Jeq-eq coupling. This is consistent with the adjacent 
CH proton being in an equatorial position (axial methyl group) and allowed the assignment 
of the minor diastereomer as exo-141 (Figure 3.3).  
 
Figure 3.3 - Multiplet analysis for the diastereomeric outcome of the hydrogenation of 60 into 141. 
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The major diastereomer is formed by hydrogenation on the less hindered exo face of the 
bicyclic scaffold as we had previously observed for normorphan-derived 3-D building block 
94. On the other hand, the minor diastereomer is presumably formed by a minor competing 
pathway of endo face hydrogenation. 
Enamine 142 was also identified by NMR spectroscopic analysis. Namely, the 1H NMR 
spectrum of enamine 142 showed a signal in the high end of the alkene region at δH 6.79 (q, 
J = 1.5 Hz, 1H) which was assigned as the =CH proton. This had a long distance 4J coupling 
to a methyl group δH 1.62 (d, J = 1.5 Hz, 3H). This, alongside reported NMR spectroscopy 
data for 6-membered ring N-Ts enamines,93 led us to conclude that enamine 142 was the by-
product formed. We hypothesise that enamine 142 is formed by Pd-mediated isomerisation 
of the alkene to a product stabilized by the strongly electron withdrawing effect of the 
sulfonamide.  
Based on this, we set out to find conditions that would allow us to obtain morphan 141 with 
good diastereoselectivity while avoiding the formation of enamine 142. After the conclusion 
of the work presented in this thesis, it was reported53 that using high pressures (20 atm) with 
10% Pd/C afforded good yields and excellent diastereoselectivity for morphans similar to 
60. Additionally,  Li and co-workers94,95 reported the use of Crabtree’s catalyst for the 
diastereoselective hydrogenation of a diverse set of structurally complex morphans. 
Likewise, PtO2 has been reported for the hydrogenation of exocyclic alkenes in sulfonamide 
and sulfinamide protected pyrrolidines.96 Thus, we decided to explore the possibility of using 
PtO2 for the hydrogenation of morphan 60 into 141. Using H2 with PtO2 in EtOAc at rt for 6 
h afforded morphan 141 in 15% yield and >97:3 dr. However, while the formation of 
enamine 142 was not observed, a new product, which accounted for the remaining mass, was 
formed (Scheme 3.7). Unfortunately, purification of this by-product was not possible, and 
this made full characterisation impossible. Nonetheless, HRMS analysis suggested the 
formation of a product from the addition of 4H to morphan 60. Additionally, IR 
spectroscopic analysis of the impure product suggested that reduction of the ketone had 
occurred since no carbonyl bands were observed. All of this information led us to tentatively 
assign this by-product as alcohol 143, formed by the hydrogenation of the exocyclic alkene 





Thus, in order to correctly characterise alcohol 143, we proposed to reduce the ketone in 
morphan 141 to form alcohol 143 and compare the NMR spectra of both products. 
Consequently, NaBH4 reduction of morphan 141 in MeOH at 0 °C for 2 h was attempted. 
This gave alcohol 143 in 96% yield and >97:3 dr from the product of hydride addition from 
the exo-face of the bicyclic scaffold (Scheme 3.8). 
 
Scheme 3.8 
Formation of alcohol 143 was confirmed by HRMS, NMR and IR spectroscopic analysis. 
The 1H NMR spectrum of alcohol 143 showed a signal at δH 3.97 (dddd, J = 11.0, 7.0, 4.5, 
1.5 Hz, 1H) which, due to its chemical shift and COSY couplings, was assigned as the HOCH 
proton. Additionally, the coupling pattern, containing a large 3Jax-ax = 11.0 Hz, two small 
3Jax-eq = 7.0 and 4.5 Hz and a small 
3J coupling to the OH proton led us to assign it as the 
product from exo addition of the hydride into the carbonyl group. Characterisation of alcohol 
143 allowed us to confirm that this was the main constituent of the by-product isolated from 
the PtO2-catalysed hydrogenation of morphan 60. Despite this, it was not possible to 
determine what other compounds were observed alongside it. 
We then hypothesised that hydrogenation of the carbonyl group could be slower than 
hydrogenation of the alkene. Therefore, a shorter reaction time was attempted. Use of PtO2 
in EtOAc at rt for 45 min on a 0.3 mmol scale gave morphan 141 in 61% yield, albeit with 
a slightly diminished diastereoselectivity of 95:5. Since it was hoped that the product could 
be recrystalised to diastereopurity, this reaction was scaled up to 3.2 mmol. Unfortunately, 
while morphan 141 was isolated in 76% yield, the diastereoselectivity was reduced 





Additionally, the expected reduction of the ketone when submitting normorphan 141 to the 
conditions for removal of the N-Ts protecting group (i.e. Li, naphthalene or Mg, MeOH) led 
us to believe that N-Ts protected substrates were not ideal. Consequently, we hypothesised 
that starting from a N-Boc protected substrate might prove to be a more efficient route 
towards 3-D building block 95. It was expected that despite N-Boc protected substrates 
giving diminished yields and enantioselectivities in the asymmetric variant of the 
cyclisation, the shorter overall route would overcome the reduced yield. Additionally, we 
hoped that the likelihood of vinyl MIDA boronate 95 being crystalline would allow us to 




3.3 Investigation of the Synthesis of a Morphan-Derived 3-D Building Block Using a 
Boc Protecting Group 
Since sulfonamide protected morphans proved non-ideal for the synthesis of 3-D building 
block 95 and with the aim of streamlining the synthesis by avoiding protecting group 
exchanges, we moved on to investigate the N-Boc protecting group. We envisaged that the 
N-Boc protecting group would be carried throughout the synthesis without any need to be 
deprotected and, ideally, improving the diastereoselectivity issues in the hydrogenation of 
the exocyclic alkene. 
Thus, amino ketone 144 was synthesised in a three-step synthesis using our general 
approach. 1,4-Cyclohexadione monoethylene acetal 29 (32.3 mmol scale) was reacted with 
propargylamine and NaBH(OAc)3 to give the crude amine quantitatively. The ketal 
protecting group was deprotected with 3 M HCl(aq) in THF to give the crude amino ketone. 
This crude amino ketone was protected using Boc2O in THF to give, after chromatography, 
N-Boc amino ketone 144 in 77% yield over the three-step sequence (Scheme 3.10). 
 
Scheme 3.10 
As in the case of amino ketones 136 and 59, formation of amino ketone 144 was confirmed 
by HRMS and 1H and 13C NMR spectroscopic analysis. Namely, despite broadening due to 
rotamers, signals were observed at δH 4.59–4.16 (br m, 1H), 3.92 (br s, 2H) and 2.21–1.86 
(m, 3H). These signals were assigned as the NCH, NCH2 and ≡CH/CH2 protons respectively. 
Additionally, a singlet for 9H, assigned as the t-Bu group, was observed at δH 1.48. The 
13C 
NMR spectrum of amino ketone 144 showed a signal at δC 154.8 which was assigned as the 
C=O from the Boc group with all spectroscopic data matching those reported in the 
literature.69 
We then moved on to attempt the racemic cyclisation into morphan 87. Gratifyingly, using 
the conditions of Cu(OTf)2, PPh3 and pyrrolidine and scaling up to 7.96 mmol scale, gave 
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morphan 87 in 77% yield after chromatography (Scheme 3.11). Formation of morphan 87 
was evidenced primarily by 1H NMR spectroscopic analysis. Particularly, two rotameric 
signals were observed for one of the alkene’s CHH’ protons at δH 5.07 (s, 0.55H), 5.04 (s, 
0.45H,). A second signal in the alkene region appeared at δH 4.99 (s, 1H) and was assigned 




Having accessed morphan scaffold 87, our attention turned to the hydrogenation step which 
had presented some difficulties for N-Ts morphan 60. With this in mind, the hydrogenation 
was initially explored using H2 and 10% Pd/C (0.1 eq) in EtOAc. This gave the crude product 
which contained (by 1H NMR spectroscopy) a 90:8:2 mixture of enamine 145, morphan 
endo-138 and morphan exo-138 (Scheme 3.12). Formation of enamine 145 was evidenced 
primarily by 1H NMR spectroscopy of the crude product. Namely, the =CH signal from the 
enamine appeared as two rotameric signals at δH 7.03–6.94 (m, 0.5H) and 6.85–6.76 (m, 
0.5H). This was confirmed by isolation and characterisation from a subsequent experiment 
(see Table 3.1). 
 
Scheme 3.12 
Formation of morphans endo- and exo-138 was confirmed by HRMS and NMR 
spectroscopic analysis. Particularly, the 1H NMR spectrum of the mixture of N-Boc 
morphans endo- and exo-138 showed very similar features to those of the N-Ts analogues. 
A 3H doublet at δH 0.85 for the Me group of morphan endo-138 was observed. Likewise, 
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the signals for the NCHH’ protons were observed at δH 4.04 (dd, J = 14.0, 6.5 Hz, 0.5H), 
3.92 (dd, J = 14.0, 6.5 Hz, 0.5H) and 2.83–2.66 (m, 1H) for morphan endo-138. However, 
there was significant broadening of the signals due to the presence of rotamers, which made 
it difficult to identify the diastereomers by multiplet analysis. Nonetheless, the signals for 
the NCHH’ protons for the minor diastereomer exo-138, observed at δH 3.58 (dd, J = 13.5, 
5.5 Hz, 0.5H), 3.37 (dd, J = 13.5, 5.5 Hz, 0.5H), 3.27 (dd, J = 13.5, 5.5 Hz, 0.5H) and 3.12 
(dd, J = 13.5, 5.5 Hz, 0.5H), point towards the adjacent CH proton being in an equatorial 
position (Figure 3.4). This, alongside the diastereomeric outcome of the hydrogenation of 
N-Ts protected morphan 60, suggest that the major diastereomer from the hydrogenation was 
endo-138. 
 
Figure 3.4 - Multiplet analysis for the diastereomeric outcome of the hydrogenation of 87 into 138. 
Since the result from this hydrogenation gave mostly enamine 145, we moved on to explore 
different conditions that would allow us access to morphans 138 in good yields and 
selectivity. Thus, a small optimisation of the hydrogenation was attempted (Table 3.1). A 
change in solvent from EtOAc to EtOH using 10% Pd/C was initially made. However, after 
work-up, only a complex mixture of products was observed (Entry 2). Likewise, using 
AcOH (5 eq) as additive in the hope of protonating the enamine, with 10% Pd/C in EtOAc 
gave a similar outcome (Entry 3). It has been suggested that transfer hydrogenation with 
ammonium formate can effectively hydrogenate difficult substrates such as deactivated 
enamines.97 Therefore, transfer hydrogenation conditions with NH4
+HCO2
– and 10% Pd/C 
were attempted on morphan 87 but, unfortunately, only a complex mixture of products was 




Table 3.1 - Optimisation of the hydrogenation of morphan 87 into 138 
 
Entry Conditions Temp 
145 : endo-138 : exo-138 
 
1 
H2, 10 % Pd/C (0.1 eq), 
EtOAc 
rt 90 : 8 : 2a 
2 
H2, 10 % Pd/C (0.1 eq), 
EtOH 
rt Complex mixturea 
3 
H2, 10 % Pd/C (0.1 eq), 
AcOH (5.0 eq), EtOAc 
rt Complex mixturea 
4 
10% Pd/C (0.02 eq), 
NH4CO2H (10 eq), 
MeOH 
reflux Complex mixturea 
a) Determined by 1H NMR spectroscopy 
Next, a change of catalyst from 10% Pd/C to 20% Pd(OH)2/C was made while keeping the 
equivalents constant. In this way, morphan endo-138 was obtained in 18% yield and 90:10 
dr with enamine 145 being obtained in 72% yield (Scheme 3.13). 
 
Scheme 3.13 
With the poor results obtained with Pd catalysts, we hypothesised that, as in the case with 
N-Ts morphan 60, hydrogenation of N-Boc morphan 87 using PtO2 would afford the product 
from the hydrogenation of both the alkene and the ketone. This could hopefully be purified 
and then oxidised to give the desired morphan endo-138. Thus, morphan 87 was 
hydrogenated in the presence of PtO2 in EtOAc. This gave a 90:10 mixture of alcohols endo- 
and exo-146 in 86% yield, together with its corresponding enamine 147 in 10% yield as a 





Formation of morphans endo- and exo-146 was confirmed by HRMS and NMR spectroscopy 
and the diastereomeric outcome of the reaction was identified by 1H NMR spectroscopy. In 
particular, the signals for the NCH2 protons in each diastereomer were diagnostic, while the 
CH signal adjacent to the alcohol allowed the assignment of this stereocentre. The major 
diastereomer showed rotameric signals at δH 3.81 (dd, J = 13.5, 6.0 Hz, 0.55H), 3.71 (dd, J 
= 13.5, 6.0 Hz, 0.45H), 3.02 (dd, J = 13.5, 13.0 Hz, 0.55H) and 2.98 (dd, J = 13.5, 13.0 Hz, 
0.45H) for the NCH2 protons (Figure 3.5). The signals at δH 3.81 and 3.71 correspond to the 
equatorial proton and have a large 2J = 13.5 Hz coupling and a small 3Jeq-eq = 6.0 Hz coupling 
to the adjacent CH. The other signals at δH 3.02 and 2.98 correspond to the NCH2 axial 
proton and showed two large couplings, one 2J = 13.5 Hz and one 3Jax-ax = 13.0 Hz. This was 
consistent with the proton adjacent to the NCH2 protons being in an axial position (Me in an 
equatorial position) and allowed the assignment of the major diastereomer as morphan endo-
146 (Figure 3.5). With respect to the stereoselectivity of the carbonyl reduction, the major 
diastereomer showed a signal at δH 3.97 (ddd, J = 11.0, 5.5, 5.5 Hz, 1H) which was assigned 
as the CHOH proton. This signal shows one large 3Jax-ax = 11.0 Hz coupling to one of the 
adjacent CH2 protons and two small 
3Jax-eq = 5.5 Hz couplings. This is consistent with this 
proton being in an axial position (OH equatorial) as shown in Figure 3.5. As in the case of 
N-Ts morphan 141 (see Section 3.2), this outcome is presumably derived from a major 
pathway involving hydrogenation from the exo-face of the bicyclic core on both the alkene 
and the ketone functionalities. We hypothesised that the minor diastereomer in the 





Figure 3.5 - Multiplet analysis for the diastereomeric outcome of the hydrogenation of 87 into 146 
In a similar way, the formation of enamine 147 was confirmed by NMR spectroscopic 
analysis. The 1H NMR spectrum of enamine 147 showed characteristic signals similar to 
those observed for enamine 145. Namely, rotameric signals were observed at δH 6.94 (s, 
0.5H) and 6.77 (s, 0.5H) and were assigned as the =CH proton. The signal for the CH proton 
adjacent to the OH appeared at δH 3.86 (dddd, J = 10.0, 4.5, 4.5, 4.5 Hz, 1H) which, by the 
same analysis as that for morphan endo-146 (see Figure 3.5), confirms that the alcohol is in 
an equatorial position.  
In order to explore improving the diastereoselectivity, we decided to investigate reduction 
of the ketone into the alcohol first and then study the hydrogenation of the exocyclic alkene. 
In addition, protection of the alcohol and hydrogenation would allow us to explore the 
hypothesis of hydroxyl-directed hydrogenation. Consequently, morphan 87 was reduced 
with NaBH4 in MeOH to give, after work-up, alcohol 148 as a sufficiently pure product in 
95% yield as a single diastereomer (Scheme 3.15). The 1H NMR spectrum of alcohol 148 
showed the signal for the CH proton adjacent to the alcohol at δH 3.72–3.59 (m, 1H). 
However, although the diastereomeric outcome of the reduction could not be determined 
directly by 1H NMR spectroscopy of alcohol 148, it was possible to determine it from the 





A range of conditions was then explored for the hydrogenation of morphan 148 (Table 3.2). 
We first attempted the use of 10% Pd/C as a catalyst for the hydrogenation. However, when 
morphan 148 was hydrogenated in the presence of 10% Pd/C as catalyst in EtOH, only 
enamine 147 was obtained in 96% yield (Entry 1). We hypothesised that using AcOH as an 
additive could protonate enamine 147 thus making the overall reduction easier. Nonetheless, 
when morphan 148 was hydrogenated using 10% Pd/C as catalyst in the presence of AcOH 
only a complex mixture of products were observed after work-up (Entry 2). It was then 
decided to change the catalyst to 20% Pd(OH)2/C. Using this catalyst, enamine 147 was 
obtained as the single product of the hydrogenation in 94% yield after work-up (Entry 3). 
As previously mentioned, it has been suggested that transfer hydrogenation conditions can 
be effective for unreactive alkenes.97 Using these conditions, a 75:25 mixture of morphans 
endo- and exo-146 was isolated in 42% yield and enamine 147 was isolated in 55% yield 
(Entry 4). It was then decided to use PtO2 as the catalyst since it had previously shown the 
highest efficiency for the hydrogenation of ketone substrates (see Scheme 3.9 and Scheme 
3.14). Gratifyingly, hydrogenation of morphan 148 using PtO2 as catalyst gave morphan 
endo-146 in 90% yield and 75:25 dr with enamine 147 being isolated in only 6% yield (Entry 
5). 







H2, 10% Pd/C, EtOH,   
2 h 
rt 0% 96% 
2 
H2, 10% Pd/C, AcOH, 
EtOH, 2 h 
rt Complex mixtureb 
3 
H2, 20% Pd(OH)2, 
EtOAc, 2h 














a) isolated % yield; b) by 1H NMR spectroscopy of the crude product; c) 
determined by 1H NMR spectroscopy 
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The diminished diastereoselectivity in the hydrogenation of morphan 148 (Table 3.2, Entries 
4 and 5) with respect to morphan 87 (Table 3.1, Entry 1) supports the hypothesis that the 
minor diastereomer is generated by a competing pathway of hydroxyl-directed 
hydrogenation. Presumably, starting from alcohol 148, this pathway is more significant. 
Consequently, we decided that protecting the hydroxyl group in morphan 148 with a bulky 
group such as TBDMS would hinder this minor pathway both sterically and by impeding 
coordination of the hydroxyl group to the metal catalyst. As such, morphan 148 was O-
protected by using TBDMS and imidazole in DMF. This gave O-TBDMS morphan 149 in 
83% yield (Scheme 3.16). 
 
Scheme 3.16 
Formation of O-TBDMS morphan 149 was confirmed by HRMS and NMR spectroscopy. 
In particular, the 1H NMR spectrum of morphan 149 showed the expected signals for the 
=CHH’ protons at δH 5.02–4.96 (m, 1H) and 4.95–4.89 (m, 1H). Signals were also observed 
at δH 0.87 (s, 9H) and 0.07–0.03 (m, 6H) which were assigned as the t-Bu and Me groups 
from the TBDMS group. On the other hand, the 
13C NMR spectrum of morphan 149 showed 
four signals at δC –4.3 to –4.4 which were assigned to the Me groups adjacent to the Si. 
O-TBDMS morphan 149 was then hydrogenated using our previously established conditions 
with H2 and PtO2 as catalyst at rt for 16 h. Use of these conditions with morphan 149 gave 
hydrogenated morphan endo-150 in 20% yield as a single diastereomer and enamine 151 in 
55% yield (Scheme 3.17). The 1H NMR spectrum of morphan 150 showed rotameric signals 
at δH 3.84 (dd, J = 13.5, 6.0 Hz, 0.5H), 3.73 (dd, J = 13.5, 6.0 Hz, 0.5H), 3.07 (dd, J = 13.5, 
13.0 Hz, 0.5H) and 3.03 (dd, J = 13.5, 13.0 Hz, 0.5H) which were assigned as the NCHH’ 
protons. Following the same analysis as that for morphans endo-138 and -endo-146 (see 
Figure 3.4 and Figure 3.6) allowed us to conclude that the diastereomer formed is the endo 
product. Formation of enamine 151 was also confirmed by HRMS and NMR analysis. 
Particularly, the 1H NMR spectrum of enamine 151 showed characteristic rotameric signals 
at δH 6.88 (s, 0.4H) and 6.73 (s, 0.6H) which were assigned to the =CH proton of the enamine 
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and the Me signal was observed at δH  1.78–1.75 (m, 3H). On the other hand, the 
13C NMR 
spectrum showed signals at δC 122.2, 121.8, 115.3 and 114.4 with the first two being 




The diastereomeric outcome of this hydrogenation, namely the formation of morphan endo-
150 in >97:3 dr, suggests that, due to the absence of a hydroxyl-directed pathway, the 
reaction is completely sterically controlled. This therefore supports our previously outlined 
hypothesis that the minor product, exo-146, from the hydrogenation of 148 is being formed 
by a minor pathway of hydroxyl-directed hydrogenation. However, our efforts to improve 
the outcome of the hydrogenation using TBDMS protection did not prove of much use since, 
despite increasing the diastereoselectivity of the reaction, increasing the steric bulk on the 
endo face of morphan 149 also led to significantly diminished yields. Thus, we decided that 
converting morphan 87 into a 90:10 mixture of alcohols endo-146 and exo-146 by 
hydrogenation (see Scheme 3.14) and then oxidising this  mixture back into the ketone using 
Dess-Martin periodinane (DMP) would be the best course of action. We hypothesised that 
the vinyl MIDA boronate, which we expected to be a crystalline solid, could be recrystallised 
to diastereopurity. As such, we first attempted the oxidation of a 90:10 mixture of alcohols 
endo-146 and exo-146 using DMP in CH2Cl2 at rt for 2 h. This gave a 90:10 mixture of keto-
morphans endo-138 and exo-138 in 84% yield (Scheme 3.18). Spectroscopic data for keto-





In order to facilitate purification and increase the yield, we investigated whether this 
oxidation could be performed on the crude product from the hydrogenation of morphan 87. 
In this way, morphan 87 was hydrogenated using H2 and PtO2 in EtOAc and the crude 
product from this reaction was treated with DMP in CH2Cl2. Gratifyingly, this gave morphan 
endo-138 in 71% yield and 90:10 dr with a single purification while enamine 145 was 
obtained in 15% yield (Scheme 3.19). This represents a negligible decrease in yield, which 
on top of the easier purification constitutes a useful alternative for the synthesis of a 90:10 
mixture of morphans endo- and exo-138. 
 
Scheme 3.19 
The next step involved turning the ketone in morphans 138 into a vinyl triflate. This was 
attempted using NaHMDS and PhNTf2, previously identified from our work on the 
normorphan scaffold (see Section 2.2). Thus, morphan endo-138 (90:10 dr) was treated with 
NaHMDS in THF at –78 °C for 1 h and the formed enolate was trapped with PhNTf2 from 
–78 °C to rt for 18 h. In this way, vinyl triflate endo-139 (90:10 dr) was obtained in 70% 
yield after chromatography (Scheme 3.20). Formation of vinyl triflates endo- and exo-139 
was confirmed by HRMS and NMR spectroscopy. In particular, the 1H NMR spectrum of 
vinyl triflates 139 showed a signal at δH 5.92 (dd, J = 4.0, 4.0 Hz) which was assigned to the 
=CH proton of the major diastereomer. On the other hand, the 13C NMR spectrum of vinyl 






The last step involved turning vinyl triflate endo-139 (90:10 dr) into vinyl pinacol boronate 
endo-152 and this into vinyl MIDA boronate 95. We envisaged doing this with the 
previously used method of a Miyaura borylation using B2pin2, PdCl2(PPh3)2, PPh3 and KOPh 
to form vinyl pinacol boronate endo-152. Then, based on previous experience with 
normorphan 3-D building block 94 (see Section 2.2), taking the crude pinacol boronate endo-
152 and transesterifying it into vinyl MIDA boronate 95 using MIDA and HC(OEt)3. Thus, 
vinyl triflate endo-139 (90:10 dr) was treated with B2pin2, PdCl2(PPh3)2, PPh3 and KOPh in 
toluene at rt for 18 h and the crude product was treated with MIDA and HC(OEt)3 in DMSO 
at 100 °C for 48 h. However, after chromatography, vinyl MIDA boronate 95 was isolated 
as a mixture with unidentified products (Scheme 3.21). Nonetheless, the formation of vinyl 
MIDA boronate 95 was confirmed by both HRMS and NMR spectroscopy. The 1H NMR 
spectrum of vinyl MIDA boronate 95 showed a signal at δH 6.22–6.17 (m, 1H) which was 
assigned as the =CH proton. In addition, rotameric signals for one of the NCHH’ protons 
were observed at δH 4.51–4.43 (m, 0.6H), 4.35–4.30 (m, 0.4H). Unfortunately, due to time 
constraints and the overall impracticality of the synthesis of morphan-derived building block 
95, no further attempts at synthesising vinyl MIDA boronate 95 were made. 
 
Scheme 3.21 
Thus, the synthesis of an impure sample of vinyl MIDA boronate 95 was achieved using the 
N-Boc protected series of compounds. The route was accomplished up to vinyl triflate endo-
139 with a 29% overall yield and 90:10 dr (Scheme 3.22). This was achieved using a three-
step sequence to give amino ketone 144, followed by a Cu/amine co-catalysed 
cycloisomerisation into morphan 87, diastereoselective hydrogenation and oxidation into 
morphan 138 and finishing with a vinyl triflate formation to give 139. Borylation-
transesterification into vinyl MIDA boronate 95 was also attempted, but impure vinyl MIDA 
boronate 95 was isolated. Further exploration into the diastereoselective hydrogenation was 








To summarise, the synthesis of a morphan-derived 3-D building block was partially 
achieved. Initially, use of a sulfonamide protected series of compounds was explored with 
limited success. A change into the N-Boc protected series of compounds afforded the late-
stage vinyl triflate endo-139 in 29% overall yield over seven steps. This was achieved by a 
three-step sequence to give aminoketone 144 which was cyclised with pyrrolidine and a 
Cu(OTf)2 catalyst to afford the morphan scaffold which was subsequently converted into 
vinyl triflate endo-139. Formation of the objective vinyl MIDA boronate 95 was attempted 
but only an impure sample was obtained. Different approaches for the hydrogenation of both 
the N-Ts and N-Boc substrates were investigated. Reduction of the ketone moiety and 
protection of the formed alcohol as an O-TBDMS group were explored with little success. 
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Chapter 4 Suzuki-Miyaura Cross-Coupling and Further 
Functionalisation of the Normorphan-derived 3-D 
Building Block 
In order to demonstrate the utility of normorphan-derived building block 94 in the 
construction of drug-like and lead-like compounds for medicinal chemistry, this Chapter 
summarises some of the functionalisation possibilities that were explored (Scheme 4.1). 
Section 4.1 focuses on Suzuki-Miyaura cross-coupling with the vinyl MIDA boronate 
handle on building block 94. Section 4.2 shows further functionalisation of the 3-D building 
block including hydrogenation of the alkene, reduction of the amide moiety and 
deprotection of the N-DMB group. Finally, Section 4.3 provides an overview of the 







4.1 Suzuki-Miyaura Arylations of the Normorphan-Derived 3-D Building Block 
With the aim to showcase the functionalisation possibilities of 3-D building block 94, our 
attention turned to Suzuki-Miyaura cross-couplings using the vinyl MIDA boronate installed 
in the building block (Scheme 4.2). Initially, it was planned to explore conditions for the 
cross-coupling using 4-bromoanisole and 4-bromobenzotrifluoride as coupling partners. 
Then, a variety of aromatic and heteroaromatic aryl bromides would be explored. It was also 
desired to include a set of aryl bromides based on FragLites, introduced by Waring and co-
workers, 98 as medicinally-relevant aryl groups. 
 
Scheme 4.2 
Various sets of conditions have been developed for the use of MIDA boronates in Suzuki-
Miyaura cross-couplings, which are essentially classified into those that use a slow-release 
strategy and a deprotection strategy.99 The slow-release strategy, developed by Burke and 
coworkers,82 hydrolyses the MIDA boronate in situ under standard aqueous Suzuki-Miyaura 
conditions to generate the free boronic acid which is subsequently transmetallated into the 
catalytic cycle to minimize by-products generated in the presence of large quantities of free 
boronic acid in the reaction media (Scheme 4.3). On the other hand, the deprotection 
strategy, mainly used in iterative cross-coupling100 and anhydrous Suzuki-Miyaura cross-
couplings81 relies on the full release of the boronic acid into a dilute solution for its further 






Taking these strategies into consideration and with the idea of having a simple and reliable 
method for performing the Suzuki-Miyaura cross-coupling of vinyl MIDA boronate 94, our 
attention turned to the slow-release method developed by Burke et al.82 using Pd(OAc)2 as 
a Pd source, SPhos as a ligand and K3PO4(aq) for the release of the boronic acid. Using this 
set of conditions, vinyl MIDA boronate 94 was successfully coupled to 4-bromoanisole to 
give, after chromatography, arylated normorphan 153 in 86% yield (Scheme 4.4) as the only 
product. Incorporation of the 4-anisole group was confirmed by HRMS and 1H NMR 
spectroscopy where the signal corresponding to the vinylic proton was observed at δH 5.67 
in arylated normorphan 153, Additionally, signals corresponding to the methoxy groups in 





With this result in hand, coupling to 4-bromobenzotrifluoride was attempted. However, 1H 
NMR spectroscopy of the crude reaction mixture revealed the appearance of three products 
as well as the desired arylated normorphan 154. Thus, after chromatography, arylated 
normorphan 154 was isolated in 61% yield. A second product, identified as alkene 115, was 
isolated in 20% yield while another two products subsequently identified as bis-normorphans 
155a and 155b were isolated in 2% and 4% yield as 75:25 and 95:5 mixtures with SPhos 
respectively (Scheme 4.5). Incorporation of the benzotrifluoride moiety in normorphan 154 
was confirmed by HRMS and NMR spectroscopic analysis. Namely, signals observed in the 
1H NMR spectrum of normorphan 154 in the aromatic region at δH 7.68–7.63 and 7.60–7.55 
as multiplets were assigned as those from the benzotrifluoride motif. Additionally, the 13C 
NMR spectrum of normorphan 154 showed signals at δC 129.1 (q, J = 32.5 Hz) and 125.5 
(q, J = 4.0 Hz) which were assigned as the ipso and ortho carbons to the CF3 group. The CF3 
carbon appeared at δC 124.4 (q, J = 272.0 Hz). 
 
Scheme 4.5 
The first of the observed by-products that was isolated in 20% yield was identified as alkene 
115 by comparison with previously isolated samples (see Section 2.2). We hypothesise that 
alkene 115 is formed by protodeborylation of the transient boronic acid species formed by 
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hydrolysis of vinyl MIDA boronate 94. On the other hand, 1H NMR spectroscopic analysis 
of the other two isolated products 155a and 155b (2% and 4% yield respectively) showed 
that they had very similar spectra. Particularly, the 1H NMR spectra of both compounds 
contained all the signals from the normorphan core. For bis-normorphan 155a signals 
appeared at δH 5.85 (s), 3.67 (d, J = 5.0 Hz) and 3.08 (d, J = 5.0 Hz) for the =CH, NCH and 
C(O)CH protons of the normorphan core respectively. For bis-normorphan 155b these same 
signals were seen at δH 6.05–5.62 (m), 3.72–3.67 (m) and 3.16 (d, J = 5.0 Hz). This was 
consistent to a coupled normorphan bearing a vinyl substituent that showed no signals in the 
1H NMR spectrum with the exception of those belonging to the normorphan core (Figure 
4.1). Additionally, the 13C NMR spectra for both 155a and 155b showed only signals that 
belonged to the normorphan core. 
 
Figure 4.1 - 1H NMR spectra of 155a (blue) and 155b (red) 
Thus, we propose that a dimerisation by oxidative homocoupling of the boron-containing 
species had occurred giving rise to the formation diastereomeric bis-normorphans 155a/b. 
This was confirmed by HRMS analysis. It is likely that these products are generated by a 
minor competing pathway in which small quantities of oxygen present in the reaction,101 
coupled with high concentrations of the transient boronic acid species,102 lead to the 
formation of the homocoupled product.   
With the previous results in hand, we moved on to study the scope of aryl bromides that 
could be coupled to normorphan-derived 3-D building block 94. Use of 5-bromopyrimidine 
gave arylated normorphan 156 in 60% yield, alkene 115 in 5% yield and bis-normorphans 
155a/b in 3% and 7% yields respectively. Likewise, use of N-TIPS azaindole 157 as 
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coupling partner afforded arylated normorphan 158 in 58% yield with only trace by-products 
formed (Scheme 4.6). 
 
Scheme 4.6 
Use of 4-bromo-acetanilide gave arylated normorphan 159 in 45% yield as a 90:10 mixture 
with bis-normorphan 155b (7% yield). This coupling also afforded alkene 115 in 40% yield 
and bis-normorphan 155a in 3% yield. Coupling to 2-methoxy-5-bromopyrimidine gave 
arylated normorphan 160 in 66% yield as a 95:5 mixture with bis-normorphan 155a (5% 
yield). This coupling also gave alkene 115 and bis-normorphan 155b in 6% and 7% yield 




Scheme 4.7 - a) Isolated as a 90:10 mixture with bis-normorphan 155b; b) Isolated as a 95:5 mixture with 
bis-normorphan 155a 
A selection of less successful results is summarised in Scheme 4.8. Use of 3-bromo-2-
methoxy-pyridine afforded only alkene 115 in 55% yield and bis-normorphans 155a/b in 
6% and 10% yield respectively after chromatography. However, it should be noted that 
formation of arylated morphan 161 was evidenced in the 1H NMR spectrum of the crude 
product. Similarly, coupling using 2-bromo-5-fluoro-3-methylpyridine gave only alkene 115 
in 60% yield and bis-normorphans 155a/b in 3% and 8% yield respectively despite evidence 
of the formation or arylated normorphan 162 by 1H NMR spectroscopy of the crude product. 
Finally, 1H NMR spectroscopic analysis of the crude reaction mixtures of couplings using 
4-bromo-2-hydroxypyridine, 4-bromo-isoxazole and 4-bromo-pyrazole showed formation 




Scheme 4.8 - a) Formation of product evidenced by 1H NMR spectroscopy of the crude product. 
Thus, 3-D building block 94 was coupled to a variety of aryl bromides, including 
heteroaromatic ones, in moderate to good yields, proving the potential utility of the 3-D 
building block in the synthesis of lead-like compounds. However, it is important to note that 
non-protected groups such as free NH or OH moieties proved in many cases detrimental to 
the yield. Additionally, the appearance of different by-products by competing pathways was 
inconvenient as some of them were difficult to separate from the desired product.  
It is known99 that modifying the reaction conditions, for slower release of the boronic acid  
(e.g. lower concentrations of base), as well as utilising different precatalyst/ligand 
combinations82 can have a beneficial effect by reducing the formation of the undesired 
products of cross-couplings. Thus, we propose that while the current conditions prove 
adequate for the Suzuki-Miyaura coupling of 3-D building block 94, an optimisation of the 
reaction conditions could be performed to allow for coupling with the more problematic 




4.2 Further Functionalisation of the Normorphan-Derived 3-D Building Block 
With the scope of the Suzuki-Miyaura arylation briefly explored, we moved on to the further 
functionalisation that was proposed for 3-D building block 94. Once Suzuki-Miyaura 
functionalisation had been performed, it was envisaged that the arylated normorphan could 
be taken on through two distinct routes. The first involved diastereoselective hydrogenation 
of the alkene in 163 into normorphan 164. Normorphan 164 could then be deprotected to 
give normorphan 165 upon which conditions for N-functionalisation could be explored. On 
the other hand, the amide in arylated normorphan 163 could be reduced to obtain amine 166 
which could then be deprotected to obtain normorphan 167 (Scheme 4.9). 
 
Scheme 4.9 
The first step investigated was the diastereoselective hydrogenation of the alkene. We 
expected that, due to the inherent shape of building block 94, hydrogenation of the alkene 
would likely be diastereoselective due to preferential hydrogenation on the less sterically 
hindered exo-face of the bicyclic scaffold. With this in mind, we utilised standard 
hydrogenation conditions with 10% Pd/C as catalyst under a hydrogen atmosphere to 
perform the hydrogenation on arylated normorphan 153. To our delight, using these 
conditions, hydrogenated normorphan 168 was isolated in 92% yield as a single 





Formation of normorphan 168 was confirmed by HRMS and NMR spectroscopy. The 1H 
NMR spectrum of normorphan 168 showed a signal at δH 2.84 (ddd, J = 12.0, 5.0, 1.5 Hz, 
1H) which was assigned as the proton in the benzylic position. Another signal at δH 1.85 
(ddd, J = 14.0, 5.0, 5.0 Hz, 1H) was assigned to one of the protons in the CHH’ in the 3-
position of the normorphan scaffold. The other CHH’ proton signal was observed underneath 
other signals. Since normorphan 168 is an oil, the stereochemical outcome was assigned as 
the expected exo product from X-ray crystallographic analysis of a subsequent derivative 
(see Figure 4.2).  
In contrast, attempted hydrogenation of aza-indole arylated normorphan 158 into 
normorphan 169 proved unsuccessful (Scheme 4.11), The 1H NMR spectroscopic analysis 
of the crude product revealed a low number of aromatic signals, with new aliphatic signals 
appearing. This could be evidence of hydrogenation of the aza-indole aromatic ring or 
formation of a dearomatized unidentified product.  
 
Scheme 4.11 
We then moved on to search for deprotection conditions for the N-DMB protecting group 
that is present in arylated normorphan 168. The majority of methods used for the 
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deprotection of the N-DMB group make use of its ability to generate a stable, benzylic 
carbocation. As such, many methods for deprotection use acidic conditions such as TFA 
with cation scavengers such as water79 or 1,3-dimethoxybenzene,103 or Lewis acids such as 
BCl3.
104 N-DMB groups have also been deprotected under oxidative conditions such as 
DDQ105 or ceric ammonium sulfate.106 With this knowledge, a first set of conditions using 
aqueous TFA at rt was attempted. Pleasingly, this gave amide 170 in 68% yield after 72 h 
(Scheme 4.12).  
 
Scheme 4.12 
Removal of the N-DMB group to give NH amide 170 was confirmed by HRMS and by 1H 
NMR spectroscopic analysis. Particularly, the 1H NMR spectrum of amide 170 showed a 
broad singlet at δH 6.69, which had no carbons attached and was assigned as the NH proton. 
This was evidence of the removal of the N-DMB group. Gratifyingly, amide 170 proved to 
be a solid and analysis by X-ray crystallography (Figure 4.2) allowed us to confirm the 
stereochemical outcome of the hydrogenation of arylated normorphan 94. As expected, the 
relative stereochemistry of the stereocentre generated at the benzylic position was that from 
hydrogenation from the least sterically hindered exo face of the alkene. 
  
Figure 4.2 - X-ray crystal structure of amide 170 
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However, since the deprotection of the N-DMB group in amide 168 proved to be slow, with 
some starting material observed after 72 h, we moved on to finding conditions which could 
provide amide 170 more quickly and efficiently. Making use of the different ways to 
deprotect N-DMB groups, oxidative conditions were employed. In this manner, using DDQ 
as oxidant and water as scavenger gave amide 168 in 25% yield with significant formation 
of unidentified by-products observed (Entry 2). Thus, we returned to the use of acidic 
conditions while heating to speed the reaction up and hopefully achieve full conversion. 
Accordingly, using 80% TFA(aq) at 60 °C afforded amide 170 in 73% yield after 18 h (Entry 
3). However, while these conditions proved adequate for the deprotection of amide 168, we 
thought that some functionalities that could be introduced in previous steps of the synthesis, 
such as the BMIDA,107 could be labile to aqueous acid. As such, we turned our attention to 
a different cation scavenger to use with our acidic conditions. Use of anhydrous TFA and 
1,3-dimethoxybenzene as scavenger103 gave amide 170 in 52% yield. However, the reaction 
proved to be slow, taking 72 h with presence of some starting material remaining in the crude 
product (Entry 4). 
Table 4.1 - Optimisation of N-DMB deprotection. 
 






1 80% TFA(aq), CH2Cl2 rt 72 68 
2 DDQ, H2O, CH2Cl2 rt 24 25 
3 80% TFA(aq) 60 18 73 
4 TFA, 1,3-dimethoxybenzene, CH2Cl2 rt 72 52 
a) % isolated yield 
With different conditions for the deprotection of the N-DMB group in hand, we were 
interested in exploring whether the N-DMB group could be removed from vinyl MIDA 
boronate 94 and if the product from this deprotection could be selectively functionalised in 
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the presence of the N-H amide. Initially, attempting the deprotection of the N-DMB in vinyl 
MIDA boronate 94 by using our highest yielding conditions (80% TFA(aq) at 60 °C)  failed 
to give N-H-amide 171, giving a complex mixture of unidentified products (Scheme 4.13). 




Therefore, we changed the cation scavenger to 1,3-dimethoxybenzene in the absence of 
water. Pleasingly, using anhydrous TFA with 1,3-dimethoxybenzene in CH2Cl2 at rt, amide 
171 was generated in 60% yield (Scheme 4.14). The formation of amide 171 was confirmed 
by both HRMS and NMR spectroscopy. Namely, the 1H NMR spectrum of amide 171 
showed a singlet at δH 7.55 which was assigned to the newly formed N-H. Likewise, the 
proton signals expected for the NCH2 protons from the MIDA group were observed at δH 
4.25, 4.13, 3.91 and 3.90 as doublets due to their diastereomeric nature. Likewise, the 13C 
NMR spectrum of amide 171 showed signals for the MIDA boronate being observed at δC 
170.4 (C=O, ester), 169.2 (C=O, ester) and 46.6 (NMe). Nevertheless, despite success at 
obtaining deprotected 3-D building block 171, it suffered from extremely low solubility in 
most common organic solvents, which makes amide 171 inconvenient as a building block 
for further elaboration. 
 
Scheme 4.14 
Finally, we explored whether we could obtain an amine version of our building block. This 
would allow us to expand the accessible set of elaboration vectors by changing the 
hybridisation of the nitrogen and thus the geometry of the bicyclic scaffold (see Section 2.1). 
Hence, it was envisaged that reduction of the amide in arylated normorphan 153 would allow 
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easy access into the desired amine. This could, in principle, be achieved by using a variety 
of reducing agents such as LiAlH4,
108 DIBAlH,109 BH3 complexes,
110 or even transition 
metal hydride complexes111 with varying degrees of selectivity. However, since arylated 
normorphan 153 did not contain particularly reactive functionalities, LiAlH4 was used. 
Reduction of arylated normorphan 153 with LiAlH4 in THF at reflux afforded amine 172 in 
70% yield after chromatography (Scheme 4.15). 
 
Scheme 4.15 
Successful reduction of the amide 153 to give amine 172 was confirmed by HRMS, NMR 
and IR spectroscopy. The 1H NMR spectrum of amine 172 showed a 2H multiplet δH 3.12–
3.02 which is the region expected for a CH2 next to a heteroatom. This led us to assign this 
signal as the newly formed CH2 in amine 172. Additionally, the signal for the proton at the 
7-position of the normorphan scaffold in amine 172 was observed as a doublet of doublets 




To summarise, we have shown that 3-D building block 94 can be functionalised in diverse 
ways. Namely, we have shown that Suzuki-Miyaura cross-coupling on 94 can be performed 
with a variety of aryl bromides, including some heteroaromatics in moderate to good yields 
(Scheme 4.16).  
 
Scheme 4.16 - a) Isolated as a 90:10 mixture with bis-normorphan 155b; b) Isolated as a 95:5 mixture with 
bis-normorphan 155a 
Diastereoselective hydrogenation of the alkene in normorphan 153 was also exemplified 
obtaining an excellent yield and complete diastereoselectivity towards the product from 
hydrogenation from the exo face. This was confirmed by X-ray crystallographic analysis. 
Deprotection conditions for the N-DMB group were also identified by using aqueous TFA 
at 60 °C. Likewise, for hydrolysis-sensitive groups, anhydrous deprotection conditions were 
also found by using 1,3-dimethoxybenzene as a cation scavenger. Gratifyingly, these last 
conditions were successfully applied to the deprotection of 3-D building block 94 which 
unfortunately proved inadequate for further functionalisation due to solubility problems. 
Finally, we were able to access a different set of elaboration vectors by converting the amide 
into an amine by reduction with LiAlH4 in good yield. 
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Chapter 5 Conclusions and Future Work 
In conclusion, normorphan-derived building block 94 was synthesised in its racemic form in 
an overall 30% yield via a seven-step sequence (Figure 5.1). This sequence consisted of a 
three-step synthesis of an aminoketone that was then cyclised to give the normorphan. This 
was then converted into the vinyl triflate to enable a Miyaura borylation and 
transesterification sequence to give normorphan-derived building block 94. Two approaches 
for the enantioenriched synthesis of building block 94 were also explored, namely, an 
organocatalytic asymmetric cyclisation and a diastereomeric resolution approach. However, 
both approaches ultimately proved unsuccessful. 
 
Figure 5.1 - Normorphan-derived building block 94 
Suzuki-Miyaura arylations of 3-D building block 94 were showcased with a variety of aryl 
bromides including heteroaromatic ones in yields of 46-86%. Further functionalisation of 
building block 94 such as diastereoselective hydrogenation of the alkene, N-deprotection and 
reduction of the amide were also successful to give the products shown in Figure 5.2. 
 
Figure 5.2 - Products from further functionalisation of building block 94 
92 
 
Future work on the synthesis of building block 94 could include the exploration of alternative 
routes for the synthesis of enantioenriched building block 94. For example, a more in-depth 
study into the organocatalytic cyclisation of trichloroacetamide 108 into normorphan 109 
could be carried out. In this study, catalysts such as (R)-40 utilised by Ye and co-workers53 
in their Conia-ene methodology, could be explored (Scheme 5.1). 
 
Scheme 5.1 
Ye and co-workers53 also explored the cleavage of the alkene in the products of their 
asymmetric Conia-ene type reaction (173 to 174 to 175). This could be utilised to obtain a 
sulfonamide protected version of the normorphan scaffold 175. Then, selective conditions 
for the deprotection of the sulfonamide group could be explored to afford enantioenriched 
building block 94 or a derivative (Scheme 5.2). 
 
Scheme 5.2 
Alternatively, different conditions for the formation of the vinyl MIDA boronate could be 
explored to allow for the formation and resolution of the diastereomeric MIDA* boronates. 
Namely, hydrolysis of the pinacol boronate 111 into boronic acid 176 and installation of the 
chiral MIDA derivatives using the conditions reported by Burke and co-workers81 could be 







On the other hand, further work on the functionalisation of normorphan-derived scaffold 94 
could include further exploration of the scope and conditions for Suzuki-Miyaura cross-
coupling of the vinyl MIDA boronate 94 to enable coupling with a more diverse and 
medicinally-relevant set of heteroaromatic aryl bromides. N-Functionalisation of the 
building block such as N-alkylation and N-arylation could also be explored on amide-based 
scaffold 178 (Scheme 5.4a). Furthermore, conditions for hydrogenation, deprotection and N-
functionalisation of amine-based scaffold 179 could also be explored (Scheme 5.4b). 
  
Scheme 5.4 
With regards to morphan-derived building block 95, the synthesis of this building block 
proved more challenging. Late-stage enol triflate 139 was obtained in 29% overall yield and 
only 90:10 dr. However, formation of vinyl MIDA boronate 956 from enol triflate 169 failed 
to give a pure sample of vinyl MIDA boronate 95 (Scheme 5.5). Different routes involving 
sulfonamide and N-Boc protected series of substrates were studied for the synthesis of 





Further work in this scaffold should involve the synthesis and characterisation of a pure 
sample of vinyl MIDA boronate 95 which could be achieved by attempting purification of 
the intermediate vinyl pinacol boronate instead of using the crude product. Development of 
a route into diastereopure building block 95 is also important. A possible approach would be 
to use the hydrogenation conditions reported by Ye and co-workers53 (10% Pd/C with H2 at 
20 bar) (Scheme 5.6). Alternatively, a different approach to access a morphan scaffold 
without the methylene group could be investigated. For example Dixon and co-workers68 
reported the synthesis of 180 after which decarboxylation could  be performed to access the 
diastereopure morphan building block 95 (Scheme 5.6). Finally, Suzuki-Miyaura 
functionalisation of the vinyl MIDA boronate, hydrogenation of the alkene, and N-





Chapter 6 Experimental 
6.1 Computational Methods 
Computational vector analysis was performed  by generating the lowest energy conformer 
of the compound of interest using a Pipeline Pilot protocol developed in the O’Brien group.77 
Prior to conformer generation a wash step was performed, which involved stripping salts 
and ionising the molecule at pH 7.4. Any stereocentre created here was left with undefined 
stereochemistry. SMILES strings were converted to their canonical representation. A list of 
allowed chirality at each centre is generated and a SMILES file with all possible 
stereoisomers was written. Conformers were generated using the BEST method in Catalyst 
using the rel option, run directly on the server and not through the built-in Conformation 
Generator component with a chosen maximum relative energy threshold of 20 kcal mol-1, 
maximum of 255 conformers for each compound. Conformations were read, ones that cannot 
be represented by the canonical SMILES are discarded, with the remaining ones standardised 
to a single enantiomer. Duplicates were filtered with a RMSD threshold of 0.1. Minimisation 
with 200 steps of Conjugate Gradient minimisation with an RMS gradient tolerance of 0.1 
was performed using the CHARMm forcefield with Momany-Rone partial charge estimation 
and a Generalised Born implicit solvent model. Duplicates were filtered again with a RMSD 
threshold of 0.1. 
Following this, the lowest energy conformer was selected for each compound and a MDL 
Molfile containing the 3-D coordinates of atoms was generated. The variation points and 
vectors were individually defined and the file was inputted into Grygorenko’s19 Python™ 
protocol which gave the processed data for r, Φ1, Φ2, and θ. 
 
6.2 Synthetic Methods 
6.2.1 General Methods 
All non-aqueous reactions were carried out under oxygen-free Ar atmosphere using flame-
dried glassware. THF was freshly distilled from sodium and benzophenone. Alkyllithiums 
were titrated against N-benzylbenzamide before use.112 Et3N, i-Pr2NH and pyrrolidine were 
distilled over CaH2 before use. Brine refers to a saturated NaCl(aq) solution. Water is distilled 
water. Flash column chromatography was carried out using Fluka Chemie GmbH silica (220- 
440 mesh). Thin layer chromatography was carried out using commercially available Merck 
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F254 aluminium backed silica plates. Proton (400 MHz) and carbon (100.6 MHz) NMR 
spectra were recorded on a Jeol ECX-400 instrument using an internal deuterium lock. For 
samples recorded in CDCl3, chemical shifts are quoted in parts per million relative to CHCl3 
(δH 7.26) and CDCl3 (δC 77.0, central line of triplet). For samples recorded in d6-DMSO, 
chemical shifts are quoted in parts per million relative to DMSO (δH 2.50, central line of 
quintet) and d6-DMSO (δC 39.5, central line of septet). For samples recorded in d6-acetone, 
chemical shifts are quoted in parts per million relative to acetone (δH 2.05, central line of 
quintet) and d6-acetone (δC 29.8, central line of septet). Carbon NMR spectra were recorded 
with broad band proton decoupling and assigned using DEPT experiments. Coupling 
constants (J) are quoted in Hertz. Melting points were carried out on a Gallenkamp melting 
point apparatus. Infrared spectra were recorded on an ATI Mattson Genesis FT-IR 
spectrometer. Electrospray high and low resonance mass spectra were recorded at room 
temperature on a Bruker Daltronics microOTOF spectrometer. 
6.2.2 General Procedures 
General Procedure A: Suzuki-Miyaura cross coupling of vinyl MIDA boronate 94 
A solution of vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), Pd(OAc)2 (3 mg, 
0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq) and the aryl bromide (0.28 mmol, 
1.2 eq) in dioxane (2.35 mL) in a sealed tube was stirred at rt for 15 min under Ar. 3 M 
K3PO4(aq) (0.59 mL, 1.755 mmol, 7.5 eq), degassed by sparging with Ar, was added and the 
resulting mixture was stirred and heated at 60 °C in a sealed tube for 20 h. H2O (5 mL) was 
added and the mixture was extracted with Et2O (3 × 10 mL). The combined organic extracts 
were washed with brine (10 mL), dried (Na2SO4) and evaporated under reduced pressure to 









6.2.3 Experimental Procedures and Characterisation Data 
2,2,2-Trichloro-N-(2,4-dimethoxybenzyl)-N-(4-oxocyclohexyl)acetamide 108 
 
A solution of 1,4-cyclohexadione monoethylene acetal 29 (4.00 g, 25.6 mmol, 1.0 eq), 2,4-
dimethoxybenzylamine (3.9 mL, 25.6 mmol, 1.0 eq) and NaBH(OAc)3 (7.60 g, 35.9 mmol, 
1.4 eq) in CH2Cl2 (100 mL) was stirred at rt for 16 h. Saturated NH4Cl(aq) (10mL) was added. 
Then, 1 M NaOH(aq) was added until pH ≈ 10 was reached. The mixture was extracted with 
CH2Cl2 (3 × 20 mL). The combined organic extracts were washed with brine (50 mL) dried 
(Na2SO4) and evaporated under reduced pressure to give the crude amine as a pale yellow 
oil. To the crude amine was added 3 M HCl(aq) (140 mL) and the resulting solution was 
stirred at rt for 48 h. Solid Na2CO3 was added until pH ≈ 9 was reached and the mixture was 
extracted with CH2Cl2 (3 × 20 mL). The combined organic extracts were washed with brine 
(50 mL), dried (Na2SO4) and evaporated under reduced pressure to give the crude amino 
ketone as a pale yellow oil. The crude amino ketone was dissolved in CH2Cl2 (80 mL). The 
resulting solution was cooled to 0 °C and Et3N (6.8 mL, 48.6 mmol, 1.9 eq) was added under 
Ar. Then, trichloroacetyl chloride (5.2 mL, 45.0 mmol, 1.8 eq) was added dropwise and the 
solution was allowed to warm to rt. The resulting solution was stirred at rt for 4 h and then 
poured into water (30 mL). The mixture was extracted with CH2Cl2 (3 × 20 mL) and the 
combined organic extracts were washed with brine (50 mL), dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 4:6 to 7:3 Et2O-hexane as eluent gave trichloroacetamide 108 
(9.45 g, 90%) as a white solid, mp 122-124 °C; RF (4:6 Et2O-hexane) 0.22; IR (ATR) 2956, 
1717 (C=O, ketone), 1674 (C=O, amide), 1615, 1507, 1417, 1259, 1208, 1157, 1123, 1036, 
825, 812, 730, 667 cm‒1; 1H NMR (400 MHz, CDCl3) (65:35 mixture of rotamers) δ 7.25–
7.15 (m, 0.35H, Ar), 6.96 (d, J = 8.5 Hz, 0.65H, Ar), 6.52–6.35 (m, 2H, Ar), 5.00 (br t, J = 
12.0 Hz, 0.65H, NCH), 4.93–4.79 (m, 0.35H, NCH), 4.60–4.52 (m, 1.3H, NCHAr), 4.04–
3.92 (m, 0.35H, NCHAr), 3.84–3.74 (m, 6.35H, NCHAr, OMe), 2.49–2.37 (m, 3.3H, CH), 
2.36–2.21 (m, 0.7H, CH), 2.21–2.10 (m, 2.05H, CH), 2.10–1.91 (m, 1.95H, CH). 13C NMR 
(100.6 MHz, CDCl3) (mixture of rotamers) δ 208.4 (C=O, ketone), 160.7 (C=O, amide), 
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160.1 (ipso-Ar), 157.2 (ipso-Ar), 128.7 (Ar, only resolved in HMQC), 127.1 (Ar), 117.4 
(ipso-Ar), 104.3 (ipso-Ar), 98.5 (Ar), 93.8 (CCl3), 57.2 (NCH), 55.5 (OMe), 46.9 (NCH), 
42.1 (NCH2), 39.8 (CH2), 29.3 (CH2) (1 × OMe resonance not resolved); HRMS (ESI) m/z 
calcd for C17H20
35Cl3NO4 (M + Na)
+ 430.0350, found 430.0344 (+1.4 ppm error). 
Lab book reference: ARG-1-007 
 
A solution of 1,4-cyclohexadione monoethylene acetal 29 (875 mg, 5.62 mmol, 1.0 eq), 2,4-
dimethoxybenzylamine (0.9 mL, 5.84 mmol, 1.0 eq) and NaBH(OAc)3 (1.70 g, 7.86 mmol, 
1.4 eq) in CH2Cl2 (25 mL) was stirred at rt for 16 h. Saturated NH4Cl(aq) (5mL) was added. 
Then, 1 M NaOH(aq) was added until pH ≈ 10 was reached. The mixture was extracted with 
CH2Cl2 (3 × 10 mL). The combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude amine as a pale-yellow oil. To the crude amine was 
added 3 M HCl(aq) (40 mL) and the resulting solution was stirred at rt for 48 h. Solid Na2CO3 
was added until pH ≈ 9 was reached and the solution was extracted with CH2Cl2 (3 × 10 
mL). The combined organic extracts were dried (Na2SO4) and evaporated under reduced 
pressure to give the crude amino ketone as a pale-yellow oil. The crude amino ketone was 
dissolved in CH2Cl2 (20 mL). The resulting solution was cooled to 0 °C and Et3N (1.5 mL, 
10.8 mmol, 1.9 eq) was added. Then, trichloroacetyl chloride (1.1 mL, 9.80 mmol, 1.8 eq) 
was added dropwise and the solution was allowed to warm to rt. The resulting solution was 
stirred at rt for 4 h and then poured into water (10 mL). The mixture was extracted with 
CH2Cl2 (3 × 10 mL) and the combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 4:6 to 7:3 Et2O-hexane as eluent gave trichloroacetamide 108 
(2.04 g, 89%) as a white solid, identical (by 1H and 13C NMR spectroscopy) to that described 
above. 
Lab book reference: ARG-1-003 
 
A solution of 1,4-cyclohexadione monoethylene acetal 29 (4.06 g, 26.0 mmol, 1.0 eq), 2,4-
dimethoxybenzylamine (4.0 mL, 26.0 mmol, 1.0 eq) and NaBH(OAc)3 (7.70 g, 36.4 mmol, 
1.4 eq) in CH2Cl2 (107 mL) was stirred at rt for 12 h. Saturated NH4Cl(aq) (10mL) was added. 
Then, 1 M NaOH(aq) was added until pH ≈ 10 was reached. The mixture was extracted with 
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CH2Cl2 (3 × 20 mL). The combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude amine as a pale-yellow oil. To the crude amine was 
added 3 M HCl(aq) (140 mL) and the resulting solution was stirred at rt for 48 h. Solid Na2CO3 
was added until pH ≈ 9 was reached and the solution was extracted with CH2Cl2 (3 × 20 
mL). The combined organic extracts were dried (Na2SO4) and evaporated under reduced 
pressure to give the crude amino-ketone as a pale-yellow oil. The crude amino-ketone was 
dissolved in CH2Cl2 (80 mL). The resulting solution was cooled to 0 °C and Et3N (7.0 mL, 
49.4 mmol, 1.9 eq) was added. Then, trichloroacetyl chloride (5.3 mL, 46.8 mmol, 1.8 eq) 
was added dropwise and the solution was allowed to warm to rt. The resulting solution was 
stirred at rt for 4 h and then poured into water (30 mL). The mixture was extracted with 
CH2Cl2 (3 × 20 mL) and the combined organic extracts were dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by triturating the crude solid 
with Et2O (2 × 50 mL) gave trichloroacetamide 108 (6.38 g, 60%) as a white solid, identical 
(by 1H and 13C NMR spectroscopy) to that described above. 




A mixture of trichloroacetamide 108 (501 mg, 1.22 mmol, 1.0 eq) and pyrrolidine (0.11 mL, 
1.22 mmol, 1.0 eq) in toluene (0.3 mL) was stirred and heated at 100 °C in a sealed vial for 
1 h. The crude mixture was directly purified by flash column chromatography on silica with 
1:1 to 4:1 EtOAc-hexane as eluent to give normorphan 109 (281 mg, 80%) as a red oil, RF 
(1:1 EtOAc-hexane) 0.17; IR (ATR) 2953, 1723 (C=O, ketone), 1689 (C=O, amide), 1613, 
1588, 1508, 1418, 1295, 1209, 1158, 1125, 1034, 835 cm–1; 1H NMR (400 MHz, CDCl3) δ 
7.24–7.21 (m, 1H, Ar), 6.48–6.44 (m, 2H, Ar), 4.60 (d, J = 14.5 Hz, 1H, NCHH'), 4.43 (d, J 
= 14.5 Hz, 1H, NCHH'), 3.85–3.78 (m, 7H, OMe, NCH), 3.18 (d, J = 5.0 Hz, 1H, C(O)CH), 
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2.56 (dddd, J = 11.5, 5.0, 5.0, 2.5 Hz, 1H, CH-4), 2.45–2.32 (m, 2H, C(O)CHH’), 2.08–2.00 
(m, 1H, CH-2), 1.98 (d, J = 11.5 Hz, 1H, CH-4), 1.79 (dddd, J = 13.5, 8.5, 8.5, 1.5 Hz, 1H, 
CH-2). 13C NMR (100.6 MHz, CDCl3) δ 203.0 (C=O, ketone), 170.8 (C=O, amide), 160.9 
(ipso-Ar), 158.7 (ipso-Ar), 131.3 (Ar), 116.8 (ipso-Ar), 104.4 (Ar), 98.6 (Ar), 58.3 (CHCO), 
55.5 (OMe), 54.8 (NCH), 39.5 (NCH2), 36.2 (CH2-4), 35.1 (CH2CO), 27.6 (CH2-2) (1 × 
OMe resonance not resolved); HRMS (ESI) m/z calcd for C16H19NO4 (M + H)
+ 290.1383, 
found 290.1387 (+1.4 ppm error). 
Lab book reference: ARG-1-019 
 
A mixture of trichloroacetamide 108 (200 mg, 0.49 mmol, 1.0 eq) and pyrrolidine (0.1 mL, 
0.98 mmol, 2.0 eq) in toluene (2 mL) was stirred and heated at reflux for 45 min. The solvent 
was evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 1:1 to 4:1 EtOAc-hexane as eluent gave normorphan 
109 (63 mg, 45%) as a red oil, identical (by 1H and 13C NMR spectroscopy) to that described 
above. 
Lab book reference: ARG-1-006 
 
A mixture of trichloroacetamide 108 (400 mg, 0.98 mmol, 1.0 eq) and pyrrolidine (0.2 mL, 
1.96 mmol, 2.0 eq) in toluene (3 mL) was stirred and heated at reflux for 3 h. The solvent 
was evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 1:1 to 4:1 EtOAc-hexane as eluent gave normorphan 
109 (93 mg, 33%) as a red oil, identical (by 1H and 13C NMR spectroscopy) to that described 
above. 
Lab book reference: ARG-1-008 
 
A mixture of trichloroacetamide 108 (500 mg, 1.22 mmol, 1.0 eq) and pyrrolidine (51 µL, 
0.61 mmol, 0.5 eq) was stirred and heated at 100 °C in a sealed vial for 1 h. The crude 
mixture was directly purified by flash column chromatography on silica with 1:1 to 4:1 
EtOAc-hexane as eluent to give normorphan 109 (222 mg, 63%) as a red oil, identical (by 
1H and 13C NMR spectroscopy) to that described above. 
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Lab book reference: ARG-1-010 
A mixture of trichloroacetamide 108 (7.00 g, 17.1 mmol, 1.0 eq) and pyrrolidine (1.43 mL, 
17.1 mmol, 1.0 eq) in toluene (4.3 mL) was stirred and heated at 100 °C in a sealed tube for 
1 h. The crude mixture was directly purified by flash column chromatography on silica with 
1:1 to 4:1 EtOAc-hexane as eluent to give normorphan 109 (3.96 g, 80%) as a red oil, 
identical (by 1H and 13C NMR spectroscopy) to that described above. 





NaHMDS (4.0 mL of a 2 M solution in THF, 8.0 mmol, 1.6 eq) was added dropwise to a 
stirred solution of normorphan 109 (1.44 g, 4.97 mmol, 1.0 eq) in THF (12 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of PhNTf2 
(2.30 g, 6.46 mmol, 1.3 eq) in THF (8 mL) was added and the resulting solution was allowed 
to warm slowly to rt. The solution was stirred at rt for 16 h. Saturated NH4Cl(aq) (15 mL) was 
added and the mixture was extracted with Et2O (4 × 15 mL). The combined organic extracts 
were washed with brine (50 mL), dried (Na2SO4) and evaporated under reduced pressure to 
give the crude product. Purification by flash column chromatography on silica with 1:1 to 
4:1 Et2O-hexane as eluent gave vinyl triflate 110 (1.25 g, 60%) as a clear oil, RF (3:2 Et2O-
hexane) 0.22; IR (ATR) 2959, 1703 (C=O), 1662 (C=C), 1589, 1508, 1415, 1206, 1138, 878, 
834, 609 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.14–7.08 (m, 1H, Ar), 6.47–6.40 (m, 2H, 
Ar), 5.56–5.51 (m, 1H, =CH), 4.50 (d, J = 14.5 Hz, 1H, NCHH'), 4.29 (d, J = 14.5 Hz, 1H, 
NCHH'), 3.83–3.77 (m, 6H, OMe), 3.76–3.71 (m, 1H, NCH), 2.98–2.94 (m, 1H, CH-5), 
2.36–2.23 (m, 3H, CH2-2, CH-4), 1.90 (d, J = 10.5 Hz, 1H, CH2-4); 
13C NMR (100.6 MHz, 
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CDCl3) δ 173.6 (C=O), 160.8 (ipso-Ar), 158.5 (ipso-Ar), 148.4 (=C), 130.9 (Ar), 118.6 (q, 
J = 320.0 Hz, CF3), 117.2 (ipso-Ar), 114.8 (=CH) , 104.5 (Ar), 98.6 (Ar), 55.5 (OMe), 55.4 
(OMe), 53.0 (NCH), 44.7 (CHCO), 38.4 (NCH2), 34.1 (CH2-4), 28.3 (CH2-2); HRMS (ESI) 
m/z calcd for C17H18F3NO6S (M + Na)
+  444.0699, found 444.0706 (–1.8 ppm error). 
Lab book reference: ARG-1-048 
 
n-BuLi (0.19 mL of a 2.2 M solution in THF, 0.41 mmol, 1.2 eq) was added dropwise to a 
stirred solution of i-Pr2NH (61 µL, 0.41 mmol, 1.2 eq) in THF (1 mL) at –78 °C under Ar. 
The resulting solution was stirred at –78 °C for 10 min. Then, a solution of normorphan 109 
(100 mg, 0.35 mmol, 1.0 eq) in THF (0.8 mL) was added. The solution was stirred for 1 h. 
Then, a solution of PhNTf2 (172 mg, 0.48 mmol, 1.4 eq) in THF (1 mL) was added and the 
resulting solution was allowed to warm slowly to rt. The solution was stirred at rt for 18 h. 
Saturated NH4Cl(aq) (2 mL) was added and the mixture was extracted with Et2O (3 × 10 mL). 
The combined organic extracts were washed with brine (10 mL), dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 to 4:1 Et2O-hexane as eluent gave vinyl triflate 110 (44 
mg, 30%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described above. 
Lab book reference: ARG-1-021 
 
LiHMDS (1.0 mL of a 1 M solution in THF, 1.01 mmol, 1.4 eq) was added dropwise to a 
stirred solution of normorphan 109 (210 mg, 0.72 mmol, 1.0 eq) in THF (2.5 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of Comins’ 
reagent 113 (370 mg, 0.94 mmol, 1.3 eq) in THF (2 mL) was added and the resulting solution 
was allowed to warm slowly to rt. The solution was stirred at rt for 18 h. Saturated NH4Cl(aq) 
(5 mL) was added and the mixture was extracted with Et2O (3 × 10 mL). The combined 
organic extracts were washed with brine (20 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product which contained <10% of vinyl triflate 110 by 
1H NMR spectroscopy. 




KHMDS (0.31 mL of a 1 M solution in THF, 0.31 mmol, 1.3 eq) was added dropwise to a 
stirred solution of normorphan 109 (100 mg, 0.30 mmol, 1.0 eq) in THF (1.5 mL) at –78 °C 
under Ar. After stirring at –78 °C for 1 h, a solution of PhNTf2 (122 mg, 0.34 mmol, 1.4 eq) 
in THF (1.5 mL) was added and resulting the solution was allowed to warm slowly to rt. The 
solution was stirred at rt for 18 h. Saturated NH4Cl(aq) (5 mL) was added and the mixture was 
extracted with Et2O (3 × 15 mL). The combined organic extracts were washed with brine 
(20 mL), dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 1:1 to 4:1 Et2O-hexane as eluent 
gave vinyl triflate 110 (8 mg, 8%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) 
to that described above. 
Lab book reference: ARG-1-020 
 
NaHMDS (0.76 mL of a 2 M solution in THF, 1.53 mmol, 1.8 eq) was added dropwise to a 
stirred solution of normorphan 109 (245 mg, 0.85 mmol, 1.0 eq) in THF (3 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of PhNTf2 
(395 mg, 1.11 mmol, 1.3 eq) in THF (2.5 mL) was added and the resulting solution was 
allowed to warm slowly to rt. The solution was stirred at rt for 18 h. Saturated NH4Cl(aq) (5 
mL) was added and the mixture was extracted with Et2O (3 × 15 mL). The combined organic 
extracts were washed with cold 10% NaOH(aq) (10 mL) and brine (50 mL), dried (Na2SO4) 
and evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 1:1 to 4:1 Et2O-hexane as eluent gave vinyl triflate 
110 (150 mg, 45%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that 
described above. 
Lab book reference: ARG-1-031 
 
NaHMDS (0.76 mL of a 2 M solution in THF, 1.53 mmol, 1.8 eq) was added dropwise to a 
stirred solution of normorphan 109 (245 mg, 0.85 mmol, 1.0 eq) in THF (3 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of Comins’ 
reagent 113 (435 mg, 1.11 mmol, 1.3 eq) in THF (2.5 mL) was added and resulting the 
solution was allowed to warm slowly to rt. The solution was stirred at rt for 18 h. Saturated 
NH4Cl(aq) (5 mL) was added and the mixture was extracted with Et2O (3 × 15 mL). The 
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combined organic extracts were washed with cold 10% NaOH(aq) (10 mL) and brine (50 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 1:1 to 4:1 Et2O-hexane as eluent 
gave vinyl triflate 110 (130 mg, 36%) as a clear oil, identical (by 1H and 13C NMR 
spectroscopy) to that described above. 
Lab book reference: ARG-1-032 
 
NaHMDS (2.8 mL of a 2 M solution in THF, 1.52 mmol, 1.8 eq) was added dropwise to a 
stirred solution of normorphan 109 (230 mg, 0.79 mmol, 1.0 eq) in THF (2.8 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of PhNTf2 
(367 mg, 1.23 mmol, 1.3 eq) in THF (2.2 mL) was added and the resulting solution was 
allowed to warm slowly to rt. The solution was stirred at rt for 48 h. Saturated NH4Cl(aq) (5 
mL) was added and the mixture was extracted with Et2O (3 × 15 mL). The combined organic 
extracts were washed with brine (50 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on silica 
with 1:1 to 4:1 Et2O-hexane as eluent gave vinyl triflate 110 (113 mg, 33%) as a clear oil, 
identical (by 1H and 13C NMR spectroscopy) to that described above. 
Lab book reference: ARG-1-038 
 
NaHMDS (9.2 mL of a 2 M solution in THF, 18.4 mmol, 1.6 eq) was added dropwise to a 
stirred solution of normorphan 109 (3.55 g, 12.3 mmol, 1.0 eq) in THF (30 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of PhNTf2 
(5.70 g, 15.9 mmol, 1.3 eq) in THF (20 mL) was added and resulting the solution was 
allowed to warm slowly to rt. The solution was stirred at rt for 18 h. Saturated NH4Cl(aq) (30 
mL) was added and the mixture was extracted with Et2O (5 × 20 mL). The combined organic 
extracts were washed with brine (50 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on silica 
with 1:1 to 4:1 Et2O-hexane as eluent gave vinyl triflate 110 (3.20 g, 61%) as a clear oil, 
identical (by 1H and 13C NMR spectroscopy) to that described above. 





trifluoromethanesulfonate 110 and N-(5-chloropyridin-2-yl)-1,1,1-
trifluoromethanesulfonamide 114 
   
n-BuLi (0.25 mL of a 2.2 M solution in THF, 0.53 mmol, 1.3 eq) was added dropwise to a 
stirred solution of i-Pr2NH (75 µL, 0.53 mmol, 1.3 eq) in THF (1 mL) at –78 °C under Ar. 
The resulting solution was stirred at –78 °C for 10 min. Then, a solution of normorphan 109 
(118 mg, 0.41 mmol, 1.0 eq) in THF (1 mL) was added. The resulting solution was stirred 
at –78 °C for 1 h. Then, solution of Comins’ reagent 113 (208 mg, 0.53 mmol, 1.3 eq) in 
THF (1 mL) was added and the resulting solution was allowed to warm slowly to rt. The 
solution was stirred at rt for 18 h. Saturated NH4Cl(aq) (2 mL) was added and the mixture 
extracted with Et2O (3 × 10 mL). The combined organic extracts were washed with brine 
(10 mL), dried (Na2SO4) and the evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 1:1 to 4:1 Et2O-hexane 
as eluent gave an 80:20 mixture of vinyl triflate 110 and sulfonamide 114 (69 mg, i.e. 56.6 
mg (33%) of vinyl triflate 110) as a clear oil. Diagnostic signals for sulfonamide 114: 1H 
NMR (400 MHz, CDCl3) δ 8.15–8.10 (m, 1H), 7.82–7.75 (m, 1H), 7.72–7.64 (m, 1H). 
Lab book reference: ARG-1-022 
 
NaHMDS (0.53 mL of a 2 M solution in THF, 1.08 mmol, 1.3 eq) was added dropwise to a 
stirred solution of normorphan 109 (240 mg, 0.83 mmol, 1.0 eq) in THF (1.5 mL) at –78 °C 
under Ar. The resulting solution was stirred at –78 °C for 1 h. Then, a solution of Comins’ 
reagent 113 (424 mg, 1.08 mmol, 1.3 eq) in THF (2.5 mL) was added and the resulting 
solution was allowed to warm slowly to rt. The solution was stirred at rt for 18 h. Saturated 
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NH4Cl(aq) (5 mL) was added and the mixture was extracted with Et2O (3 × 15 mL). The 
combined organic extracts were washed with brine (20 mL), dried (Na2SO4) and evaporated 
under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 to 4:1 Et2O-hexane as eluent an 85:15 mixture of vinyl 
triflate 110 and sulfonamide 114 (219 mg, i.e. 190 mg (54%) of vinyl triflate 110) as a clear 
oil. 
Lab book reference: ARG-1-025 
 
8-(6-(2,4-Dimethoxybenzyl)-7-oxo-6-azabicyclo[3.2.1]oct-2-en-2-yl)-4-methyldihydro-
4λ4,8λ4-[1,3,2]oxazaborolo[2,3-b][1,3,2]oxazaborole-2,6(3H,5H)-dione 94 and 6-(2,4-
dimethoxybenzyl)-6-azabicyclo[3.2.1]oct-2-en-7-one 115 
           
A solution of vinyl triflate 110 (1.98 g, 4.70 mmol, 1.0 eq), PdCl2(PPh3)2 (97 mg, 0.14 mmol, 
0.03 eq), PPh3 (73 mg, 0.28 mmol, 0.06 eq), KOPh (931 mg, 7.05 mmol, 1.5 eq) and B2pin2 
(1.31 g, 5.17 mmol, 1.1 eq) in toluene (30 mL) under Ar was stirred and heated at 50 °C for 
16 h. The solids were removed by filtration through Celite® and the filtrate was evaporated 
under reduced pressure to give the crude pinacol boronate. The crude pinacol boronate was 
dissolved in DMSO (24 mL) and MIDA (4.49 g, 30.54 mmol, 6.5 eq) and HC(OEt)3 (3.70 
mL, 21.14 mmol, 4.5 eq) were added. The resulting mixture was stirred and heated at 100 
°C under Ar for 48 h. Saturated NH4Cl(aq) (10 mL) was added and the mixture was extracted 
with EtOAc (4 × 30 mL). The combined organic extracts were washed with brine (50 mL), 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. Purification 
by flash column chromatography on silica with 9:1 to 7:3 CH2Cl2-acetone as eluent gave 
alkene 115 (192 mg, 15%) as a clear oil, RF (9:1 hexane-acetone) 0.1; IR (ATR) 2940, 2835, 
1685 (C=O), 1612, 1587, 1506, 1411, 1206, 1031, 832, 669 cm–1; 1H NMR (400 MHz, 
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CDCl3) δ 7.09–7.03 (m, 1H, Ar), 6.42–6.34 (m, 2H, Ar), 6.07 (dddd, J = 9.0, 7.0, 1.0, 1.0 
Hz, 1H, =CH-6), 5.51 (dddd, J = 9.0, 3.5, 3.0, 1.5 Hz, 1H, =CH-1), 4.50 (d, J = 15.0 Hz, 1H, 
NCHH'), 4.16 (d, J = 15.0 Hz, 1H, NCHH'), 3.76–3.71 (m, 6H, OMe), 3.66–3.62 (m, 1H, 
NCH), 2.75 (dd, J = 7.0, 4.5 Hz, 1H, CH-5), 2.17 – 2.04 (m, 3H, CHH'-2, CHH'-4), 1.71 (d, 
J = 10.0 Hz, 1H, CHH'-4); 13C NMR (100.6 MHz, CDCl3) δ 177.5 (C=O), 160.4 (ipso-Ar), 
158.5 (ipso-Ar), 130.3 (Ar), 129.2 (=CH-6), 126.0 (=CH-1), 117.8 (ipso-Ar), 104.3 (Ar), 
98.4 (Ar), 55.4 (OMe), 54.3 (NCH), 40.8 (CH-5), 37.8 (NCH2), 33.9 (CH2-4), 28.3 (CH2-2) 
(1 × OMe resonance not resolved); HRMS (ESI) m/z calcd for C16H19NO3 (M+Na)
+ 
296.1257, found 296.1250 (+2.7 ppm error) and vinyl MIDA boronate 94 (1.40 g, 70%) as 
an off-white crystalline solid, mp 80-82 °C; RF (4:1 CH2Cl2-acetone) 0.29; IR (ATR) 2958, 
1760 (C=O, ester), 1673 (C=O, amide), 1614, 1508, 1457, 1292, 1180, 1036, 823 cm–1; 1H 
NMR (400 MHz, d6-acetone) δ 7.08 (d, J = 8.5 Hz, 1H, Ar), 6.53 (d, J = 2.5 Hz, 1H, Ar), 
6.45 (dd, J = 8.5, 2.5 Hz, 1H, Ar), 5.98 (ddd, J = 3.0, 3.0, 3.0 Hz, 1H, =CH), 4.41 (d, J = 
15.0 Hz, 1H, NCHH'), 4.27–4.07 (m, 4H, NCHH', CHH'CO2), 3.96 (d, J = 17.0 Hz, 1H, 
CHH'CO2), 3.81 (s, 3H, OMe), 3.78–3.71 (m, 4H, OMe, NCH), 2.84 (s, 3H, NMe), 2.64 (d, 
J = 4.5 Hz, 1H, CH-5), 2.24–2.17 (m, 2H, CHH'-2), 2.16 (ddd, J = 10.5, 5.5, 4.5 Hz, 1H, 
CHH'-4), 1.67 (d, J = 10.5 Hz, 1H, CHH'-4); 13C NMR (100.6 MHz, d6-acetone) δ 177.0 
(C=O, amide), 169.2 (C=O, ester), 167.9 (C=O, ester), 160.7 (ipso-Ar), 158.6 (ipso-Ar), 
134.1 (=CH), 130.0 (Ar), 117.8 (ipso-Ar), 104.6 (Ar), 98.2 (Ar), 62.0 (CH2CO2), 61.3 
(CH2CO2), 55.0 (OMe), 54.8 (OMe), 54.3 (NCH), 45.8 (NMe), 41.8 (CH-5), 37.6 (NCH2), 
33.7 (CH2-4), 28.8 (CH2-2, only resolved in DEPT-135) (=C-B resonance not resolved); 
HRMS (ESI) m/z calcd for C21H25BN2O7 (M + Na)
+  451.1647, found 451.1654 (–0.2 ppm 
error) 
Lab book reference: ARG-2-114 
 
PdCl2(dppf) (22 mg, 0.03 mmol, 0.06 eq), dppf  (17 mg, 0.03 mmol, 0.06 eq), KOAc (134 
mg, 1.37 mmol, 3.0 eq) and B2pin2 (137 mg, 0.54 mmol, 1.2 eq) were added to a stirred 
solution of vinyl triflate 110 (193 mg, 0.46 mmol, 1.0 eq) in dioxane (3 mL) at rt under Ar. 
The resulting mixture was stirred and heated at 80 °C under Ar for 16 h. H2O (10 mL) was 
added and the mixture was extracted with EtOAc (3 × 10 mL). The combined organic 
extracts were washed with brine (20 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give the crude pinacol boronate. Purification by flash column chromatography 
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on silica with 4:6 EtOAc-hexane as eluent gave impure pinacol boronate 111 (100 mg) which 
was dissolved in DMSO (1.2 mL). MIDA (228.5 mg, 1.55 mmol, 6.2 eq) and HC(OEt)3 
(0.17 mL, 1.0 mmol, 4.0 eq) were added. The resulting mixture was stirred and heated at 100 
°C under Ar for 48 h. Saturated NH4Cl(aq) (10 mL) was added and the mixture was extracted 
with EtOAc (3 × 10 mL). The combined organic extracts were washed with brine (20 mL), 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. Purification 
by flash column chromatography on silica with 9:1 to 7:3 CH2Cl2-acetone as eluent gave 
vinyl MIDA boronate 94 (49 mg, 25%) as an off-white crystalline solid identical (by 1H and 
13C NMR spectroscopy) to that described above. Diagnostic signals for pinacol boronate 
111: 1H NMR (400 MHz, CDCl3) δ 7.11–7.07 (m, 1H, Ar), 6.43–6.39 (m, 2H, Ar), 6.39–
6.37 (m, 1H, =CH), 4.52 (d, J = 15.0 Hz, 1H, NCHH'), 4.14 (d, J = 15.0 Hz, 1H, NCHH’), 
3.84–3.74 (m, 6H, OMe), 3.66–3.60 (m, 1H, NCH), 3.07 (d, J = 4.5 Hz, 1H, C(O)CH), 2.11 
(ddd, J = 10.5, 5.5, 5.5 Hz, 1H, CHH’), 1.64 (d, J = 10.5 Hz, 1H, CHH’); HRMS (ESI) m/z 
calcd for C22H30BNO5 (M + Na)
+  422.2109, found 422.2117 (–1.0 ppm error). 
Lab book reference: ARG-1-015 
 
A solution of vinyl triflate 110 (219 mg, 0.52 mmol, 1.0 eq), PdCl2(PPh3)2 (15 mg, 0.02 
mmol, 0.03 eq), PPh3 (8 mg, 0.03 mmol, 0.06 eq), KOPh (103 mg, 0.78 mmol, 1.5 eq) and 
B2pin2 (145 mg, 0.57 mmol, 1.1 eq) in toluene (3 mL)was stirred and heated at 50 °C under 
Ar for 16 h. H2O (15 mL) was added, and the mixture was extracted with EtOAc (4 × 10 
mL). The combined organic extracts were washed with brine (10 mL), dried (Na2SO4) and 
evaporated under reduced pressure to give the crude pinacol boronate. Purification by flash 
column chromatography on silica with 4:6 EtOAc-hexane as eluent gave impure pinacol 
boronate 111 (158 mg) which was dissolved in DMSO (1.8 mL). MIDA (343 mg, 2.33 
mmol, 6.2 eq) and HC(OEt)3 (0.25 mL, 1.50 mmol, 4.0 eq) were added. The reaction mixture 
was heated and stirred at 100 °C under Ar for 48 h. Saturated NH4Cl(aq) (10 mL) was added 
and the mixture was extracted with EtOAc (4 × 10 mL). The combined organic extracts were 
washed with brine (20 mL), dried (MgSO4) and evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 9:1 to 7:3 
CH2Cl2-acetone as eluent gave vinyl MIDA boronate 94 (122 mg, 54%) as an off-white 
crystalline solid, identical (by 1H and 13C NMR spectroscopy) to that described above. 




A solution of vinyl triflate 110 (1.45 g, 3.44 mmol, 1.0 eq), PdCl2(PPh3)2 (72 mg, 0.10 mmol, 
3 mol%), PPh3 (54 mg, 0.21 mmol, 6 mol%), KOPh (682 mg, 5.16 mmol, 1.5 eq) and B2pin2 
(961 mg, 3.78 mmol, 1.1 eq) in toluene (22 mL) was stirred and heated at 50 °C  under Ar 
for 16 h. The solids were removed by filtration through Celite® and the filtrate was 
evaporated under reduced pressure to give the crude pinacol boronate 111. The crude pinacol 
boronate was dissolved in DMSO (18 mL) and MIDA (1.52 g, 10.32 mmol, 3.0 eq) and 
HC(OEt)3 (2.4 mL, 13.76 mmol, 4.0 eq) were added. The reaction mixture was stirred and 
heated to 100 °C under Ar for 48 h. Saturated NH4Cl(aq) (10 mL) was added and the mixture 
extracted with EtOAc (4 × 30 mL). The combined organic extracts were washed with brine 
(50 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 9:1 to 7:3 CH2Cl2-acetone as 
eluent gave alkene 115 (150 mg, 17%) as a clear oil, identical (by 1H and 13C NMR 
spectroscopy) to that described above and vinyl MIDA boronate 94 (850 mg, 60%) as an 
off-white crystalline solid, identical (by 1H and 13C NMR spectroscopy) to that described 
above. 
Lab book reference: ARG-2-120 
 
tert-Butyl ((1R,2R)-2-(3-methylthioureido)cyclohexyl)carbamate (R,R)-118 
 
 
Methyl isothiocyanate (419 mg, 5.60 mmol, 3 eq) was added to a stirred solution of tert-
butyl ((1R,2R)-2-aminocyclohexyl)carbamate (R,R)-117 (400 mg, 1.87 mmol, 1.0 eq) in 
CH2Cl2 (8.5 mL) under Ar at rt. The solution was stirred at rt for 24 h. 1 M NaOH(aq) (10 
mL) was added and the mixture was extracted with EtOAc (3 × 20 mL). The combined 
organic extracts were washed with brine (20 mL), dried (Na2SO4) and evaporated under 
reduced pressure to give the crude product. Purification by flash column chromatography on 
silica with 4:6 EtOAc-hexane as eluent gave N-Boc-thiourea (R,R)-118 (484 mg, 90%) as a 
white gum, [α]D –4.1 (c 2.1 CHCl3) (lit.,
68 [α]D –4.3 (c 2.1 CHCl3)); RF (1:1 EtOAc-hexane) 
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0.32; IR (ATR) 3332 (NH), 2933, 1674 (C=O), 1504, 1414, 1165 cm‒1; 1H NMR (400 MHz, 
d4-methanol) δ 4.13–3.97 (m, 1H, NCH), 2.87 (br s, 3H, NMe), 2.10–1.87 (m, 2H), 1.77–
1.62 (m, 2H), 1.47–1.36 (m, 10H), 1.33–1.19 (m, 5H); 13C NMR (100.6 MHz, d4-methanol) 
δ 157.2 (C=O), 78.7 (OCMe3), 60.2, 54.0, 32.3, 32.0, 27.4, 24.7, 24.5, 13.2 (C=S resonance 
not resolved); HRMS (ESI) m/z calcd for C13H25N3O2S (M + Na)
+ 310.1560, found 310.1561 
(–0.4 ppm error). Spectroscopic data consistent with those reported in the literature.68 




4 M HCl in dioxane (1.79 mL, 7.18 mmol, 9.6 eq) was added to a stirred solution of N-Boc-
thiourea (R,R)-118 (215 mg, 0.748 mmol, 1.0 eq) in CH2Cl2 (4.7 mL) at rt under Ar. The 
resulting solution was stirred at rt for 6 h. The solvent was evaporated under reduced 
pressure. CH2Cl2 (5 mL) was added. Then 1 M NaOH(aq) (10 mL) was added and brine (5 
mL) was added. The layers were separated and the aqueous layer was extracted with CH2Cl2 
(6 × 5 mL). The combined organic extracts were washed with brine (10 mL), dried (Na2SO4) 
and evaporated under reduced pressure to give the thiourea (R,R)-77 (180 mg, 96%) as a 
white gum, [α]D +7.5 (c 3.0 CHCl3) (lit.,
68 [α]D +7.3 (c 3.0 CHCl3)); IR (ATR) 2933, 1515, 
1414 cm‒1; 1H NMR (400 MHz, d4-methanol) δ 4.18–3.63 (m, 1H, NCH), 2.95 (s, 3H, NMe), 
2.59–2.46 (m, 1H, NCH), 2.00–1.93 (m, 2H), 1.84–1.67 (m, 2H), 1.50–1.16 (m, 4H); 13C 
NMR (100.3 MHz, d4-methanol) δ 55.8, 35.2, 33.0, 26.7, 26.0 (C=S, NMe, NCH resonances 
not resolved); HRMS (ESI) m/z calcd for C8H17N3S (M + H)
+ 188.1216, found 188.1213 
(+1.5 ppm error). Spectroscopic data consistent with those reported in the literature.68 









1-Isothiocyanato-3,5-bis(trifluoromethyl)benzene 120 (938 mg, 3.46 mmol, 1.4 eq) was 
added to a stirred solution of tert-butyl (S)-2-(aminomethyl)pyrrolidine-1-carboxylate (S)-
119 (630 mg, 3.46 mmol, 1.0 eq) in CH2Cl2 (21 mL) at rt under Ar. The resulting solution 
was stirred at rt for 24 h. 1 M NaOH(aq) (20 mL) was added and the mixture was extracted 
with CH2Cl2 (3 × 20 mL). The combined organic extracts were washed with brine (30 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 1:1 EtOAc-hexane as eluent 
gave N-Boc-thiourea (S)-121 (1.27 g, 85%) as an off-white solid, mp 94-96 °C; RF (1:1 
EtOAc-hexane) 0.22; IR (ATR) 2978, 1658 (C=O), 1368, 1274, 681 cm‒1; 1H NMR (400 
MHz, d6-DMSO, 120 °C) δ 9.87 (br s, 1H, NH), 8.30 (s, 2H, Ar), 8.04 (br s, 1H, NH), 7.64 
(s, 1H, Ar), 4.05–3.97 (m, 1H, NCH), 3.83 – 3.74 (m, 1H, NCHH’), 3.64–3.55 (m, 1H, 
NCHH’), 3.42–3.24 (m, 2H, C(O)NCHH’), 2.02–1.76 (m, 4H, CH2), 1.43 (s, 9H, CMe3); 
13C NMR (100.6 MHz, d6-DMSO, 120 °C) δ 181.9 (C=S), 154.8 (C=O), 142.7 (ipso-Ar), 
130.9 (q, J = 33.0 Hz, ipso-Ar), 125.2, 122.5, 79.4 (CMe3), 56.8, 47.5, 46.9, 28.7 (CMe3) 
(Ar, CF3 resonances not resolved) HRMS (ESI) m/z calcd for C19H23F6N3O2S (M + Na)
+ 
494.1307, found 494.1296 (+2.4 ppm error). 




TFA (4.0 mL, 47.7 mmol, 150 eq) was added to a stirred solution of N-Boc-thiourea (S)-121 
(150 mg, 0.32 mmol, 1.0 eq) in CH2Cl2 (4 mL) at rt under Ar. The resulting solution was 
stirred at rt for 2 h. 1 M NaOH(aq) (4 mL) was added and the mixture was extracted with 
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CH2Cl2 (4 × 10 mL). The combined organic extracts were washed with brine (30 mL), dried 
(Na2SO4) and evaporated under reduced pressure to give thiourea (S)-116 (117 mg, 99%) as 
an off-white solid, [α]D –26.3 (c 0.70 CHCl3) (lit.,
89 [α]D –26.7 (c 0.695 CHCl3)); mp 102-
104 °C (lit.,89 102 °C); IR (ATR) 3246 (NH), 2958, 1550, 1276, 681 cm‒1; 1H NMR (400 
MHz, d4-methanol) δ 8.10 (s, 2H, Ar), 7.50 (s, 1H, Ar), 3.89–3.79 (m, 3H, NCH, NCH2), 
3.24 (ddd, J = 11.5, 7.5, 7.5 Hz, 1H, C(O)NCHH’), 3.18–3.11 (m, 1H, C(O)NCHH’), 2.11–
2.01 (m, 1H, CH), 2.00–1.86 (m, 2H, CH), 1.75–1.64 (m, 1H, CH); 13C NMR (100.6 MHz, 
d4-methanol) δ 184.2 (C=S), 142.8 (ipso-Ar), 132.7 (q, J = 33.5 Hz, ipso-Ar), 124.7 (q, J = 
272.0 Hz, CF3), 124.2 (br, Ar), 118.3 (br, Ar), 61.8 (NCH), 46.5 (NCH2), 45.5 (NCH2), 28.6 
(CH2), 24.2 (CH2); HRMS (ESI) m/z calcd for C14H15F6N3S (M + H)
+ 372.0964, found 
372.0962 (+0.4 ppm error). Spectroscopic data consistent with those reported in the 
literature.89 




A solution of trichloroacetamide 108 (200 mg, 0.49 mmol, 1.0 eq) and (S)-prolinamide (S)-
38 (28 mg, 0.24 mmol, 0.5 eq) in DMSO (2.0 mL) was stirred and heated at 50 °C in a sealed 
tube for 5 days. Water (5 mL) was added and the mixture extracted with EtOAc (3 × 10 mL). 
The combined organic extracts were washed with brine (3 × 10 mL), dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 to 4:1 EtOAc-hexane as eluent gave enantioenriched 
normorphan 109 (33 mg, 25%, 77:23 er by CSP-HPLC) as a red oil, identical (by 1H and 13C 
NMR spectroscopy) to that described above; CSP-HPLC: Chiracel IC (1 i-PrOH, 0.5 mL 
min–1) 40.4 min (major), 56.5 min (minor) (Figure 6.1). 
Lab book reference: ARG-1-009 
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A solution of trichloroacetamide 108 (200 mg, 0.49 mmol, 1.0 eq), thiourea (R,R)-77 (6 mg, 
0.02 mmol, 0.05 eq) and benzoic acid (1.5 mg, 0.01 mmol, 0.02 eq) in CH2Cl2 (2.5 mL) was 
stirred and heated at 50 °C in a sealed tube for 7 days. The solvent was evaporated under 
reduced pressure to give the crude product which contained (by 1H and 13C NMR 
spectroscopy) no trace of product. 
Lab book reference: ARG-1-044 
 
A solution of trichloroacetamide 108 (100 mg, 0.24 mmol, 1.0 eq) and thiourea (R,R)-77 (20 
mg, 0.12 mmol, 0.5 eq) in DMSO (1.0 mL) was stirred and heated at 50 °C in a sealed tube 
for 5 days. Water (5 mL) was added and the mixture was extracted with EtOAc (3 × 10 mL). 
The combined organic extracts were washed with brine (3 × 10 mL), dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 to 4:1 EtOAc-hexane as eluent gave enantioenriched 
normorphan 109 (9 mg, 12%, 60:40 er by CSP-HPLC) as a red oil, identical (by 1H and 13C 
NMR spectroscopy) to that described above. CSP-HPLC: Chiracel IC (1 i-PrOH, 0.5 mL 
min–1) 35.6 min (major), 49.4 min (minor) (Figure 6.2). 
Lab book reference: ARG-1-065 
 
A solution of trichloroacetamide 108 (100 mg, 0.24 mmol, 1.0 eq) and thiourea (S)-116 (45 
mg, 0.12 mmol, 0.5 eq) in DMSO (1.0 mL) was stirred and heated at 50 °C in a sealed tube 
for 5 days. Water (5 mL) was added and the mixture extracted with EtOAc (3 × 10 mL). The 
combined organic extracts were washed with brine (3 × 10 mL), dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 to 4:1 EtOAc-hexane as eluent gave enantioenriched 
normorphan 109 (21 mg, 30%, 55:45 er by CSP-HPLC) as a red oil, identical (by 1H and 13C 
NMR spectroscopy) to that described above. CSP-HPLC: Chiracel IC (1 i-PrOH, 0.5 mL 
min–1) 35.7 min (major), 49.1 min (minor) (Figure 6.3). 







A solution of 1,4-cyclohexadione monoethylene acetal 29 (1.73 g, 7.51 mmol, 1.0 eq), 
propargylamine (0.5 mL, 7.81 mmol, 1.04 eq) and NaBH(OAc)3 (2.23 g, 10.51 mmol, 1.4 
eq) in CH2Cl2 (25 mL) was stirred at rt for 24 h. Saturated NH4Cl(aq) (10 mL) was added. 
Then, 1 M NaOH(aq) was added until pH ≈ 10 was reached. The mixture was extracted with 
CH2Cl2 (3 × 15 mL). The combined organic extracts were washed with brine (10 mL), dried 
(Na2SO4) and evaporated under reduced pressure to give the crude amine as a pale yellow 
oil. To a solution of the crude amine in THF (18 mL) was added 3 M HCl(aq) (18 mL) and 
the resulting solution was stirred at rt for 72 h. Solid Na2CO3 was added until pH ≈ 9 was 
reached and the mixture was extracted with EtOAc (3 × 15 mL). The combined organic 
extracts were washed with brine (10 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give the crude amino ketone as a red oil. The crude amino ketone and DMAP (88 
mg, 0.72 mmol, 0.1 eq) were dissolved in CH2Cl2 (36 mL). The resulting solution was cooled 
to 0 °C and Et3N (1.25 mL, 9.01 mmol, 1.25 eq) was added under Ar. Then, a solution of 4-
nitrobenzenesulfonyl chloride (2.00 g, 9.01 mmol, 1.25 eq) in CH2Cl2 (4.5 mL) was added 
dropwise and the solution was allowed to warm to rt. The resulting solution was stirred at rt 
for 18 h and then 1 M HCl(aq) (10 mL) was added. The resulting mixture was extracted with 
CH2Cl2 (3 × 15 mL) and the combined organic extracts were washed with brine (10 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with CH2Cl2 as eluent gave alkynyl 
amino ketone 136 (2.51 g, 45%) as an off-white solid, mp 146-148 °C (lit.,69 147-148 °C); 
RF (CH2Cl2) 0.32; IR (ATR) 2954, 1716 (C=O), 1529 (NO2), 1350 (S=O), 1163, 735, 613 
cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.41–8.31 (m, 2H, Ar), 8.20–8.08 (m, 2H, Ar), 4.36–
4.18 (m, 1H, NCH), 4.18 (d, J = 2.5 Hz, 2H, NCH2), 2.51–2.35 (m, 4H, CH2-2), 2.17 (t, J = 
2.5 Hz, 1H, ≡CH), 2.11–1.94 (m, 4H, CH2-3); 
13C NMR (100.6 MHz, CDCl3) δ 207.9 (C=O), 
150.2 (ipso-Ar), 146.4 (ipso-Ar), 128.7 (Ar), 124.4 (Ar), 78.8 (≡C-6), 73.9 (≡CH-7), 56.3 
(NCH), 39.8 (NCH2), 32.8 (CH2-2), 30.2 (CH2-3); HRMS (ESI) m/z calcd for C15H16N2O5S 
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(M + Na)+ 359.0672, found 359.0676 (–1.1 ppm error). Spectroscopic data consistent with 
those reported in the literature.69 




A solution of 1,4-cyclohexadione monoethylene acetal 29 (5.05 g, 32.3 mmol, 1.0 eq), 
propargylamine (2.2 mL, 32.6 mmol, 1.04 eq) and NaBH(OAc)3 (9.59 g, 42.3 mmol, 1.4 eq) 
in CH2Cl2 (108 mL) was stirred at rt for 24 h. Saturated NH4Cl(aq) (25 mL) was added. Then, 
1 M NaOH(aq) was added until pH ≈ 10 was reached. The mixture was extracted with CH2Cl2 
(4 × 25 mL). The combined organic extracts were washed with brine (30 mL), dried 
(Na2SO4) and evaporated under reduced pressure to give the crude amine as a pale yellow 
oil. To a solution of the crude amine in THF (40 mL) was added 3 M HCl(aq) (120 mL) and 
the resulting solution was stirred at rt for 72 h. Solid Na2CO3 was added until pH ≈ 9 was 
reached and the mixture was extracted with EtOAc (4 × 25 mL). The combined organic 
extracts were washed with brine (30 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give the crude amino ketone as red oil. The crude amino ketone and DMAP (394 
mg, 3.23 mmol, 0.1 eq) were dissolved in CH2Cl2 (160 mL). The resulting solution was 
cooled to 0 °C and Et3N (5.63 mL, 40.4 mmol, 1.25 eq) was added under Ar. Then, a solution 
of p-toluenesulfonyl chloride (7.70 g, 40.4 mmol, 1.25 eq) in CH2Cl2 (20 mL) was added 
dropwise and the mixture was allowed to warm to rt. The resulting solution was stirred at rt 
for 18 h and then 1 M HCl(aq) (25 mL) was added. The resulting mixture was extracted with 
CH2Cl2 (4 × 20 mL) and the combined organic extracts were washed with brine (30 mL), 
dried (Na2SO4) and evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 1:3 EtOAc-hexane as eluent 
gave alkynyl amino ketone 59 (8.44 g, 85%) as an off-white solid, mp 125-127 °C (lit.,69 
126-127 °C); RF (1:3 EtOAc-hexane) 0.21; IR (ATR) 2954, 1714 (C=O), 1326 (S=O), 1157, 
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1044, 656, 571 cm‒1; 1H NMR (400 MHz, CDCl3) δ 7.82–7.78 (m, 2H, Ar), 7.32–7.27 (m, 
2H, Ar), 4.26–4.12 (m, 1H, NCH), 4.10 (d, J = 2.5 Hz, 2H, NCH2), 2.46–2.33 (m, 7H, Me, 
CH2-2), 2.16 (t, J = 2.5 Hz, 1H, ≡CH), 2.12–1.90 (m, 4H, CH2-3);
 13C NMR (100.6 MHz, 
CDCl3) δ 208.7 (C=O), 143.8 (ipso-Ar), 137.6 (ipso-Ar), 129.8 (Ar), 127.4 (Ar), 79.8 (≡CH), 
73.1 (≡C), 55.7 (NCH), 40.0 (CH2-2), 32.6 (NCH2), 30.1 (CH2-3), 21.7 (Me); HRMS (ESI) 
m/z calcd for C16H19NO3S (M + Na)
+ 238.0978, found 328.0978 (–0.1 ppm error). 
Spectroscopic data consistent with those reported in the literature.69 




Cu(OTf)2 (11 mg, 0.03 mmol, 0.05 eq), PPh3 (31 mg, 0.12 mmol, 0.20 eq) and pyrrolidine 
(10 µL, 0.12 mmol, 0.2 eq) were added to a stirred solution of amino ketone 136 (200 mg, 
0.60 mmol, 1.0 eq) in THF (3 mL) in a sealed tube at rt under Ar. The resulting mixture was 
stirred at rt for 15 min and then stirred and heated at 90 °C for 18 h. The mixture was allowed 
to cool to rt and the solids were removed by filtration through Celite®. The filtrate was 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with CH2Cl2 as eluent gave morphan 86 (170 mg, 85%) as an  off-
white solid, mp 172-174 °C; RF (CH2Cl2) 0.32; IR (ATR) 2954, 1714 (C=O), 1529, (NO2), 
1650, 1164 (S=O), 738 cm‒1; 1H NMR (400 MHz, CDCl3) δ 8.43–8.38 (m, 2H, Ar), 8.07–
8.02 (m, 2H, Ar), 5.14 (d, J = 1.5 Hz, 1H, =CHH'), 5.07 (d, J = 1.5 Hz, 1H, =CHH'), 4.24 
(d, J = 14.5 Hz, 1H, NCHH'), 4.13 (dd, J = 3.0, 3.0 Hz, 1H, NCH), 3.83 (dd, J = 14.5, 1.0 
Hz, 1H, NCHH'), 3.30–3.23 (m, 1H, CH-2), 2.78 (ddd, J = 16.0, 13.0, 8.0 Hz, 1H, CHH'-6), 
2.42–2.30 (m, 2H, CHH'-6, CHH'-5), 2.02–1.88 (m, 3H, CHH'-5, CHH'-3); 13C NMR (100.6 
MHz, CDCl3) δ 207.4 (C=O), 150.3 (ipso-Ar), 143.8 (ipso-Ar), 137.2 (=C), 128.6 (Ar), 
124.7 (Ar), 115.9 (=CH2), 50.1 (CH-2), 48.4 (NCH), 47.4 (NCH2), 34.8 (CH2-6), 32.3 (CH2-
5), 30.7 (CH2-3); HRMS (ESI) m/z calcd for C15H16N2O5S (M + Na)
+ 359.0672, found 
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359.0672 (–0.1 ppm error). Spectroscopic data consistent with those reported in the 
literature.69 




Cu(OTf)2 (89 mg, 0.25 mmol, 0.05 eq), PPh3 (258 mg, 0.98 mmol, 0.20 eq) and pyrrolidine 
(82 µL, 0.982 mmol, 0.20 eq) were added to a stirred solution of amino ketone 59 (1.5 g, 
4.91 mmol, 1.0 eq) in THF (25 mL) in a sealed tube at rt under Ar. The resulting mixture 
was stirred at rt for 15 min and then stirred and heated at 90 °C for 18 h. The mixture was 
allowed to cool to rt and the solids were removed by filtration through Celite®. The filtrate 
was evaporated under reduced pressure to give the crude product. Purification by flash 
column chromatography on silica with 1:4 to 1:1 EtOAc-hexane as eluent gave morphan 60 
(1.25 g, 83%) as an off-white solid, mp 138-140 °C (lit.,69 136-138 °C); RF (1:4 EtOAc-
hexane) 0.08; IR (ATR) 2952, 1713 (C=O), 1342, 1160 (S=O), 1095, 547 cm‒1; 1H NMR 
(400 MHz, CDCl3) δ 7.75–7.70 (m, 2H, Ar), 7.35–7.31 (m, 2H, Ar), 5.10 (d, J = 2.0 Hz, 1H, 
=CHH'), 5.01 (d, J = 2.0 Hz, 1H, =CHH'), 4.16 (d, J = 14.0 Hz, 1H, NCHH'), 4.09 (dd, J = 
3.5, 3.0 Hz, 1H, NCH), 3.75 (d, J = 14.0 Hz, 1H, NCHH'), 3.22 (br s, 1H, CH-2), 2.80 (ddd, 
J = 16.0, 13.0, 7.5 Hz, 1H, CHH'-6), 2.43 (s, 3H, Me), 2.40–2.31 (m, 1H,CHH'-5), 2.27 (dd, 
J = 16.0, 6.0 Hz, 1H, CHH'-6), 1.96 (dddd, J = 14.0, 3.5, 3.5, 3.5 Hz, 1H, CHH'-3), 1.87 
(ddd, J = 14.0, 3.0, 3.0 Hz, 1H, CHH'-3), 1.90–1.80 (m, 1H, CHH'-5); 13C NMR (100.6 
MHz, CDCl3) δ 208.3 (C=O), 143.0 (ipso-Ar), 138.2 (=C), 134.8 (ipso-Ar), 130.0 (Ar), 
127.4 (Ar), 115.2 (=CH2), 50.2 (CH-2), 48.0 (NCH), 47.2 (NCH2), 34.8 (CH2-6), 32.5 (CH2-
5), 30.5 (CH2-3), 21.6 (Me).; HRMS (ESI) m/z calcd for C16H19NO3S (M + Na)
+ 329.0978, 
found 328.0971 (+2.2 ppm error). Spectroscopic data consistent with those reported in the 
literature.69 




toluenesulfonyl-2-azabicyclo[3.3.1]non-3-en-6-one 142 and 4-methyl-2-
toluenesulfonyl-2-azabicyclo[3.3.1]nonan-6-ol 143 
 
   
PtO2 (39 mg, 0.17 mmol, 0.06 eq) was added to a stirred solution of morphan 60 (846 mg, 
2.77 mmol, 1 eq) in EtOAc (14 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 6 h. The solids were removed by 
filtration through Celite® and the filtrate was evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 1:4 to 3:2 Et2O-
hexane as eluent gave hydrogenated morphan endo-141 (124 mg, 15%, >97:3 dr) as a white 
solid, mp 146-148 °C; RF (2:3 Et2O-hexane) 0.15; IR (ATR) 2929, 1702 (C=O), 1338, 1158 
(S=O), 546 cm–1;  1H NMR (400 MHz, CDCl3) δ 7.73–7.68 (m, 2H, Ar), 7.34–7.29 (m, 2H, 
Ar), 4.29 (dd, J = 3.5, 3.0 Hz, 1H, NCH), 3.83 (dd, J = 13.5, 6.0 Hz, 1H, NCHH'), 2.81 (dd, 
J = 13.5, 12.5 Hz, 1H, NCHH'), 2.48–2.38 (m, 5H, ArMe, CH-2, CHH'-6 ), 2.10 (ddd, J = 
18.0, 10.5, 8.5 Hz, 1H, CHH'-6), 2.04–1.84 (m, 5H, CHH'-5, CHH'-3, CH-8), 0.84 (d, J = 
7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 211.0 (C=O), 143.6 (ipso-Ar), 137.3 
(ipso-Ar), 130.0 (Ar), 127.1 (Ar), 49.0 (CH-2), 47.4 (NCH2), 46.1 (NCH), 39.3 (CH2-6), 
32.8 (CH2-5), 32.7 (CH-8), 28.6 (CH-3), 21.6 (ArMe), 16.8 (CHMe); HRMS (ESI) m/z calcd 
for C16H21NO3S (M + Na)
+ 330.1164, found 330.1129 (+1.6 ppm error) and impure alcohol 
143 (670 mg) as an off-white solid. 
Lab book reference: ARG-2-024 
 
10 % Pd/C (49 mg, 0.04 mmol, 0.10 eq) was added to a stirred solution of morphan 60 (150 
mg, 0.49 mmol, 1 eq) in MeOH (20 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and then with H2 three times. 
The mixture was stirred under a balloon of H2 (760 mmHg) for 16 h. The solids were 
119 
 
removed by filtration through Celite® and the filtrate was evaporated under reduced pressure 
to give the crude product which contained (by 1H NMR spectroscopy) a complex mixture of 
products.  
Lab book reference: ARG-2-007 
 
10 % Pd/C (100 mg, 0.08 mmol, 0.25 eq) was added to a stirred solution of morphan 60 (100 
mg, 0.33 mmol, 1 eq) in EtOAc (16 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and then with H2 three times. 
The mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 1:4 to 3:2 
Et2O-hexane as eluent gave a 75:25 mixture (by 
1H NMR spectroscopy) of hydrogenated 
morphans endo-141 and exo-141 (43 mg, 40%) as a white solid and a 95:5 mixture (by 1H 
NMR spectroscopy) of enamine 142 and morphan 60 (59 mg, i.e. 56 mg (56%) of 142 and 
3 mg (3%) of 60) as an off-white solid, RF (3:2 Et2O-hexane) 0.52; IR (ATR) 2932, 1706 
(C=O), 1358, 1158 (S=O), 944, 663 cm–1; 1H NMR (400 MHz, CDCl3) for 142: δ 7.68–7.64 
(m, 2H, Ar), 7.28 (m, 2H, Ar), 6.79 (q, J = 1.5 Hz, 1H, =CH-7), 4.12–4.09 (m, 1H, NCH), 
2.69 (dd, J = 1.5, 1.5 Hz, 1H, CH-2), 2.54 (ddd, J = 15.5, 13.5, 7.5 Hz, 1H, CHH'-6), 2.38 
(s, 3H, ArMe), 2.35–2.28 (m, 1H, CHH'-5), 2.12 (dd, J = 15.5, 6.0 Hz, 1H, CHH'-6), 1.87 
(ddd, J = 13.5, 6.0, 3.0 Hz, 1H, CHH'-5), 1.80 (ddd, J = 13.0, 2.5, 2.5 Hz, 1H, CHH'-3), 1.62 
(d, J = 1.5 Hz, 3H, =CMe), 1.27 (dddd, J = 13.0, 3.5, 3.5, 3.0 Hz, 1H CHH'-3); 13C NMR 
(100.6 MHz, CDCl3) for 142: δ 208.3 (C=O), 144.0 (ipso-Ar), 135.8 (ipso-Ar), 130.0 (Ar), 
126.9 (Ar), 122.8 (=CH-7), 113.6 (=C-8), 49.7 (CH-2), 47.6 (NCH), 34.5 (CH2-5), 33.7 
(CH2-6), 27.7 (CH2-3), 21.6 (ArMe), 19.5 (=CMe); HRMS (ESI) m/z calcd for C16H19NO3S 
(M + Na)+ 328.0978, found 328.0971 (+1.2 ppm error). Diagnostic signals for morphan exo-
141: 1H NMR (400 MHz, CDCl3) δ 4.20–4.12 (m, 1H, NCH), 3.25 (dd, J = 12.5, 5.0 Hz, 
1H, NCHH'), 2.98 (dd, J = 12.5, 6.0 Hz, 1H, NCHH'), 1.07 (d, J = 7.0 Hz, 3H, CHMe). 
Lab book reference: ARG-2-012 
 
PtO2 (3.3 mg, 0.01 mmol, 0.05 eq) was added to a stirred solution of morphan 60 (100 mg, 
0.33 mmol, 1 eq) in EtOAc (2 mL) at rt under Ar. The reaction flask was evacuated under 
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reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 45 min. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 1:4 to 3:2 
Et2O-hexane as eluent gave a 95:5 mixture (by 
1H NMR spectroscopy) of hydrogenated 
morphans endo-141  and exo-141 (61 mg, 61%) as a white solid and impure alcohol 143 (35 
mg) as an off-white solid.  
Lab book reference: ARG-2-029 
 
PtO2 (32 mg, 0.36 mmol, 0.05 eq) was added to a stirred solution of morphan 60 (991 mg, 
3.24 mmol, 1 eq) in EtOAc (16 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 45 min. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 1:4 to 3:2 
Et2O-hexane as eluent gave a 85:15 mixture (by 
1H NMR spectroscopy) of hydrogenated 
morphans endo-141  and exo-141 (760 mg, 76%) as a white solid and impure alcohol 143 
(210 mg) as an off-white solid.  





NaBH4 (62 mg, 1.63 mmol, 5.0 eq) was added to a stirred solution of morphan endo-141 
(100 mg, 0.33 mmol, 1 eq) in MeOH (2 mL) at 0 °C under Ar. The resulting mixture was 
stirred at 0 °C for 1 h. EtOAc (10 mL) and water (10 mL) were added. The layers were 
separated and the organic layer was washed with brine (10 mL), dried (MgSO4) and 
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evaporated under reduced pressure to give alcohol 143 (97 mg, 96%, >97:3 dr) as a white 
solid, mp 90-92 °C; RF (3:2 Et2O-hexane) 0.18; IR (ATR) 3521 (OH), 2925, 1327, 1154 
(S=O), 671 cm–1;  1H NMR (400 MHz, CDCl3) δ 7.70–7.65 (m, 2H, Ar), 7.28–7.24 (m, 2H, 
Ar), 4.02 (dddd, J = 3.0, 3.0, 3.0, 3.0 Hz, 1H, NCH), 3.97 (dddd, J = 11.0, 7.0, 5.0, 1.5 Hz, 
1H, HOCH), 3.69 (dd, J = 12.5, 7.0 Hz, 1H, NCHH'), 3.18 (dd, J = 12.5, 12.5 Hz, 1H, 
NCHH'), 2.40 (s, 3H, ArMe), 2.06–1.93 (m, 2H, CH-2, CH-8), 1.86 (ddd, J = 13.5, 5.0, 3.0 
Hz, 1H, CHH'-6), 1.82–1.74 (m, 1H, CHH'), 1.71–1.47 (m, 5H, CHH'-6, CHH', CH2, OH), 
1.15 (d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) δ 143.1 (Ar), 137.0 (Ar), 
129.8 (ipso-Ar), 127.0 (ipso-Ar), 74.4 (HOCH), 49.7 (NCH2), 46.6 (NCH), 37.7 (CH-2), 
34.9 (CH2), 34.3 (CH-8), 31.0 (CH2), 29.7 (CH2-6), 21.6 (ArMe), 18.6 (CMe3); HRMS (ESI) 
m/z calcd for C16H23NO3S (M + Na)
+ 332.1291, found 333.1288 (+0.4 ppm error). 
Lab book reference: ARG-2-030 
 
tert-Butyl (4-oxocyclohexyl)(prop-2-yn-1-yl)carbamate 144 
 
A solution of 1,4-cyclohexadione monoethylene acetal 29 (5.05 g, 32.3 mmol, 1.0 eq), 
propargylamine (2.2 mL, 32.6 mmol, 1.04 eq) and NaBH(OAc)3 (9.59 g, 42.3 mmol, 1.4 eq) 
in CH2Cl2 (108 mL) was stirred at rt for 24 h. Saturated NH4Cl(aq) (25 mL) was added. Then, 
1 M NaOH(aq) was added until pH ≈ 10 was reached. The mixture was extracted with CH2Cl2 
(4 × 25 mL). The combined organic extracts were washed with brine (30 mL), dried 
(Na2SO4) and evaporated under reduced pressure to give the crude amine as a pale yellow 
oil. To a solution of the crude amine in THF (40 mL) was added 3 M HCl(aq) (120 mL) and 
the resulting solution was stirred at rt for 72 h. Solid Na2CO3 was added until pH ≈ 9 was 
reached and the mixture was extracted with EtOAc (4 × 25 mL). The combined organic 
extracts were washed with brine (30 mL), dried (Na2SO4) and evaporated under reduced 
pressure to give the crude amino ketone as a red oil. The crude amino ketone was dissolved 
in THF (34 mL) and Boc2O (8.487 g, 37.2 mmol, 1.2 eq) was added at rt. The resulting 
solution was stirred at rt for 18 h and then water (25 mL) was added. The resulting mixture 
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was extracted with CH2Cl2 (4 × 20 mL). The combined organic extracts were washed with 
brine (30 mL), dried (Na2SO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 1:5 EtOAc-hexane as 
eluent gave alkynyl amino ketone 144 (6.21 g, 77%) as a white solid, mp 72-74 °C (lit.,69 
71-72 °C); RF (1:4 EtOAc-hexane) 0.20; IR (ATR) 2973, 1717 (C=O), 1689 (C=O), 1165, 
681 cm‒1; 1H NMR (400 MHz, CDCl3) δ 4.59–4.16 (br m, 1H, NCH), 3.92 (br s, 2H, NCH2), 
2.53–2.31 (m, 4H, CH2-2), 2.21–1.86 (m, 3H, ≡CH, CH2-3), 1.48 (s, 9H, CMe3);
 13C NMR 
(100.6 MHz, CDCl3) δ 209.6 (C=O, ketone), 154.8 (C=O, Boc), 81.1 (CMe3), 80.8 (≡C), 
70.8 (≡CH), 53.7 (NCH), 40.1 (CH2-2), 32.5 (NCH2), 29.8 (CH2-3), 28.5 (CMe3); HRMS 
(ESI) m/z calcd for C14H21NO3 (M + Na)
+ 274.1414, found 274.1415 (–0.5 ppm error). 
Spectroscopic data consistent with those reported in the literature.69 
Lab book reference: ARG-2-086 
 
tert-Butyl 4-methylene-6-oxo-2-azabicyclo[3.3.1]nonane-2-carboxylate 87 
 
Cu(OTf)2 (144 mg, 0.398 mmol, 0.05 eq), PPh3 (419 mg, 1.59 mmol, 0.20 eq) and 
pyrrolidine (130 µL, 1.59 mmol, 0.20 eq) were added to a stirred solution of amino ketone 
144 (2.0 g, 7.96 mmol, 1.0 eq) in THF (30 mL) in a sealed tube at rt under Ar. The resulting 
mixture was stirred at rt for 15 min and then stirred and heated at 90 °C for 18 h. The mixture 
was allowed to cool to rt and the solids were removed by filtration through Celite®. The 
filtrate was evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica with 1:9 to 1:1 EtOAc-hexane as eluent gave 
morphan 87 (1.54 g, 77%) as a white solid, mp 78-80 °C; RF (1:2 EtOAc-hexane) 0.2; IR 
(ATR) 2972, 1716 (C=O, ketone), 1686 (C=O, Boc), 1389, 1164, 1100 cm‒1; 1H NMR (400 
MHz, CDCl3) (55:45 mixture of rotamers) δ 5.07 (s, 0.55H, =CHH'), 5.04 (s, 0.45H, =CHH'), 
4.99 (s, 1H, =CHH'), 4.38 (d, J = 16.0 Hz, 0.55H, NCHH' ), 4.32 (dd, J = 3.5, 3.0 Hz, 0.45H, 
NCH), 4.24 (d, J = 16.0 Hz, 0.45H, NCHH'), 4.19 (dd, J = 3.5, 3.0 Hz, 0.55H, NCH), 4.07 
(d, J = 16.0 Hz, 0.45H, NCHH'), 4.01 (d, J = 16.0 Hz, 0.55H, NCHH'), 3.33 (s, 1H, CH-2), 
2.74–2.54 (m, 1H, CHH'-6), 2.42–2.19 (m, 3H, CHH'-6, CHH'-5, CHH'-3), 2.00 (ddd, J = 
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14.0, 13.5, 3.0 Hz, 1H, CHH'-3), 1.85–1.73 (m, 1H, CHH'-5), 1.53–1.45 (m, 9H, CMe3); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 209.3 (C=O, ketone), 209.0 (C=O, ketone), 155.2 
(C=O, Boc), 154.9 (C=O, Boc), 139.8 (=C), 139.6 (=C), 114.2 (=CH2), 113.8 (=CH2), 80.2 
(CMe3), 51.3 (CH-2), 50.8 (CH-2), 46.3 (NCH2), 46.3 (NCH), 45.6 (NCH2), 45.4 (NCH), 
35.3 (CH2-6), 34.9 (CH2-6), 31.4 (CH2), 31.2 (CH2), 30.6 (CH2), 28.6 (CMe3); HRMS (ESI) 
m/z calcd for C14H21NO3 (M + Na)
+ 274.1414, found 274.1412 (+0.6 ppm error). 
Spectroscopic data consistent with those reported in the literature.69 
Lab book reference: ARG-2-052 
 
tert-Butyl 4-methyl-6-oxo-2-azabicyclo[3.3.1]nonane-2-carboxylate endo-138 and tert-
Butyl 4-methyl-6-oxo-2-azabicyclo[3.3.1]non-3-ene-2-carboxylate 145 
  
PtO2 (213 mg, 0.936 mmol, 0.1 eq) was added to a stirred solution of morphan 87 (2.35 g, 
7.36 mmol, 1 eq) in EtOAc (47 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 16 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. The crude product was dissolved in CH2Cl2 (100 mL) and Dess-Martin 
periodinane (5.95 g, 14.0 mmol, 1.5 eq) was added at rt under Ar. The resulting mixture was 
stirred at rt for 2 h. Saturated NaHCO3(aq) (50 mL) was added and the mixture was stirred for 
30 min. The layers were separated and the organic layer was washed with saturated 
Na2S2O3(aq) (15 mL) and brine (25 mL), dried (MgSO4) and the evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on silica 
with 1:9 to 2:3 Et2O-hexane as eluent gave enamine 145 (360 mg, 15%) as a clear oil, RF 
(2:3 Et2O-hexane) 0.24; IR (ATR) 2933, 1693 (C=O, ketone), 1665 (C=O, Boc), 1392, 1152, 
729 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 7.03–6.94 (m, 0.5H, 
=CH), 6.85–6.76 (m, 0.5H, =CH), 4.46–4.38 (m, 0.5H, NCH), 4.32–4.24 (m, 0.5H, NCH), 
2.83–2.76 (m, 1H, CH-2), 2.62–2.46 (m, 1H, CHH'-6), 2.35–2.18 (m, 1H, CHH'-6), 2.20–
2.07 (m, 1H, CHH'), 2.07–1.94 (m, 1H, CHH'), 1.98–1.75 (m, 2H, CHH', CHH'), 1.62 (d, J 
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= 1.5 Hz, 3H, =CMe), 1.52–1.45 (m, 9H, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) 
δ 209.4 (C=O, ketone), 209.3 (C=O, ketone), 152.1 (C=O, Boc), 151.5 (C=O, Boc), 123.5 
(=CH), 123.3 (=CH), 111.6 (=C), 110.7 (=C), 81.2 (CMe3), 81.0 (CMe3), 50.3 (CH-2), 50.0 
(CH-2), 45.6 (NCH), 44.7 (NCH), 33.7 (br, CH2-6), 33.4 (CH2), 32.8 (CH2), 29.3 (CH2), 
29.1 (CH2), 28.35 (CMe3), 28.3 (CMe3), 19.4 (Me), 19.3 (Me); HRMS (ESI) m/z calcd for 
C14H21NO3 (M + Na)
+ 374.1414, found 374.1406 (+2.9 ppm error) and a 90:10 mixture (by 
1H NMR spectroscopy) of hydrogenated morphans endo-138 and exo-138 (1.67 g, 71%) as 
an off-white solid, RF (2:3 Et2O-hexane) 0.17; IR (ATR) 2930, 1684 (C=O), 1402, 1339, 
1167, 1096 cm–1; 1H NMR (400 MHz, CDCl3) for endo-138 (50:50 mixture of rotamers): δ 
4.52–4.28 (m, 1H, NCH), 4.04 (dd, J = 14.0, 6.5 Hz, 0.5H, NCHH'), 3.92 (dd, J = 14.0, 6.5 
Hz, 0.5H, NCHH'), 2.83–2.66 (m, 1H, NCHH'), 2.56–2.46 (m, 2H, CH-2, CHH'-6), 2.29–
2.16 (m, 1H, CHH'-6), 2.14–1.89 (m, 5H, CH2-3, CH2-5, CH-8), 1.44 (s, 9H, CMe3), 0.85 
(d, J = 7.0 Hz, 3H, CHMe); 13C NMR (100.6 MHz, CDCl3) for endo-141 (rotamers): δ 212.0 
(C=O, ketone), 211.8 (C=O, ketone), 155.1 (C=O, Boc), 155.0 (C=O, Boc), 80.0 (CMe3), 
49.7 (CH-2), 49.6 (CH-2), 47.3 (NCH2), 46.6 (NCH2), 44.4 (NCH), 43.3 (NCH), 39.6 (CH2-
6), 33.0 (CH2), 32.8 (CH2), 32.6 (CH-8), 30.5 (CH2), 29.9 (CH2), 28.5 (CMe3), 17.1 (CHMe); 
C14H23NO3 (M + Na)
+ 276.1570, found 276.1570 (0.0 ppm error). Diagnostic signals for exo-
138: 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 3.58 (dd, J = 13.5, 5.5 Hz, 
0.5H, NCHH’), 3.37 (dd, J = 13.5, 5.5 Hz, 0.5H, NCHH’), 3.27 (dd, J = 13.5, 5.5 Hz, 0.5H, 
NCHH’), 3.12 (dd, J = 13.5, 5.5 Hz, 0.5H, NCHH’). 
Lab book reference: ARG-2-090 
 
Dess-Martin periodinane (365 mg, 0.86 mmol, 2.0 eq) was added to a stirred solution of a 
90:10 mixture of morphans endo-146 and exo-146 (110 mg, 0.43 mmol, 1.0 eq) in CH2Cl2 
(7 mL) at rt under Ar. The resulting mixture was stirred at rt for 2 h. Saturated NaHCO3(aq) 
(10 mL) was added and the mixture was stirred for 30 min. The layers were separated and 
the organic layer was washed with saturated Na2S2O3(aq) (10 mL) and brine (10 mL), dried 
(MgSO4) and evaporated under reduced pressure to give the crude product. Purification by 
flash column chromatography on silica with 1:9 to 2:3 Et2O-hexane as eluent gave a 90:10 
mixture (by 1H NMR spectroscopy) of hydrogenated morphans endo-138 and exo-138 (89 




Lab book reference: ARG-2-079 
 
10% Pd/C (40 mg, 0.04 mmol, 0.1 eq) was added to a stirred solution of morphan 87 (100 
mg, 0.40 mmol, 1.0 eq) in EtOAc (2 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and then with H2 three times. 
The mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product which contained (by 1H NMR spectroscopy) a 90:8:2 mixture of enamine 
145, morphan endo-138 and morphan exo-138 
Lab book reference: ARG-2-041 
 
10% Pd/C (21 mg, 0.02 mmol, 0.1 eq) was added to a stirred solution of morphan 87 (50 
mg, 0.20 mmol, 1.0 eq) in EtOH (1 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and then with H2 three times. 
The mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product which contained (by 1H NMR spectroscopy) a complex mixture of 
products. 
Lab book reference: ARG-2-053 
 
10% Pd/C (21 mg, 0.02 mmol, 0.1 eq) was added to a stirred solution of morphan 87 (50 
mg, 0.20 mmol, 1.0 eq) and AcOH (56 µL, 1.0 mmol, 5 eq) in EtOAc (1 mL) at rt under Ar. 
The reaction flask was evacuated under reduced pressure and back-filled with Ar three times 
and then with H2 three times. The mixture was stirred under a balloon of H2 (760 mmHg) 
for 2 h. The solids were removed by filtration through Celite® and the filtrate was evaporated 
under reduced pressure to give the crude product which contained (by 1H NMR 
spectroscopy) a complex mixture of products. 
Lab book reference: ARG-2-053 
20% Pd(OH)2/C (14 mg, 0.02 mmol, 0.1 eq) was added to a stirred solution of morphan 87 
(50 mg, 0.20 mmol, 1.0 eq) in EtOAc (1 mL) at rt under Ar. The reaction flask was evacuated 
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under reduced pressure and back-filled with Ar three times and then with H2 three times. 
The mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 1:9 to 2:3 
Et2O-hexane as eluent gave enamine 145 (36 mg, 72%) as a clear oil, identical (by 
1H and 
13C NMR spectroscopy) to that described above and a 90:10 mixture (by 1H NMR 
spectroscopy) of hydrogenated morphans endo-138 and exo-138 (9 mg, 18%) as an off-white 
solid, identical (by 1H and 13C NMR spectroscopy) to that described above. 
Lab book reference: ARG-2-057 
 
10% Pd/C (10 mg, 0.01 mmol, 0.02 eq) was added to a stirred solution of morphan 87 (100 
mg, 0.40 mmol, 1.0 eq) and NH4
+HCO2
– (251 µL, 3.98 mmol, 10 eq) in MeOH (2 mL) at rt 
under Ar. The resulting mixture was stirred and heated at reflux for 2 h under Ar. The solids 
were removed by filtration through Celite® and the filtrate was evaporated under reduced 
pressure to give the crude product which contained (by 1H NMR spectroscopy) a complex 
mixture of products. 
Lab book reference: ARG-2-064 
 
tert-Butyl 6-hydroxy-4-methyl-2-azabicyclo[3.3.1]nonane-2-carboxylate endo-146 and 
tert-butyl 6-hydroxy-4-methyl-2-azabicyclo[3.3.1]non-3-ene-2-carboxylate 147 
   
PtO2 (9.0 mg, 0.04 mmol, 0.1 eq) was added to a stirred solution of morphan 87 (100 mg, 
0.40 mmol, 1.0 eq) in EtOAc (2 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 16 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 1:9 to 1:4 
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EtOAc-hexane as eluent gave enamine 147 (10 mg, 10%, >97:3 dr) as an off-white solid, mp 
140-142 °C; RF (2:3 EtOAc-hexane) 0.20; IR (ATR) 3440 (OH), 2934, 1665 (C=O), 1392, 
1156 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 mixture of rotamers) δ 6.94 (s, 0.5H, =CH-
7), 6.77 (s, 0.5H, =CH-7), 4.18–4.14 (m, 0.5H, NCH), 4.05–4.02 (m, 0.5H, NCH), 3.86 
(dddd, J = 10.0, 4.5, 4.5, 4.5 Hz, 1H, HOCH), 2.38 (ddd, J = 4.5, 3.5, 3.5 Hz, 1H, CH-2), 
1.98–1.84 (m, 1H, CHH’), 1.79 (s, 3H, Me), 1.74–1.51 (m, 4H, CHH’, CHH’), 1.49–1.38 
(m, 10H, CHH’, CMe3); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 152.3 (C=O, Boc), 
151.7 (C=O, Boc), 123.0 (=CH-7), 122.7 (=CH-7), 113.7 (=C), 113.1 (=C), 80.6 (CMe3), 
80.3 (CMe3), 74.8 (HOCH), 74.7 (HOCH), 45.7 (NCH), 44.9 (NCH), 39.8 (CH-2), 39.5 
(CH-2), 31.3 (CH2), 30.7 (CH2), 28.8 (CH2), 28.6 (CH2), 28.5 (CMe3), 28.4 (CMe3), 27.8 
(CH2), 27.7 (CH2), 22.5 (CH2), 22.4 (CH2); HRMS (ESI) m/z calcd for C14H23NO3 (M + Na)
+ 
276.1570, found 276.1568 (+0.9 ppm error) and a 90:10 mixture (by 1H NMR spectroscopy) 
of hydrogenated morphans endo-146 and exo-146 (86 mg, 86%) as an off-white solid, RF 
(2:3 EtOAc-hexane) 0.18; IR (ATR) 3436 (OH), 2928, 1662 (C=O), 1402, 1168 cm–1; 1H 
NMR (400 MHz, CDCl3) (55:45 mixture of rotamers) for endo-146 δ 4.17–4.12 (m, 0.45H, 
NCH), 4.03–4.00 (m, 0.55H, NCH), 3.97 (ddd, J = 11.0, 5.5, 5.5 Hz, 1H, HOCH), 3.81 (dd, 
J = 13.5, 6.0 Hz, 0.55H, NCHH’), 3.71 (dd, J = 13.5, 6.0 Hz, 0.45H, NCHH’), 3.02 (dd, J = 
13.5, 13.0 Hz, 0.55H, NCHH’), 2.98 (dd, J = 13.5, 13.0 Hz, 0.45H, NCHH’), 2.18 (s, 1H, 
OH), 2.05–1.95 (m, 2H, CH-2, CH-8), 1.92–1.80 (m, 2H, CHH’), 1.77–1.63 (m, 2H, CHH’), 
1.59–1.47 (m, 2H, CHH’), 1.44–1.36 (m, 9H, CMe3), 1.16 (d, J = 7.0 Hz, 3H, CHMe); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 155.4 (C=O), 155.8 (C=O), 79.4 (CMe3), 79.3 
(CMe3), 74.7 (HOCH), 74.67 (HOCH), 49.6 (NCH2), 49.0 (NCH2), 44.8 (NCH), 43.8 
(NCH), 38.2 (CH), 38.0 (CH), 34.5 (CH2), 34.46 (CH2), 34.2 (CH), 34.0 (CH), 30.9 (CH2), 
30.8 (CH2), 30.6 (CH2), 30.0 (CH2), 28.5 (CMe3), 18.9 (CHMe), 18.8 (CHMe); HRMS (ESI) 
m/z calcd for C14H25NO3 (M + Na)
+ 278.1727, found 278.1721 (+2.0 ppm error). Diagnostic 
signals for exo-146: 1H NMR (400 MHz, CDCl3) δ 2.65–2.50 (m, 1H, NCHH’), 0.91 (d, J = 
7.0 Hz, 3H, CHMe).  
Lab book reference: ARG-2-067 
 
10% Pd/C (28 mg, 0.03 mmol, 0.1 eq) was added to a stirred solution of morphan 148 (65 
mg, 0.25 mmol, 1.0 eq) in EtOH (1.3 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and then with H2 three times. 
128 
 
The mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
enamine 147 (63 mg, 96%) as an off white solid, identical (by 1H and 13C NMR 
spectroscopy) to that described above. 
Lab book reference: ARG-2-047 
 
10% Pd/C (21 mg, 0.02 mmol, 0.1 eq) was added to a stirred solution of morphan 148 (50 
mg, 0.20 mmol, 1.0 eq) and AcOH (56 µL, 1.0 mmol, 5.0 eq) in EtOH (1 mL) at rt under 
Ar. The reaction flask was evacuated under reduced pressure and back-filled with Ar three 
times and then with H2 three times. The mixture was stirred under a balloon of H2 (760 
mmHg) for 2 h. The solids were removed by filtration through Celite® and the filtrate was 
evaporated under reduced pressure to give the crude product which contained (by 1H NMR 
spectroscopy) a complex mixture of products. 
Lab book reference: ARG-2-055 
 
20% Pd(OH)2/C (14 mg, 0.02 mmol, 0.1 eq) was added to a stirred solution of morphan 148 
(50 mg, 0.20 mmol, 1.0 eq) in EtOAc (1 mL) at rt under Ar. The reaction flask was evacuated 
under reduced pressure and back-filled with Ar three times and then with H2 three times. 
The mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
enamine 147 (47 mg, 94%) as an off white solid, identical (by 1H and 13C NMR 
spectroscopy) to that described above. 
Lab book reference: ARG-2-057 
 
10% Pd/C (10 mg, 0.01 mmol, 0.02 eq) was added to a stirred solution of morphan 148 (100 
mg, 0.40 mmol, 1.0 eq) and NH4
+HCO2
– (251 mg, 3.98 mmol, 10 eq) in MeOH (2 mL) at rt 
under Ar. The resulting mixture was stirred and heated at reflux for 2 h. The solids were 
removed by filtration through Celite® and the filtrate was evaporated under reduced pressure 
to give the crude product. Purification by flash column chromatography on silica with 1:9 to 
1:4 EtOAc-hexane as eluent gave enamine 147 (55 mg, 55%) as an off-white solid, identical 
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(by 1H and 13C NMR spectroscopy) to that described above and a 75:25 mixture (by 1H NMR 
spectroscopy) of hydrogenated morphans endo-146 and exo-146 (42 mg, 42%) as an off-
white solid. 
Lab book reference: ARG-2-065 
 
PtO2 (4 mg, 0.02 mmol, 0.1 eq) was added to a stirred solution of morphan 148 (50 mg, 0.2 
mmol, 1.0 eq) in EtOAc (1 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 2 h. The solids were removed by 
filtration through Celite® and the filtrate was evaporated under reduced pressure to give the 
crude product. Purification by flash column chromatography on silica with 1:9 to 1:4 EtOAc-
hexane as eluent gave enamine 147 (3 mg, 6%) as an off-white solid, identical (by 
1H and 
13C NMR spectroscopy) to that described above and a 75:25 mixture (by 1H NMR 
spectroscopy) of hydrogenated morphans endo-146 and exo-146 (40 mg, 90%) as an off-
white solid. 
Lab book reference: ARG-2-050 
 
tert-Butyl 6-hydroxy-4-methylene-2-azabicyclo[3.3.1]nonane-2-carboxylate 148 
 
NaBH4 (1.04 g, 27.6 mmol, 5.0 eq) was added to a stirred solution of morphan 87 (1.39 g, 
5.52 mmol, 1.0 eq) in MeOH (28 mL) at 0 °C under Ar. The resulting mixture was allowed 
to warm to rt. The mixture was stirred at rt for 4 h. EtOAc (10 mL) and water (10 mL) were 
added. The layers were separated and the organic layer was washed with brine (10 mL), 
dried (MgSO4) and evaporated under reduced pressure to give alcohol 148 (1.33 g, 95%, 
>97:3 dr) as a white solid, mp 112-114 °C; RF (3:2 EtOAc-hexane) 0.23; IR (ATR) 3432 
(OH), 2935, 1670 (C=O), 1395, 1168 cm–1; 1H NMR (400 MHz, CDCl3) δ 5.09–5.05 (m, 
1H, =CHH’), 4.96–4.91 (m, 1H, CHH’), 4.26–3.95 (m, 3H, NCH, NCHH’), 3.72–3.59 (m, 
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1H, HOCH), 2.72 (br dd, J = 4.0, 4.0 Hz, 1H, CH-2), 2.06–1.91 (m, 2H, CHH’), 1.86–1.61 
(m, 3H, CHH’, OH), 1.48–1.37 (m, 10H, CMe3, CHH’), 1.34–1.20 (m, 1H, CHH’); 
13C 
NMR (100.6 MHz, CDCl3) (rotamers) δ 155.2 (C=O), 154.9 (C=O), 142.0 (=C), 141.8 (=C), 
112.9 (=CH2), 112.8 (=CH2), 79.6 (CMe3), 71.0 (HOCH), 47.6 (NCH2), 46.7 (NCH2), 45.8 
(NCH), 44.9 (NCH), 41.8 (CH-2), 41.3 (CH-2), 30.3 (CH2), 30.1 (br, CH2), 29.3 (CH2), 29.2 
(CH2), 28.8 (CH2), 28.6 (br, CMe3); HRMS (ESI) m/z calcd for C14H23NO3 (M + Na)
+ 
276.1570, found 276.1564 (+2.4 ppm error). 





TBDMSCl (144 mg, 0.96 mmol, 1.2 eq) was added to a stirred solution of morphan 148 (200 
mg, 0.79 mmol, 1.0 eq) and imidazole (134 mg, 1.97 mmol, 2.5 eq) in DMF (3 mL) at rt 
under Ar. The resulting solution was stirred at rt for 48 h. Saturated NaHCO3(aq) (15 mL) was 
added and the resulting mixture was extracted with Et2O (3 × 15 mL). The combined organic 
extracts were washed brine (3 × 10 mL), dried (MgSO4) and evaporated under reduced 
pressure to give the crude product. Purification by flash column chromatography on silica 
with 99:1 to 9:1 hexane-Et2O gave morphan 149 (240 mg, 83%) as a clear oil, RF (9:1 
hexane-Et2O) 0.25; IR (ATR) 2930, 1692 (C=O), 1391, 1095, 835 cm
–1; 1H NMR (400 MHz, 
CDCl3) δ 5.02–4.96 (m, 1H, =CHH’), 4.95–4.89 (m, 1H, =CHH’), 4.21–3.91 (m, 3H, NCH, 
NCHH’), 3.73–3.64 (m, 1H, OCH), 2.61 (s, 1H, CH-2), 2.04–1.88 (m, 2H, CHH’), 1.67–
1.48 (m, 3H, CHH’, CHH’), 1.48–1.31 (m, 10H, OCMe3, CHH’), 0.87 (s, 9H, SiCMe3), 
0.07–0.03 (m, 6H, SiMe2); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 155.3 (C=O), 155.2 
(C=O), 141.5 (=C), 141.0 (=C), 113.4 (=CH2), 113.1 (=CH2), 79.6 (CMe3), 79.5 (CMe3), 
73.0 (OCH), 72.95 (OCH), 48.1 (NCH2), 47.2 (NCH2), 46.1 (NCH), 45.4 (NCH), 42.1 (CH-
2), 41.7 (CH-2), 30.8 (CH2), 30.7 (CH2), 30.3 (CH2), 29.5 (CH2), 29.1 (CH2), 28.8 (OCMe3), 
131 
 
26.1 (SiCMe3), –4.30 (SiMe), –4.32 (SiMe), –4.40 (SiMe), –4.42 (SiMe); HRMS (ESI) m/z 
calcd for C20H37NO3Si (M + Na)
+ 390.2435, found 390.2428 (+1.8 ppm error). 
Lab book reference: ARG-2-063 
 
tert-Butyl 6-((tert-butyldimethylsilyl)oxy)-4-methyl-2-azabicyclo[3.3.1]nonane-2-
carboxylate endo-150 and tert-butyl 6-((tert-butyldimethylsilyl)oxy)-4-methyl-2-
azabicyclo[3.3.1]non-3-ene-2-carboxylate 151 
  
PtO2 (13 mg, 0.06 mmol, 0.1 eq) was added to a stirred solution of morphan 149 (150 mg, 
0.41 mmol, 1.0 eq) in EtOAc (2 mL) at rt under Ar. The reaction flask was evacuated under 
reduced pressure and back-filled with Ar three times and then with H2 three times. The 
mixture was stirred under a balloon of H2 (760 mmHg) for 16 h. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 99:1 to 95:5 
hexane-Et2O as eluent gave enamine 151 (82 mg, 55%) as a clear oil, RF (9:1 hexane-Et2O) 
0.34; IR (ATR) 2930, 1697 (C=O), 1390, 1156, 1083, 773 cm–1; 1H NMR (400 MHz, CDCl3) 
(60:40 mixture of rotamers) δ 6.88 (s, 0.4H, =CH), 6.73 (s, 0.6H, =CH), 4.16–4.11 (m, 0.6H, 
NCH), 4.03–3.96 (m, 0.4H, NCH), 3.84–3.77 (m, 1H, OCH), 2.27–2.22 (m, 1H, CH-2), 
1.94–1.78 (m, 1H, CHH’), 1.78–1.75 (m, 3H, =CMe), 1.69–1.50 (m, 4H, CHH’, CHH’), 
1.48–1.37 (m, 10H, CHH’, OCMe3), 0.88–0.82 (m, 9H, SiCMe3), 0.05–0.00 (m, 6H, SiMe2); 
13C NMR (100.6 MHz, CDCl3) (rotamers) δ 152.3 (C=O), 151.7 (C=O), 122.2 (=CH), 121.8 
(=CH), 115.3 (=C), 114.4 (=C), 80.3 (OCMe3), 80.0 (OCMe3), 75.4 (OCH), 75.2 (OCH), 
45.8 (NCH), 44.9 (NCH), 40.2 (CH-2), 40.0 (CH-2), 31.3 (CH2), 30.7 (CH2), 29.1 (CH2), 
28.9 (CH2), 28.4 (OCMe3), 28.3 (CH2), 28.1 (CH2), 26.0 (SiCMe3), 22.4 (=CMe), 22.2 
(=CMe), 18.2 (SiCMe3), 18.17 (SiCMe3), –4.61 (SiMe), –4.64 (SiMe), –4.7 (SiMe).; HRMS 
(ESI) m/z calcd for C20H37NO3Si (M + Na)
+ 390.2435, found 390.2434 (+0.2 ppm error) 
hydrogenated morphan endo-150 (30 mg, 20% >97:3 dr) as a clear oil, RF (9:1 hexane-Et2O) 
0.27; IR (ATR) 2928, 1689 (C=O), 1092, 834, 773 cm–1; 1H NMR (400 MHz, CDCl3) (50:50 
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mixture of rotamers) δ 4.18 (br dd, J = 3.0, 3.0 Hz, 0.5H, NCH), 4.04 (br dd, J = 3.0, 3.0 Hz, 
0.5H, NCH), 3.97–3.90 (m, 1H, OCH), 3.84 (dd, J = 13.5, 6.0 Hz, 0.5H, NCHH’), 3.73 (dd, 
J = 13.5, 6.0 Hz, 0.5H, NCHH’), 3.07 (dd, J = 13.5, 13.0 Hz, 0.5H, NCHH’), 3.03 (dd, J = 
13.5, 13.0 Hz, 0.5H, NCHH’), 2.10–1.96 (m, 1H, CH-2), 1.95–1.89 (m, 1H, CHMe), 1.79–
1.65 (m, 4H, CHH’, CHH’), 1.61–1.50 (m, 1H, CHH’), 1.51–1.41 (m, 9H, OCMe3), 1.17 (d, 
J = 7.0 Hz, 3H, CHMe), 0.87 (s, 9H, SiCMe3), 0.08– -0.06 (m, 6H, SiMe2); 
13C NMR (100.6 
MHz, CDCl3) (rotamers) δ 155.5 (C=O), 79.25 (OCMe3), 79.2 (OCMe3), 75.2 (OCH), 75.17 
(OCH), 49.8 (NCH2), 49.1 (NCH2), 45.0 (NCH), 44.0 (NCH), 38.5 (CHMe), 38.3 (CHMe), 
34.8 (CH2), 34.7 (CH2), 34.5 (CH-2), 34.4 (CH-2), 32.0 (CH2), 31.9 (CH2), 30.8 (CH2), 30.2 
(CH2), 28.65 (OCMe3), 26.0 (SiCMe3), 19.2 (CHMe), 18.2 (CHMe), –4.68 (SiMe), –4.7 
(SiMe); HRMS (ESI) m/z calcd for C20H39NO3Si (M + Na)
+ 392.2591, found 392.2592 (–0.1 
ppm error).  





NaHMDS (0.95 mL of a 2 M solution in THF, 1.90 mmol, 1.6 eq) was added dropwise to a 
stirred solution of a 90:10 mixture of morphans endo-138  and exo-138 (300 mg, 1.18 mmol, 
1.0 eq) in THF (3 mL) at –78 °C under Ar. The resulting solution was stirred at –78 °C for 
1 h. Then, a solution of PhNTf2 (550 mg, 1.54 mmol, 1.3 eq) in THF (2 mL) was added and 
the resulting solution was allowed to warm slowly to rt. The mixture was stirred at rt for 16 
h. Saturated NH4Cl(aq) (10 mL) was added and the mixture was extracted with Et2O (3 × 15 
mL). The combined organic extracts were washed with brine (25 mL), dried (Na2SO4) and 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 99:1 to 9:1 hexane-acetone as eluent gave a 90:10 mixture 
(by 1H NMR spectroscopy) of vinyl triflates endo-139  and exo-139 (320 mg, 70%) as a clear 
oil, RF (98:2 hexane-acetone) 0.14; IR (ATR) 2972, 1691 (C=O), 1414, 1209, 1143, 847, 611 
cm–1; 1H NMR (400 MHz, CDCl3) for endo-139 (55:45 mixture of rotamers) δ 5.92 (dd, J = 
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4.0, 4.0 Hz, 1H, =CH), 4.55–4.49 (m, 0.55H, NCHH’), 4.38–4.32 (m, 0.45H, NCHH’), 3.99–
3.90 (m, 0.45H, NCHH’), 3.84–3.75 (m, 0.55H, NCHH’), 2.64–2.45 (m, 3H, NCH, CH-2, 
CHH’), 2.18–2.07 (m, 1H, CHH’), 1.94–1.84 (m, 3H, CHH’, CHMe), 1.49–1.41 (m, 9H, 
CMe3), 0.92 (d, J = 7.0 Hz, 3H, CHMe); 
13C NMR (100.6 MHz, CDCl3) for endo-139 
(rotamers) δ 154.8 (C=O), 148.2 (=C), 119.5 (br, =CH), 118.6 (q, J = 320.0 Hz, CF3), 80.1 
(CMe3), 44.3 (NCH2), 43.4 (NCH2), 42.3 (br, NCH), 37.9 (CH-2), 33.6 (CHMe), 33.4 
(CHMe), 32.2 (CH2), 32.0 (CH2), 31.2 (br, CH2), 28.6 (CMe3), 17.2 (CHMe); HRMS (ESI) 
m/z calcd for C15H22F3NO5S (M + Na)
+  408.1063, found 408.1064 (–0.3 ppm error). 
Diagnostic signals for exo-139 1H NMR (400 MHz, CDCl3) (55:45 mixture of rotamers) δ 
5.90–5.84 (m, 1H, =CH), 3.71 (br d, J = 13.5 Hz, 0.45H, NCHH’), 3.62 (br d, J = 13.5 Hz, 
0.55H, NCHH’), 3.20 (dd, J = 13.5, 4.5 Hz, 0.55H, NCHH’), 3.11 (dd, J = 13.5, 4.5 Hz, 
0.45H, NCHH’), 1.11 (d, J = 7.0 Hz, 3H, CHMe). 






A solution of enol triflate 139 (318 mg, 0.82 mmol, 1.0 eq), PdCl2(PPh3)2 (17 mg, 0.025 
mmol, 3 mol%), PPh3 (13 mg, 0.05 mmol, 6 mol%), KOPh (164 mg, 1.24 mmol, 1.5 eq) and 
B2Pin2 (230 mg, 0.91 mmol, 1.1 eq) in toluene (6 mL) under Ar was stirred and heated at 50 
°C and stirred for 16 h. The solids were removed by filtration through Celite® and the filtrate 
was evaporated under reduced pressure to give the crude pinacol boronate. The crude pinacol 
boronate was dissolved in DMSO (5 mL) and MIDA (607 mg, 4.12 mmol, 5.0 eq) and 
HC(OEt)3 (0.62 mL, 3.71 mmol, 4.5 eq) were added. The resulting mixture was stirred and 
heated at 100 °C under Ar for 48 h. Saturated NH4Cl(aq) (10 mL) was added and the mixture 
was extracted with EtOAc (4 × 30 mL). The combined organic extracts were washed with 
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brine (50 mL), dried (MgSO4) and evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 1:4 to 1:1 hexane-
acetone as eluent gave impure vinyl MIDA boronate 95 (150 mg) as a white solid, RF (6:4 
hexane-acetone) 0.26; 1H NMR (400 MHz CDCl3) diagnostic signals for endo-95 (60:40 
mixture of rotamers) δ 6.22–6.17 (m, 1H, =CH), 4.51–4.43 (m, 0.6H, NCHH’), 4.35–4.30 
(m, 0.4H, NCHH’), 2.78 (s, 1.4H, NMe), 2.75 (s, 1.6H, NMe), 1.40 (s, 9H, CMe3), 1.00 (d, 
J = 7.0 Hz, 1.4H, CHMe), 0.80 (d, J = 7.0 Hz, 1.6H, CHMe); HRMS (ESI) m/z calcd for 
C19H29BN2O6 (M + Na)+  415.2011, found 415.2015 (+0.9 ppm error) 




Using general procedure A, MIDA boronate 94 (750 mg, 1.75 mmol, 1.0 eq), Pd(OAc)2 (20 
mg, 0.09 mmol, 5 mol%), SPhos (72 mg, 0.17 mmol, 10 mol%), 4-bromoanisole (0.27 mL, 
2.11 mmol, 1.2 eq) and 3 M K3PO4(aq) (5.74 mL, 17.2 mmol, 7.5 eq),   in dioxane (28 mL) 
gave the crude product. Purification by flash column chromatography on silica with 1:1 
EtOAc-hexane as eluent gave arylated normorphan 153 (565 mg, 86%) as a clear oil, RF (3:2 
EtOAc-hexane) 0.49; IR (ATR) 2938, 2835, 1686 (C=O), 1609, 1508, 1244, 1032, 835, 729 
cm–1; 1H NMR (400 MHz, CDCl3) δ 7.50–7.44 (m, 2H, Ar), 7.15–7.11 (m, 1H, Ar), 6.89–
6.84 (m, 2H, Ar), 6.45–6.41 (m, 2H, Ar), 5.70–5.63 (m, 1H, =CH), 4.57 (d, J = 15.0 Hz, 1H, 
NCHH'), 4.25 (d, J = 15.0 Hz, 1H, NCHH'), 3.81–3.76 (m, 9H, OMe), 3.76– 3.73 (m, 1H, 
NCH-3), 3.23 (d, J = 5.0 Hz, 1H, CH-5), 2.63–2.27 (m, 2H, CH2-2), 2.24 (ddd, J = 10.0, 5.0, 
5.0 Hz, 1H, CHH'-4), 1.84 (d, J = 10.0 Hz, 1H, CHH'-4); 13C NMR (100.6 MHz, CDCl3) δ 
176.8 (C=O), 160.4 (ipso-Ar), 158.9 (ipso-Ar), 158.6 (ipso-Ar), 139.8 (=C), 133.5 (ipso-Ar), 
130.5 (Ar), 126.5 (Ar), 119.7 (=CH), 118.0 (ipso-Ar), 113.9 (Ar), 104.3 (Ar), 98.5 (Ar), 55.5 
(OMe), 55.4 (OMe), 53.9 (NCH), 44.3 (CHCO), 38.0 (NCH2), 34.1 (CH2-4), 28.8 (CH2-2) 
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(1 × OMe resonance not resolved); HRMS (ESI) m/z calcd for C23H25NO4 (M + H)
+  
380.1856, found 380.1858 (–0.4 ppm error). 
Lab book reference: ARG-1-070 
 
6-(2,4-Dimethoxybenzyl)-2-(4-(trifluoromethyl)phenyl)-6-azabicyclo[3.2.1]oct-2-en-7-
one 154, 6-(2,4-dimethoxybenzyl)-6-azabicyclo[3.2.1]oct-2-en-7-one 115 and 6,6'-
bis(2,4-dimethoxybenzyl)-6,6'-diaza[2,2'-bi(bicyclo[3.2.1]octane)]-2,2'-diene-7,7'-
dione 155a/B  
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 4-
bromobenzotrifluoride (63 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 
mmol, 7.5 eq) in dioxane (2.34 mL) gave the crude product. Purification by flash column 
chromatography on silica with 4:1 to 3:2 hexane-EtOAc as eluent gave alkene 115 (12 mg, 
20%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described above, 
arylated normorphan 154 (60 mg, 61%) as a clear oil, RF (3:2 hexane-EtOAc) 0.32; IR (ATR) 
2941, 2837, 1687 (C=O), 1613, 1588, 1507, 1322, 1109, 818, 730 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.68–7.63 (m, 2H, Ar), 7.60–7.55 (m, 2H, Ar), 7.16–7.11 (m, 1H, Ar), 6.47–6.39 
(m, 2H, Ar), 5.85 (ddd, J = 3.5, 3.0, 1.5 Hz, 1H, =CH-1), 4.57 (d, J = 15.0 Hz, 1H, NCHH'), 
4.26 (d, J = 15.0 Hz, 1H, NCHH'), 3.83–3.67 (m, 7H, OMe, NCH), 3.24 (d, J = 4.5 Hz, 1H, 
CH-5), 2.42–2.31 (m, 2H, CHH'-2), 2.27 (ddd, J = 10.0, 5.0, 4.5 Hz, 1H, CHH'-4), 1.86 (d, 
J = 10.0 Hz, 1H, CHH'-4); 13C NMR (100.6 MHz, CDCl3) δ 176.4 (C=O), 160.6 (ipso-Ar), 
158.6 (ipso-Ar), 144.2 (ipso-Ar), 139.6 (=C), 130.7 (Ar), 129.1 (q, J = 32.5 Hz, ipso-Ar), 
125.6 (Ar), 125.5 (q, J = 4.0 Hz, Ar), 124.4 (q, J = 272.0 Hz, CF3), 123.8 (=CH), 117.8 (ipso-
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Ar), 104.3 (Ar), 98.5 (Ar), 55.5 (OMe), 53.7 (NCH), 44.2 (CH-5), 38.2 (NCH2), 34.0 (CH2-
4), 29.1 (CH2-2) (1 × OMe resonance not resolved); HRMS (ESI) m/z calcd for C23H22F3NO3 
(M + Na)+  440.1444, found 440.1442 (+0.4 ppm error), a 75:25 mixture (by 1H NMR 
spectroscopy) of bis-normorphan 155a and SPhos (2 mg, i.e. 1.5 mg (2%) of 155a) as a clear 
oil, RF (3:2 hexane-acetone) 0.2; IR (ATR) 2928, 1689 (C=O), 1613, 1588, 1508, 1208, 1034, 
831 cm–1; 1H NMR (400 MHz, CDCl3) for 155a δ 7.14–7.06 (m, 2H, Ar), 6.48–6.39 (m, 4H, 
Ar), 5.85 (s, 2H, =CH), 4.51 (d, J = 15.0 Hz, 2H, NCHH'), 4.18 (d, J = 15.0 Hz, 2H, NCHH'), 
3.82–3.75 (m, 12H, OMe), 3.67 (d, J = 5.0 Hz, 2H, NCH), 3.08 (d, J = 5.0 Hz, 2H, CH-5), 
2.36–2.20 (m, 4H, CHH'-2), 2.16 (ddd, J = 10.5, 5.0, 5.0 Hz, 2H, CHH'-4), 1.71 (d, J = 10.5 
Hz, 2H, CHH'-4); 13C NMR (100.6 MHz, CDCl3) for 155a δ 176.4 (C=O), 160.4 (ipso-Ar), 
158.7 (ipso-Ar), 139.2 (=C), 130.5 (Ar), 119.4 (=CH), 118.0 (ipso-Ar), 104.2 (Ar), 98.5 (Ar), 
55.5 (OMe), 53.5 (NCH), 42.3 (CH-5), 38.1 (NCH2), 34.1 (CH2-4), 28.5 (CH2-2) (1 × OMe 
resonance not resolved); HRMS (ESI) m/z calcd for C32H36N2O6 (M + Na)
+ 567.2466, found 
567.2455 (+1.9 ppm error) and a 95:5 mixture (by 1H NMR spectroscopy) of bis-normorphan 
155b and SPhos (3 mg i.e. 2.85 mg (4%) of 155b) as a clear oil, RF (3:2 hexane-acetone) 
0.09; IR (ATR) 2929, 1764, 1678 (C=O), 1613, 1508, 1208, 1035, 835, 731 cm–1; 1H NMR 
(400 MHz, CDCl3) for 155b δ 7.13–7.09 (m, 2H, Ar), 6.46–6.40 (m, 4H, Ar), 6.05–5.62 (m, 
2H, =CH), 4.55 (d, J = 15.0 Hz, 2H, NCHH'), 4.16 (d, J = 15.0 Hz, 2H, NCHH'), 3.84–3.76 
(m, 12H, OMe), 3.72–3.67 (m, 2H, NCH), 3.16 (d, J = 5.0 Hz, 2H, CH-5), 2.35–2.30 (m, 
4H, CHH'-2), 2.14 (ddd, J = 10.0, 5.0, 5.0 Hz, 2H, CHH'-4), 1.76 (d, J = 10.0 Hz, 2H, CHH'-
4); 13C NMR (100.6 MHz, CDCl3) for 155b δ 176.6 (C=O), 160.4 (ipso-Ar), 158.6 (ipso-
Ar), 138.0 (=C), 130.6 (Ar), 120.1 (=CH), 117.9 (ipso-Ar), 104.3 (Ar), 98.5 (Ar), 55.5 
(OMe), 53.7 (NCH), 41.2 (CH-5), 37.9 (NCH2), 33.6 (CH2-4), 28.7 (CH2-2) (1 × OMe 
resonance not resolved); HRMS (ESI) m/z calcd for C32H36N2O6 (M + Na)
+ 567.2466, found 
567.2466 (0 ppm error). 








yl)phenyl)acetamide 159 6-(2,4-dimethoxybenzyl)-6-azabicyclo[3.2.1]oct-2-en-7-one 
115 and 6,6'-bis(2,4-dimethoxybenzyl)-6,6'-diaza[2,2'-bi(bicyclo[3.2.1]octane)]-2,2'-
diene-7,7'-dione 155a/b  
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 4-
bromoacetanilide (63 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 
7.5 eq) in dioxane (2.34 mL) gave the crude product. Purification by flash column 
chromatography on silica with 2:8 to 1:99 hexane-EtOAc as eluent gave alkene 115 (26 mg, 
40%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described above, a 
75:25 mixture (by 1H NMR spectroscopy) of bis-normorphan 155a and SPhos (3 mg, i.e. 2.3 
mg (3%) of 155a) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that 
described above and a 90:10 mixture (by 1H NMR spectroscopy) of arylated normorphan 
159 and bis-normorphan 155b (48 mg, i.e. 43.2 mg (45%) of 159 and 4.8 mg (7%) of 155b) 
as a clear oil, RF (1:99 hexane-EtOAc) 0.3; IR (ATR) 3309 (NH), 2939, 2836, 1669 (C=O), 
1613, 1591, 1508, 1208, 1035, 730 cm–1; 1H NMR (400 MHz, CDCl3) for 159 δ 8.82 (br s, 
1H, NH), 7.52–7.49 (m, 2H, Ar), 7.43–7.39 (m, 2H, Ar), 7.09 (d, J = 8.5 Hz, 1H, Ar), 6.47–
6.40 (m, 2H, Ar), 5.77–5.74 (m, 1H, =CH), 4.59 (d, J = 15.0 Hz, 1H, NCHH'), 4.25 (d, J = 
15.0 Hz, 1H, NCHH'), 3.84–3.73 (m, 7H, OMe, NCH), 3.27 (d, J = 4.5 Hz, 1H, CH-5), 2.38–
2.22 (m, 3H, CHH'-2, CHH'-4), 2.07 (s, 3H, Me), 1.88 (d, J = 10.5 Hz, 1H, CHH'-4); 13C 
NMR (100.6 MHz, CDCl3) δ 177.1 (C=O, lactam), 169.1 (C=O, NHC(O)), 160.6 (ipso-Ar), 
158.6 (ipso-Ar), 139.7 (ipso-Ar), 138.0 (ipso-Ar), 135.6 (=C), 130.2 (Ar), 125.7 (Ar), 120.5 
(=CH), 120.0 (Ar), 117.6 (ipso-Ar), 104.3 (Ar), 98.6 (Ar), 55.5 (OMe), 55.4 (OMe), 54.0 
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(NCH), 44.1 (C-5), 38.3 (NCH2), 34.1 (CH2-4), 28.8 (CH2-2), 24.4 (Me); HRMS (ESI) m/z 
calcd for C24H26N2O4 (M + Na)
+ 429.1785, found 429.1782 (+0.7 ppm error). 
Lab book reference: ARG-2-117 
 
6-(2,4-Dimethoxybenzyl)-2-(pyrimidin-5-yl)-6-azabicyclo[3.2.1]oct-2-en-7-one 156, 6-
(2,4-dimethoxybenzyl)-6-azabicyclo[3.2.1]oct-2-en-7-one 115 and 6,6'-bis(2,4-
dimethoxybenzyl)-6,6'-diaza[2,2'-bi(bicyclo[3.2.1]octane)]-2,2'-diene-7,7'-dione 155a/b 
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 5-bromo-
pyrimidine (45 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 7.5 eq) 
in dioxane (3.9 mL) gave the crude product. Purification by flash column chromatography 
on silica with 99:1 to 9:1 Et2O-MeOH as eluent gave alkene 115 (3 mg, 5%) as a clear oil, 
identical (by 1H and 13C NMR spectroscopy) to that described above, arylated normorphan 
156 (50 mg, 60%) as a clear oil, RF (9:1 Et2O-MeOH) 0.27; IR (ATR) 2942, 2866, 1687 
(C=O), 1613, 1507, 1412, 1208, 1033, 903, 823, 726 cm–1; 1H NMR (400 MHz, CDCl3) δ 
9.06 (s, 1H, Ar), 8.85 (s, 2H, Ar), 7.15–7.07 (m, 1H, Ar), 6.45–6.37 (m, 2H, Ar), 5.90 (dd, 
J = 3.5, 3.5 Hz, 1H, =CH), 4.54 (d, J = 15.0 Hz, 1H, NCHH'), 4.23 (d, J = 15.0 Hz, 1H, 
NCHH'), 3.77 (s, 7H, OMe, NCH), 3.19 (d, J = 5.0 Hz, 1H, CH-5), 2.41–2.32 (m, 2H, CHH'-
2), 2.28 (ddd, J = 10.5, 5.0, 5.0 Hz, 1H, CHH'-4), 1.86 (d, J = 10.5 Hz, 1H, CHH'-4); 13C 
NMR (100.6 MHz, CDCl3) δ 175.8 (C=O), 160.6 (ipso-Ar), 158.6 (ipso-Ar), 157.3 (Ar), 
153.5 (Ar), 135.0 (=C), 133.8 (ipso-Ar), 130.7 (Ar), 125.6 (=CH), 117.5 (ipso-Ar), 104.4 
(Ar), 98.5 (Ar), 55.5 (OMe), 53.4 (NCH), 43.6 (CH-5), 38.2 (NCH2), 33.8 (CH2-4), 29.1 
(CH2-2) (1 × OMe resonance not resolved); HRMS (ESI) m/z calcd for C20H21N3O3 (M + 
Na)+  374.1475, found 374.1471 (+0.9 ppm error), a 75:25 mixture (by 1H NMR 
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spectroscopy) of bis-normorphan 155a and SPhos (2 mg, i.e. 1.5 mg (3%) of 155a) as a clear 
oil, identical (by 1H and 13C NMR spectroscopy) to that described above and a 90:10 mixture 
(by 1H and 13C NMR spectroscopy) of bis-normorphan 155b and SPhos (4 mg, i.e. 3.6 mg 
(7%) of 155b) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described 
above. 
Lab book reference: ARG-2-106 
 
6-(2,4-Dimethoxybenzyl)-2-(2-methoxypyrimidin-5-yl)-6-azabicyclo[3.2.1]oct-2-en-7-




Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 5-bromo-2-
methoxy-pyrimidine (53 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 
7.5 eq) in dioxane (2.34 mL) gave the crude product. Purification by flash column 
chromatography on silica with 99:1 to 9:1 Et2O-MeOH as eluent gave alkene 115 (4 mg, 
6%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described above, a 
95:5 mixture (by 1H NMR spectroscopy) of arylated normorphan 160 and bis-normorphan 
155a (62 mg, i.e. 58.9 mg (66%) of 160 and 3.1 mg (5%) of 155a) as a clear oil, RF (95:5 
Et2O-MeOH) 0.46; IR (ATR) 2955, 2836, 1686 (C=O), 1613, 1589, 1471, 1412, 1207, 1032, 
823 cm–1; 1H NMR (400 MHz, CD2Cl2) for 160 δ 8.60 (s, 2H, Ar), 7.08 (d, J = 8.0 Hz, 1H, 
Ar), 6.46–6.35 (m, 2H, Ar), 5.78 (dd, J = 3.5, 2.5 Hz, 1H, =CH), 4.49 (d, J = 15.0 Hz, 1H, 
NCHH'), 4.19 (d, J = 15.0 Hz, 1H, NCHH'), 3.95 (s, 3H, OMe), 3.81–3.71 (m, 7H, OMe, 
NCH), 3.10 (dd, J = 5.0, 1.0 Hz, 1H, CH-5), 2.38–2.29 (m, 2H, CHH'-2), 2.25 (dddd, J = 
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10.0, 5.5, 4.5, 1.0 Hz, 1H, CHH'-4), 1.85 (d, J = 10.5 Hz, 1H, CHH'-4); 13C NMR (100.6 
MHz, CD2Cl2) δ 175.8 (C=O), 164.9 (ipso-Ar), 160.6 (ipso-Ar), 158.6 (ipso-Ar), 155.9 (Ar), 
134.6 (ipso-Ar), 130.2 (Ar), 128.0 (=C), 122.9 (=CH), 117.8 (ipso-Ar), 104.3 (Ar), 98.3 (Ar), 
55.41 (OMe), 55.36 (OMe), 54.8 (NCH), 43.7 (CH-5), 38.0 (NCH2), 33.6 (CH2-4), 28.8 
(CH2-2) (1 × OMe resonance not resolved); HRMS (ESI) m/z calcd for C21H23N3O4 (M + 
Na)+  404.1581, found 404.1583 ( –0.4 ppm error) and a 90:10 mixture (by 1H NMR 
spectroscopy) of bis-normorphan 155b and SPhos (5 mg, i.e. 4.5 mg of 155b, 7%) as a clear 
oil, identical (by 1H and 13C NMR spectroscopy) to that described above. 





Using general procedure A, MIDA boronate 94 (200 mg, 1.47 mmol, 1.0 eq), Pd(OAc)2 (6 
mg, 0.025 mmol, 0.05 eq), SPhos (20 mg, 0.047 mmol, 0.1 eq), 5-bromo-1-
triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 157 (198 mg, 0.56 mmol, 1.2 eq) and 3 M 
K3PO4(aq) (1.52 mL, 4.59 mmol, 7.5 eq) in dioxane (7.5 mL) gave the crude product. 
Purification by flash column chromatography on silica with 1:4 EtOAc-hexane as eluent 
gave arylated normorphan 158 (178 mg, 58%) as a clear oil, RF (1:4 EtOAc-hexane) 0.15; 
IR (ATR) 2945, 2866, 2244, 1686 (C=O), 1613, 1507, 1465, 1385, 1207, 1154, 906, 726, 
648 cm–1; 1H NMR (400 MHz, CDCl3) δ 8.41 (d, J = 2.0 Hz, 1H, Ar), 8.10 (d, J = 2.0 Hz, 
1H, Ar), 7.27 (d, J = 3.5 Hz, 1H, Ar), 7.21–7.13 (m, 1H, Ar), 6.55 (d, J = 3.5 Hz, 1H, Ar), 
6.49–6.40 (m, 2H, Ar), 5.78 (dd, J = 3.5, 3.5 Hz, 1H, =CH), 4.61 (d, J = 15.0 Hz, 1H, 
NCHH'), 4.29 (d, J = 15.0 Hz, 1H, NCHH'), 3.91–3.72 (m, 7H, OMe, NCH), 3.33 (d, J = 5.0 
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Hz, 1H, CH-5), 2.43–2.30 (m, 2H, CHH'-2), 2.29 (ddd, J = 10.0, 5.0, 5.0 Hz, 1H, CHH'-4), 
1.91 (d, J = 10.0 Hz, 1H, CHH'-4), 1.85 (sept, J = 7.5 Hz, 3H, SiCH), 1.121 (d, J = 7.5 Hz, 
9H, SiCHMe2), 1.117 (d, J = 7.5 Hz, 9H, SiCHMe2); 
13C NMR (100.6 MHz, CDCl3) δ 176.8 
(C=O), 160.5 (ipso-Ar), 158.6 (ipso-Ar), 153.4 (ipso-Ar), 140.3 (Ar), 139.0 (=C), 131.6 
(Ar), 130.6 (Ar), 129.1 (ipso-Ar), 124.7 (Ar), 122.0 (ipso-Ar), 120.5 (=CH), 118.0 (ipso-
Ar), 104.3 (Ar), 103.4 (Ar), 98.5 (Ar), 55.5 (OMe), 53.9 (NCH), 44.6 (CH-5), 38.0 (NCH2), 
34.2 (CH2-4), 29.0 (CH2-2), 18.3 (SiCHMe2), 12.4 (SiCH) (1 × OMe resonance not 
resolved); HRMS (ESI) m/z calcd for C32H44N3O3 (M + H)
+  546.3146, found 546.3147 (–
0.1 ppm error). 



















Attempted synthesis of 6-(2,4-Dimethoxybenzyl)-2-(2-methoxypyridin-3-yl)-6-
azabicyclo[3.2.1]oct-2-en-7-one 161. 6-(2,4-Dimethoxybenzyl)-6-azabicyclo[3.2.1]oct-2-
en-7-one 115 and 6,6'-bis(2,4-dimethoxybenzyl)-6,6'-diaza[2,2'-
bi(bicyclo[3.2.1]octane)]-2,2'-diene-7,7'-dione 155a/b 
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 3-bromo-2-
methoxy-pyridine (53 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 
7.5 eq) in dioxane (2.34 mL) gave the crude product. Purification by flash column 
chromatography on silica with 99:1 to 9:1 Et2O-MeOH as eluent gave alkene 115 (37 mg, 
55%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described above, a 
75:25 mixture (by 1H NMR spectroscopy) of bis-normorphan 155a and SPhos (4 mg, i.e. 3 
mg (6%) of 155a) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that 
described above and an 85:15 mixture (by 1H and 13C NMR spectroscopy) of bis-
normorphan 155b and SPhos (6 mg, i.e. 5 mg (10%) of 155b) as a clear oil, identical (by 1H 
and 13C NMR spectroscopy) to that described above. There was evidence in the 1H NMR 
spectrum of the crude product for the formation of arylated normorphan 161 but none was 
isolated after chromatography. 
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Lab book reference: ARG-2-118 
 
Attempted synthesis of 6-(2,4-dimethoxybenzyl)-2-(6-fluoro-3-methylpyridin-2-yl)-6-
azabicyclo[3.2.1]oct-2-en-7-one 162. 6-(2,4-Dimethoxybenzyl)-6-azabicyclo[3.2.1]oct-2-
en-7-one 115 and 6,6'-bis(2,4-dimethoxybenzyl)-6,6'-diaza[2,2'-
bi(bicyclo[3.2.1]octane)]-2,2'-diene-7,7'-dione 155a/b 
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 2-bromo-5-
fluoro-3-methylpyridine (33 µL, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 
mmol, 7.5 eq) in dioxane (2.34 mL) gave the crude product. Purification by flash column 
chromatography on silica with 99:1 to 9:1 Et2O-MeOH as eluent gave alkene 115 (40 mg, 
60%) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that described above, a 
80:20 mixture (by 1H NMR spectroscopy) of bis-normorphan 155a and SPhos (2 mg, i.e. 1.5 
mg (3%) of 155a) as a clear oil, identical (by 1H and 13C NMR spectroscopy) to that 
described above and an 85:15 mixture (by 1H and 13C NMR spectroscopy) of bis-
normorphan 155b and SPhos (5 mg, i.e. 4 mg (8%) of 155b) as a clear oil, identical (by 1H 
and 13C NMR spectroscopy) to that described above. There was evidence in the 1H NMR 
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spectrum of the crude product for the formation of arylated normorphan 162 but none was 
isolated after chromatography. 
Lab book reference: ARG-2-124 
 
Attempted synthesis of 6-(2,4-dimethoxybenzyl)-2-(2-hydroxypyridin-4-yl)-6-
azabicyclo[3.2.1]oct-2-en-7-one 
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 4-bromo-2-
hydroxypyridine (49 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 7.5 
eq) in dioxane (2.34 mL) gave the crude product which contained (by 1H NMR spectroscopy) 
only traces of arylated normorphan. 










Attempted synthesis of 6-(2,4-dimethoxybenzyl)-2-(isoxazol-4-yl)-6-
azabicyclo[3.2.1]oct-2-en-7-one 
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 4-bromo-
isoxazole (41 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 7.5 eq) in 
dioxane (2.34 mL) gave the crude product which contained (by 1H NMR spectroscopy) only 
traces of arylated normorphan. 
Lab book reference: ARG-2-105 
 
Attempted synthesis of 6-(2,4-dimethoxybenzyl)-2-(1H-pyrazol-4-yl)-6-
azabicyclo[3.2.1]oct-2-en-7-one 
 
Using general procedure A, vinyl MIDA boronate 94 (100 mg, 0.234 mmol, 1.0 eq), 
Pd(OAc)2 (3 mg, 0.012 mmol, 0.05 eq), SPhos (10 mg, 0.023 mmol, 0.1 eq), 4-bromo-
pyrazole (41 mg, 0.280 mmol, 1.2 eq) and 3 M K3PO4(aq) (0.59 mL, 1.755 mmol, 7.5 eq) in 
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dioxane (2.34 mL) gave the crude product which contained (by 1H NMR spectroscopy) only 
traces of arylated normorphan. 




10% Pd/C (61 mg, 0.057 mmol, 10 mol%) was added to a stirred solution of arylated 
normorphan 153 (215 mg, 0.57 mmol, 1 eq) in MeOH (3 mL) at rt under Ar. The reaction 
flask was evacuated under reduced pressure and back-filled with Ar three times and then 
with H2 three times. The resulting mixture was stirred under a balloon of H2 (760 mmHg) 
for 18 h. The solids were removed by filtration through Celite® and washed with MeOH (10 
mL). The filtrate was evaporated under reduced pressure to give hydrogenated normorphan 
168 (200 mg, 92%, >97:3 dr) as a clear oil, RF (3:2 EtOAc-hexane) 0.49; IR (ATR) 2936, 
2835, 1680 (C=O), 1611, 1587, 1508, 1243, 1032, 825, 728 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.37–7.33 (m, 2H, Ar), 7.22 (d, J = 8.5 Hz, 1H, Ar), 6.87–6.82 (m, 2H, Ar), 6.47–
6.42 (m, 2H, Ar), 4.64 (d, J = 14.5 Hz, 1H, NCHH'), 4.30 (d, J = 14.5 Hz, 1H, NCHH'), 
3.84–3.74 (m, 9H, OMe), 3.61 (dd, J = 5.5, 4.5 Hz, 1H, NCH), 2.84 (ddd, J = 12.0, 5.0, 1.5 
Hz, 1H, CH-6), 2.64 (d, J = 5.5 Hz, 1H, CH-5), 2.28 (dddd, J = 11.0, 5.5, 5.5, 1.5 Hz, 1H, 
CHH'-4), 1.85 (ddd, J = 14.0, 5.0, 5.0 Hz, 1H, CHH'-1), 1.79–1.61 (m, 3H, CHH'-1, CHH'-
2, CHH'-4), 1.52 (ddd, J = 12.0, 11.5, 5.0 Hz, 1H, CHH'-2); 13C NMR (100.6 MHz, CDCl3) 
δ 175.3 (C=O), 160.5 (ipso-Ar), 158.7 (ipso-Ar), 158.2 (ipso-Ar), 136.5 (ipso-Ar), 131.0 
(Ar), 128.7 (Ar), 117.9 (ipso-Ar), 113.7 (Ar), 104.2 (Ar), 98.4 (Ar), 55.5 (OMe), 55.4 
(OMe), 55.3 (OMe), 54.8 (NCH), 46.2 (CH-5), 44.0 (CH-6), 39.7 (CH2-4), 38.6 (NCH2), 
27.5 (CH2-1), 26.4 (CH2-2); HRMS (ESI) m/z calcd for C23H27NO4 (M + Na)
+  404.1832, 
found 404.1837 (–1.2 ppm error). 
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80% v/v TFA(aq) (8 mL) was added to a stirred solution of N-DMB-amide 168 (100 mg, 0.26 
mmol, 1.0 eq) in CH2Cl2 (1 mL) at rt. The resulting mixture was stirred and heated at 60 °C 
for 18 h. The solvent was evaporated under reduced pressure. The residue was suspended in 
toluene (10 mL) and the solvent was evaporated under reduced pressure to give the crude 
product. Purification by flash column chromatography on silica with 1:1 to 7:3 EtOAc-
hexane as eluent gave amide 170 (44 mg, 73%) as an off-white crystalline solid, mp 140-
142 °C; RF (7:3 EtOAc-hexane) 0.20; IR (ATR) 3231 (NH), 2934, 1693 (C=O), 1611, 1514, 
1247, 1181, 1035, 835, 773 cm–1; 1H NMR (400 MHz, CDCl3) δ 7.35–7.27 (m, 2H, Ar), 
6.88–6.79 (m, 2H, Ar), 6.69 (br s, 1H, NH), 3.85–3.69 (m, 4H, OMe, NCH), 2.88 (ddd, J = 
12.5, 6.0, 2.0 Hz, 1H, CH-6), 2.53 (d, J = 5.5 Hz, 1H, CH-5), 2.44 (dddd, J = 11.5, 6.0, 5.5, 
2.0 Hz, 1H, CHH'-4), 2.09–1.88 (m, 2H, CHH'-1, CHH'-2), 1.88–1.73 (m, 2H, CHH'-1, 
CHH'-4), 1.68 (ddd, J = 12.5, 12.5, 6.0 Hz, 1H, CHH'-2); 13C NMR (100.6 MHz, CDCl3) δ 
179.0 (C=O), 158.2 (ipso-Ar), 136.2 (ipso-Ar), 128.5 (Ar), 113.8 (Ar), 55.3 (OMe), 51.2 
(NCH), 45.8 (CH-5), 43.8 (CH-6), 41.0 (CH2-4), 29.1 (CH2-1), 26.8 (CH2-2); HRMS (ESI) 
m/z calcd for C14H17NO2 (M + H)
+  232.1332, found 232.1334 (–0.8 ppm error). 
Lab book reference: ARG-1-062 
 
80% v/v TFA(aq) (5 mL) was added to a stirred solution of N-DMB-amide 168 (70 mg, 0.18 
mmol, 1.0 eq) in CH2Cl2 (1 mL) at rt. The resulting mixture was stirred at rt for 72 h. The 
solvent was evaporated under reduced pressure. The residue was suspended in toluene (10 
mL) and the solvent evaporated under reduced pressure to give the crude product. 
Purification by flash column chromatography on silica with 1:1 to 7:3 EtOAc-hexane as 
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eluent gave amide 170 (27 mg, 68%) as an off-white crystalline solid, identical (by 1H and 
13C NMR spectroscopy) to that described above. 
Lab book reference: ARG-1-057 
 
DDQ (71 mg, 0.31 mmol, 1.5 eq) was added to a stirred solution of N-DMB-amide 168 (79 
mg, 0.21 mmol, 1.0 eq) in CH2Cl2 (1 mL) and H2O (0.1 mL) at rt. The resulting mixture was 
stirred at rt for 24 h. Saturated NaHCO3(aq) (5 mL) was added and the mixture was extracted 
with CH2Cl2 (3 × 5 mL). The combined organic extracts were washed with brine (10 mL), 
dried (MgSO4) and evaporated under reduced pressure to give the crude product. Purification 
by flash column chromatography on silica with 1:1 to 7:3 EtOAc-hexane as eluent gave 
amide 170 (12 mg, 25%) as an off-white crystalline solid, identical (by 1H and 13C NMR 
spectroscopy) to that described above. 
Lab book reference: ARG-1-058 
 
TFA (596 µL, 7.8 mmol, 30 eq) was added to a stirred solution of N-DMB-amide 168 (100 
mg, 0.26 mmol, 1.0 eq) and m-dimethoxybenzene (68 µL, 0.52 mmol, 2 eq) in CH2Cl2 (1.3 
mL) at rt. The resulting solution stirred at rt for 72 h. Saturated NaHCO3(aq) (5 mL) was added 
and the mixture was extracted with CH2Cl2 (3 × 5 mL). The combined organic extracts were 
washed with brine (10 mL), dried (MgSO4) and evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 1:1 to 7:3 
EtOAc-hexane as eluent gave amide 170 (31 mg, 52%) as an off-white crystalline solid, 
identical (by 1H and 13C NMR spectroscopy) to that described above. 











TFA (800 µL, 7.01 mmol, 30 eq) was added to a stirred solution of vinyl MIDA boronate 94 
(100 mg, 0.23 mmol, 1.0 eq) and m-dimethoxybenzene (60 µL, 0.46 mmol, 2 eq) in CH2Cl2 
(1.15 mL) at rt. The resulting mixture was stirred at rt for 72 h. The solvent was evaporated 
under reduced pressured. The residue was suspended in toluene (5 mL) and the solvent was 
evaporated under reduced pressure to give the crude product. Purification by flash column 
chromatography on silica with 1:1 to 8:2 CH2Cl2-acetone as eluent gave free amide 171 (39 
mg, 60%) as a white crystalline solid. mp 280-282 °C (decomposition); RF (2:8 CH2Cl2-
acetone) 0.31; IR (ATR) 3388 (NH), 1755 (C=O, ester), 1671 (C=O, amide), 1322, 110, 
1039, 558 cm–1; 1H NMR (400 MHz, d6-DMSO) δ 7.55 (s, 1H, NH), 5.86 (ddd, J = 3.0, 3.0, 
1.5 Hz, 1H, =CH-1), 4.25 (d, J = 17.5 Hz, 1H, C(O)CHH'), 4.13 (d, J = 16.5 Hz, 1H, 
C(O)CHH'), 3.91 (d, J = 17.5 Hz, 1H, C(O)CHH'), 3.90 (d, J = 16.5 Hz, 1H, C(O)CHH'), 
3.68–3.65 (m, 1H, NCH), 2.64 (s, 3H, NMe), 2.41 (d, J = 5.0 Hz, 1H, CH-5), 2.32 (ddd, J = 
19.0, 3.0, 3.0 Hz, 1H, CHH'-2), 2.07 (ddd, J = 10.5, 5.0, 5.0 Hz, 1H, CHH'-4), 2.02 (ddd, J 
= 19.0, 3.0, 1.5 Hz, 1H, CHH'-2), 1.52 (d, J = 10.5 Hz, 1H, CHH'-4); 13C NMR (100.6 MHz, 
d6-DMSO) δ 179.7 (C=O, amide), 170.4 (C=O, ester), 169.2 (C=O, ester), 134.1 (=CH), 62.2 
(CH2CO2), 61.6 (CH2CO2), 49.8 (NCH), 46.6 (NMe), 41.5 (CH-5), 34.9 (CH2-4), 33.2 (CH2-
2) (=C-B resonance not resolved); HRMS (ESI) m/z calcd for C12H15BN2O5 (M + H)
+  
301.0966, found 301.0966 (+0.8 ppm error). 
Lab book reference: ARG-1-094 
 
80% v/v TFA(aq) (7 mL) was added to a stirred solution of vinyl MIDA boronate 94 (100 
mg, 0.23 mmol, 1.0 eq) in CH2Cl2 (1.5 mL) at rt. The resulting mixture was stirred and 
heated at 60 °C for 18 h. The solvent was evaporated under reduced pressure. The residue 
was suspended in toluene (5 mL) and the solvent was evaporated under reduced pressure to 
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give the crude product which contained (by 1H NMR spectroscopy) an unidentified mixture 
of products 
Lab book reference: ARG-1-093 
6-(2,4-Dimethoxybenzyl)-2-(4-methoxyphenyl)-6-azabicyclo[3.2.1]oct-2-ene 172 
 
A solution of arylated normorphan 153 (200 mg, 0.53 mmol, 1.0 eq) in THF (7.5 mL), was 
added dropwise to a stirred suspension of LiAlH4 (80 mg, 2.11 mmol, 4 eq) in THF (3.5 mL) 
at rt under Ar. The resulting mixture was stirred and heated at reflux for 16 h under Ar. After 
allowing the mixture to cool to rt, H2O (0.15 mL), 2 M NaOH(aq) (0.32 mL) and MgSO4 (250 
mg) were added and the resulting mixture was stirred for 15 min. The solids were removed 
by filtration through Celite® and the filtrate was evaporated under reduced pressure to give 
the crude product. Purification by flash column chromatography on silica with 99:1 to 9:1 
EtOAc-MeOH as eluent gave amine 172 (136 mg, 70%) as a clear oil, RF (9:1 EtOAc-MeOH) 
0.3; IR (ATR) 2934, 2832, 1607, 1507, 1240, 1152, 1032, 819 cm–1; 1H NMR (400 MHz, 
CDCl3) δ 7.39 (d, J = 8.5 Hz, 1H, Ar), 7.31–7.27 (m, 2H, Ar), 6.87–6.82 (m, 2H, Ar), 6.48 
(dd, J = 8.5, 2.5 Hz, 1H, Ar), 6.44 (d, J = 2.5 Hz, 1H, Ar), 5.72 (ddd, J = 3.5, 3.5, 1.5 Hz, 
1H, =CH), 3.87–3.80 (m, 2H, NCHH'Ar), 3.81–3.79 (m, 9H, OMe), 3.48–3.42 (m, 1H, 
NCH), 3.12–3.02 (m, 2H, NCHH'-7), 3.00 (dd, J = 5.0, 4.5 Hz, 1H, CH-5), 2.48 (ddd, J = 
18.5, 3.5, 2.0 Hz, 1H, CHH'-2), 2.30 (ddd, J = 18.5, 3.5, 3.5 Hz, 1H, CHH'-2), 2.04 (ddd, J 
= 10.5, 5.0, 5.0 Hz, 1H, CHH'-4), 1.84 (d, J = 10.5 Hz, 1H, CHH'-4); 13C NMR (100.6 MHz, 
CDCl3) δ 159.6 (ipso-Ar), 158.6 (ipso-Ar), 158.2 (ipso-Ar), 144.2 (=C), 134.1 (ipso-Ar), 
130.2 (Ar), 126.2 (Ar), 121.3 (ipso-Ar), 119.6 (=CH), 113.8 (Ar), 103.9 (Ar), 98.4 (Ar), 63.2 
(NCH2-7), 58.2 (NCH), 55.45 (OMe), 55.43 (OMe), 55.38 (OMe), 52.6 (NCH2Ar), 38.6 
(CH-5), 34.3 (CH2-2), 33.6 (CH2-4); HRMS (ESI) m/z calcd for C23H27NO3 (M + H)
+  
366.2064, found 366.2066 (–0.5 ppm error). 
Lab book reference: ARG-1-071 
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6.2.5  Crystal Data 
Crystal data for 170 
 
Table 6.1 - Crystal data and structure refinement for paob1911 
Identification code  paob1911  
Empirical formula  C14H17NO2  
Formula weight  231.28  
Temperature/K  109.95(10)  
Crystal system  monoclinic  
Space group  P21/c  
a/Å  16.7674(7)  
b/Å  6.2020(2)  
c/Å  11.4525(4)  
α/°  90  
β/°  97.971(4)  
γ/°  90  
Volume/Å3  1179.45(8)  
Z  4  
ρcalcg/cm3  1.302  
μ/mm-1  0.695  
F(000)  496.0  
Crystal size/mm3  0.157 × 0.138 × 0.03  
Radiation  CuKα (λ = 1.54184)  
2Θ range for data collection/°  10.656 to 141.988  
Index ranges  -20 ≤ h ≤ 20, -6 ≤ k ≤ 7, -14 ≤ l ≤ 13  
Reflections collected  8760  
Independent reflections  2251 [Rint = 0.0333, Rsigma = 0.0340]  
Data/restraints/parameters  2251/0/159  
Goodness-of-fit on F2  1.048  
Final R indexes [I>=2σ (I)]  R1 = 0.0547, wR2 = 0.1437  
Final R indexes [all data]  R1 = 0.0645, wR2 = 0.1522  
Largest diff. peak/hole / e Å-3  0.57/-0.28  
 




Ac - Acetyl 
Acac - Acetylacetone 
AIBN - Azobisisobutyronitrile 
Aq - Aqueous 
Ar - Aryl 
Bn - Benzyl 
Boc - tert-butoxycarbonyl 
Br - Broad 
Cbz - Carboxybenzyl 
cm‒1 - Wavenumber 
CSP - Chiral stationary phase 
d - Doublet 
DAT - Dopamine transporter 
DBU - 1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCE - 1,2-dichlorethane 
DDQ - 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DMAP - 4-Dimethylaminopyridine 
DMB - 2,4-Dimethoxybenzyl 
DMF - Dimethylformamide 
DMP - Dess-Martin peridinane 
DMSO - Dimethylsulfoxide 
DPPA - Diphenyl phosphoryl azide 
Dppf - 1,1′-Bis(diphenylphosphino)ferrocene 
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Eq - Equivalents 
ESI - Electrospray ionisation 
Et - Ethyl 
EWG - Electron withdrawing group 
Fsp3 - Fraction of sp3 carbons 
g - Gram(s) 
h - Hour(s) 
H bond - Hydrogen bond 
HMDS - hexamethyldisilazane 
HPLC - High performance liquid chromatography 
HRMS - High resolution mass spectrometry 
HTS - High throughput screening 
Hz - Hertz 
IR - Infra-red 
i-Pr - iso-propyl 
J - Coupling constant in Hz 
kcal mol‒1 - Kilocalories per mole 
LDA - Lithium diisopropylamine 
m - Multiplet 
M - Molar  
m/z - Mass to charge ratio 
M+ - Molecular ion 
Me - Methyl 
mg - Milligrams 
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μM - Micromolar 
MIDA - Methyliminodiacetic acid 
min - Minute(s) 
mL - Millilitre(s) 
mmol - Millimole(s) 
MS - Mass spectrometry 
Ms - Mesyl 
MW - Molecular weight 
NMR - Nuclear Magnetic Resonance 
Ns - 4-Nosyl 
PG - Protecting group 
Ph - Phenyl 
Pin - Pinacolato 
Piv - Pivaloyl 
PMP - para-methoxyphenyl 
PNP - para-nitrophenyl 
ppm - Parts per million  
p-tol - para-tolyl 
q - Quartet  
Rf- Retention Factor  
R&D – Research and development 
rt - Room Temperature  
s - Singlet  
SMILES - Simplified molecular-input line-entry system  
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t - Triplet 
t-Bu - tert-butyl 
TBS - tert-butyldimethylsilyl 
TBDMS - tert-butyldimethylsilyl 
TBDPS - tert-butyldiphenylsilyl 
TIPS - Triisopropylsilyl 
Tf - Triflate 
TFA - Trifluoroacetic acid 
THF - Tetrahydrofuran 
TPMA - Tris(2-pyridylmethyl)amine 
Ts - Tosyl 
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